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Abstract 
Multiple sclerosis (MS) is a complex neurological disorder whose cause and subsequent 
clinical course are to a large part due to an interplay between environmental and genetic factors. 
Currently, apart from the well-known effects of MHC genetic risk loci, genome-wide 
association studies (GWAS) have identified 110 non-MHC risk loci. However, these findings 
can only explain part of the heritability of MS, leading to the question “where is the missing 
heritability”. This thesis presents a number of methodological analyses using different study 
designs to reveal, in part, the puzzle of the missing heritability. By examining the susceptibility 
genes for EBV infection and their roles in MS development, as well as evaluating genetic 
variations and key environmental factors in determining clinical course, the complex role of 
genetics in MS onset and progression might be better understood.   
In Chapter 2, I performed a genome-wide association study (GWAS) of anti-Epstein Barr 
Nuclear Antigen-1 (EBNA-1) IgG titers in 3,599 individuals from an unselected twin family 
cohort, followed by a meta-analysis with data from an independent EBNA-1 GWAS. I then 
examined the shared polygenic risk between the EBNA-1 GWAS (effective sample size (Neff) 
= 5,555) and a large MS GWAS (Neff = 15,231). I identified one locus of strong association 
within the human leukocyte antigen (HLA) region that associated with anti-EBNA-1 titers. 
By examining the shared polygenic risk, I show that apart from the confirmed HLA region, 
the association of anti-EBNA-1 IgG titer with MS risk is also mediated through non-HLA 
loci (1p22.1, 3p24.1, 3q13.33 and 10p15.1).  
In Chapter 3, I assessed whether SNPs within genes for relevant cytokines and their receptors 
modulate the associations of TNF-α and IFN-γ with relapse. I found variation within the 
gene, IL2RB, demonstrated a significant protective effect of TNF-α on relapse, while 
Abstract 
variation in the 3’ region of TNFRSF1B and variation in the 5’region of IL3 showed a strong 
association between IFN-γ and increased relapse risk.  
In Chapter 4, I assessed whether genetic variation in the myelin basic protein gene may 
directly, or by interaction with anti-HHV6 or EBV serological titers, determine clinical 
outcomes (conversion to MS after a first demyelinating event (FDE), relapse rate and 
disability) using the Ausimmune/AusLong Study. I found one variant, rs12959006, predicted 
worse MS clinical course in three key metrics, namely conversion to MS, relapse risk and 
annualised disability progression. I also found a significant interaction between the risk 
genotype and baseline anti-HHV6 IgG in predicting conversion to MS and relapse. These 
results, if replicated, may aid in developing prognostic algorithms in the early disease period 
in MS as well as providing further mechanistic insights. 
In Chapter 5, I addressed the key question regarding the role of epigenetics in the missing 
heritability of MS. For the first time, I assessed the effects of a functional genetic variant 
within the gene for miR-146a (a miRNA whose expression is strongly associated with MS 
disease activity) on MS clinical course in the Ausimmune/AusLong Study, a well-established 
FDE cohort. I found the risk genotype (GC+CC) of the miR-146a SNP rs2910164 not only 
itself significantly predicted relapse risk, but also showed significant additive interaction with 
markers of EBV infection in predicting CDMS and relapse, including anti-EBNA-1 and -2 
IgG and history of infectious mononucleosis, such that the associations of these 
environmental risk factors were significantly more potent among those carrying the miR-
146a risk variant. 
This thesis presents a range of studies that add significant information regarding the missing 
heritability of MS and provide more evidence for the role of classic genetic, epigenetic and 
environmental factors in the pathogenesis of MS. Additionally, this thesis demonstrates how 
Abstract 
genetic variants may influence MS clinical course and interact with environmental factors to 
enhance the effects of genetic variants in predicting critical MS progression metrics. This 
work will be useful for the scientific community in general, and will be of benefit for MS 
patients.
Table of contents 
Table of Contents 
Chapter 1:        Multiple sclerosis background and literature review ................................. 1 
1.1 The epidemiology of MS ..................................................................................................... 2 
1.2 Clinical manifestation of MS .............................................................................................. 3 
1.3 Diagnosis of multiple sclerosis ............................................................................................ 5 
1.3.1 McDonald Criteria ............................................................................................................ 5 
1.3.2 The use of conventional MRI in the diagnosis of MS ...................................................... 8 
1.4 The immunopathogenesis of MS ........................................................................................ 9 
1.4.1 The innate immune response ............................................................................................. 9 
1.4.2 The adaptive immune response ....................................................................................... 10 
1.4.3 The role of the adaptive immune system in the induction of MS ................................... 12 
1.5 Environmental factors in the development of MS .......................................................... 13 
1.5.1 Infection with Epstein-Barr virus (EBV) ........................................................................ 13 
1.5.2 Infection with HHV-6 ..................................................................................................... 15 
1.5.3 Vitamin D deficiency ...................................................................................................... 17 
1.5.4 Cigarette smoking ........................................................................................................... 18 
1.6 Genetic factors associated with MS ................................................................................. 18 
1.6.1 Linkage analysis .............................................................................................................. 19 
1.6.2 Genome-wide association studies (GWAS) .................................................................... 20 
1.6.3 GWAS in MS .................................................................................................................. 22 
1.6.3.1 The HLA region in MS ........................................................................................................ 22 
1.6.3.2 The 110 non-HLA established variants associated with MS ............................................... 25 
1.6.4 The missing heritability in MS ........................................................................................ 27 
1.6.4.1 Lower frequency variants and rare variants ......................................................................... 28 
1.6.4.2 Gene-gene interaction .......................................................................................................... 29 
1.6.4.3 Gene-environmental interaction ........................................................................................... 31 
1.6.5 Epigenetic modifications ................................................................................................. 33 
1.6.5.1 Epigenetic changes associated with MS ............................................................................... 34 
Table of contents 
1.6.5.1.1 Inflammation ................................................................................................................... 34 
1.6.5.1.2 Demyelination and remyelination ................................................................................... 36 
1.6.5.1.3 Neurodegeneration .......................................................................................................... 37 
1.6.5.2 Environmental risk factors for MS and epigenetic changes ................................................. 38 
1.6.5.3 Interaction of multiple environmental risk factors and epigenetic changes ......................... 40 
1.7 Summary ............................................................................................................................ 40 
1.8 Structure of the thesis ....................................................................................................... 42 
1.9 References .......................................................................................................................... 43 
Appendix 1.A: Publication as part of Chapter 1: “The potential role of epigenetic 
modifications in the heritability of MS” .............................................................................. 58 
Chapter 2: Genetic loci for Epstein-Barr Virus nuclear antigen-1 are associated with 
risk of multiple sclerosis ........................................................................................................ 65 
2.1 Preface ................................................................................................................................ 65 
2.2 Introduction ....................................................................................................................... 65 
2.3 Materials and methods ...................................................................................................... 68 
2.3.1 Genome-wide association analysis ................................................................................. 69 
2.3.1.1 QIMR Twin Families EBNA-1 GWAS (QTFEGWAS) ...................................................... 69 
2.3.1.2 Mexican-American families EBNA-1 GWAS (MAFEGWAS) .......................................... 70 
2.3.2 GWAS meta-analysis ...................................................................................................... 70 
2.3.2.1 EBNA-1 GWAS Meta-Analysis (EGMA) ........................................................................... 70 
2.3.2.2 MS GWAS Meta-Analysis (MGMA) .................................................................................. 71 
2.3.2.3 Shared polygenic risk between EBNA-1 GWAS and MS GWAS ...................................... 71 
2.3.2.4 SNP effect concordant analysis (SECA) .............................................................................. 72 
2.3.2.5 Genetic risk score analysis (GRS) ........................................................................................ 73 
2.3.2.6 Joint EBNA-1 and MS Meta-Analysis ................................................................................. 74 
2.3.2.7 Gene-gene interaction analysis ............................................................................................. 74 
2.4 Results ................................................................................................................................. 74 
2.4.1 HLA region as major quantitative trait loci influencing anti-EBNA-1 IgG titer ............ 74 
Table of contents 
2.4.2 Anti-EBNA-1 IgG titers as possible risk factors for the development of MS: the effect of 
HLA and non-HLA region genes ................................................................................................. 79 
2.5 Discussion ........................................................................................................................... 82 
2.6 Summary ............................................................................................................................ 84 
2.7 References .......................................................................................................................... 85 
Appendix 2.A: Publication of “Chapter 2:  Genetic loci for Epstein-Barr Virus nuclear 
antigen-1 are associated with risk of multiple sclerosis” .................................................. 106 
Chapter 3: Genetic variation in PBMC-produced IFN-γ and TNF-α association with 
relapse in multiple sclerosis ................................................................................................. 116 
3.1 Preface .............................................................................................................................. 116 
3.2 Introduction ..................................................................................................................... 116 
3.3 Methods ............................................................................................................................ 117 
3.3.1 Study design .................................................................................................................. 117 
3.3.2 Measurement of relapses ............................................................................................... 118 
3.3.3 Biological samples ........................................................................................................ 118 
3.3.4 ELISA protocol ............................................................................................................. 119 
3.3.5 SNP Identification & Genotyping ................................................................................. 119 
3.3.6 Statistical analysis ......................................................................................................... 120 
3.4 Results ............................................................................................................................... 121 
3.4.1 Cytokine SNPs to evaluate associations with TNF-α and IFN-γ production ................ 122 
3.4.2 Differential associations of TNF-α and IFN-γ with time to relapse by SNP genotype 123 
3.5 Discussion ......................................................................................................................... 125 
3.6 Summary .......................................................................................................................... 128 
3.7 References ........................................................................................................................ 130 
Appendix 3.A: Publication of “Genetic variation in PBMC-produced IFN-γ and TNF-α 
associations with relapse in multiple sclerosis ” ................................................................ 134 
Table of contents 
Chapter 4: Variation within the myelin basic protein gene predicts disease course in 
multiple sclerosis .................................................................................................................. 140 
4.1 Preface .............................................................................................................................. 140 
4.2 Introduction ..................................................................................................................... 140 
4.3 Material and Methods ..................................................................................................... 141 
4.3.1 Study design .................................................................................................................. 141 
4.3.2 Exposure & clinical course measures ........................................................................... 143 
4.3.3 Genotyping .................................................................................................................... 144 
4.3.4 Data analysis ................................................................................................................. 145 
4.4 Results ............................................................................................................................... 146 
4.4.1 Risk genotype (CT+TT) of rs12959006 directly predicts progression to MS, relapse and 
annualised change in EDSS ....................................................................................................... 146 
4.4.2 Rs12959006 genotype interacts significantly with baseline anti-HHV6 IgG levels to 
predict conversion to MS and relapse ........................................................................................ 150 
4.4.3 Discussion ..................................................................................................................... 151 
4.5 Summary .......................................................................................................................... 153 
4.6 References ........................................................................................................................ 154 
Chapter 5: Common genetic variation within miR-146a predicts disease onset & 
relapse in multiple sclerosis ................................................................................................. 159 
5.1 Preface .............................................................................................................................. 159 
5.2 Introduction ..................................................................................................................... 159 
5.3 Methods ............................................................................................................................ 161 
5.3.1 Study design .................................................................................................................. 161 
5.3.2 Exposure & clinical course measures ........................................................................... 162 
5.3.3 Genotyping .................................................................................................................... 162 
5.3.4 Data analysis ................................................................................................................. 162 
5.4 Results ............................................................................................................................... 164 
Table of contents 
5.4.1 Risk genotype (GC+CC) of rs2910164 directly predicts progression to relapse .......... 164 
5.4.2 Interactions of rs2910164 genotype with EBV related variables in predicting MS and 
 relapse. ...................................................................................................................................... 167 
5.5 Discussion ......................................................................................................................... 171 
5.6 Summary .......................................................................................................................... 174 
5.7 References: ....................................................................................................................... 174 
Chapter 6: Conclusion .................................................................................................... 177 
6.1 Genetic loci associated with EBV infection and their roles in MS risk ...................... 177 
6.2 Genetic variations within cytokines and their receptor genes in predicting MS ....... 179 
6.3 MBP and MS clinical course .......................................................................................... 181 
6.4 miR-146a in predicting disease onset and relapse ........................................................ 183 
6.5 Final conclusion of PhD .................................................................................................. 184 
6.6 Future directions ............................................................................................................. 185 
6.7 References ........................................................................................................................ 186 
Appendix: Other Publications during PhD ....................................................................... 189 
	
 
 
 
 
 
 
 
 
List of Tables 
List of Tables 
Table 1.1: Summary of the key EBV viral antigens. ............................................................... 14	
Table 1.2: Summary of the miRNAs discussed. ...................................................................... 38	
Table 2.1: Genome-wide association analysis results of QIMR twin families ........................ 77	
Table 3.1: Cohort characteristics of sample analysed. ........................................................... 122	
Table 3.2: SNP for an interactive association with TNF-α as a predictor of time to relapse. 124	
Table 3.3: SNP for an interactive association with IFN-γ as a predictor of time to relapse. . 124	
Table 4.1: Characteristics of participants with genotype data ............................................... 146	
Table 4.2: Results for rs12959006 predicting MS, relapse and annualised ΔEDSS in MS 
among participants with a classic FDE. ................................................................................. 147	
Table 4.3: Results for SNP rs12959006 predicting annualised ΔEDSS in MS including all 
bout-onset cases. .................................................................................................................... 149	
Table 4.4: Results for SNP rs12959006 interact with baseline HHV-6, baseline EBNA-1 and 
baseline EBNA-2 to predict conversion to MS and relapse in MS among classic FDEs. ..... 150	
Table 5.1: Characteristics of participants with genotype data ............................................... 164	
Table 5.2: Association between miR-146a SNP rs2910164 genotype and measures of clinical 
course. .................................................................................................................................... 165	
List of Tables 
Table 5.3: Interaction between miR-146a SNP rs2910164 with baseline EBV antibody levels 
(anti-EBNA-1 and anti-EBNA-2) and according to history of having had infectious 
mononucleosis on time to conversion to MS and relapse. ..................................................... 169	
List of Supplementary Tables 
List of Supplemental Tables 
Supplementary Table 2.1: ...................................................................................................... 100	
Supplementary Table 2.2: Top 45 significant SNPs within the HLA region ........................ 101	
Supplementary Table 2.3: The combined meta-analysis of EBNA-1 GWAS Meta-Analysis 
(EGMA) results(N = 5,555) and MS GWAS Meta-Analysis results(N = 17,698) (MGMA) 
(excluding the HLA region) ................................................................................................... 104	
Supplementary Table 2.4: Interaction analysis (p-value) results for two paired SNPs. ........ 105	
Supplementary Table 2.5: Detailed interaction results for rs2616049 (between HLA-DRB1 
and HLA-DQA1) and rs11808092 (EVI5) at each genotype level. ........................................ 105	
Supplementary Table 3.1: List of genes selected for analysis. .............................................. 133	
Supplementary Table 4-1: Results for other 7 MBP SNPs predicting CDMS, relapse and 
annualised ΔEDSS in MS among the classic FDEs. .............................................................. 157	
List of Figures 
List of Figures 
Figure 1.1: The prevalence of MS by country. .......................................................................... 3	
Figure 1.2: Classification of the course of multiple sclerosis .................................................... 5	
Figure 1.3: 2010 revision to the McDonald criteria ................................................................... 7	
Figure 1.4: Axial and sagittal FLAIR images showing common sites of MS involvement ...... 8	
Figure 1.5: Gene map of the extended HLA region ................................................................. 23	
Figure 1.6: Molecular modeling of HLA-DRB1 susceptibility alleles and resistance alleles in 
MS ............................................................................................................................................ 25	
Figure 2.1: Flow chart of the study design. ............................................................................. 68	
Figure 2.2: Anti-EBNA-1 IgG titer distribution in different age ranges for twins and their 
parents.. .................................................................................................................................... 75	
Figure 2.3: Association analysis of HLA region and EBNA-1 titers in QIMR Twin Families
.................................................................................................................................................. 76	
Figure 2.4: QQ plot for 110 non-HLA MS SNPs in the EBNA-1 GWAS Meta-Analysis 
(EGMA). .................................................................................................................................. 80	
Figure 2.5: Manhattan plot for the pooled meta-analysis of EBNA-1 GWAS Meta-Analysis 
(EGMA) and MS GWAS Meta-Analysis (MGMA) (excluding the HLA region). ................. 81	
Figure 4.1: Flow chart of the Auslong Study ......................................................................... 142	
List of Figures 
Figure 4.2: .............................................................................................................................. 148	
Figure 5.1: The predicted secondary structure of pre-miR-146a by rs2910164 polymorphism..
................................................................................................................................................ 161	
Figure 5.2: Kaplan-Meier survival plot for time to conversion to MS by category of 
rs2910164 genotype. .............................................................................................................. 166	
Figure 5.3: Kaplan-Meier survival plot for time to relapse by category of rs2910164 
genotype. ................................................................................................................................ 166	
Figure 5.4: Hazard ratios for time to convert to MS by different combinations of baseline 
anti-EBNA-1 IgG titers (Low: <=0.53, High:>0.53) and miR-146a genotype (GG, GC+CC).  
................................................................................................................................................ 168	
Figure 5.5: Hazard ratios for time relapse by different combinations of baseline anti-EBNA-1 
IgG titers (Low: <=0.53, High:>0.53) and miR-146a genotype (GG, GC+CC). .................. 169	
 
 
List of Supplementary Figures 
Lists of Supplementary Figures 
Supplementary Figure 2.1: Distribution of standardized residuals for continuous anti-EBNA-
1 titers in the QIMR sample ..................................................................................................... 90	
Supplementary Figure 2.2: Manhattan Plot for QIMR Twin Families EBNA-1 GWAS 
(QTFEGWAS) ......................................................................................................................... 91	
Supplementary Figure 2.3: QQ plot for QTFEGWAS ............................................................ 92	
Supplementary Figure 2.4: Manhattan plot for Meta-Analysis of EBNA-1 IgG GWAS fixed 
effect (EGMA). ........................................................................................................................ 93	
Supplementary Figure 2.5: Heatmap for SECA results including/ excluding HLA region ..... 94	
Supplementary Figure 2.6: Heatmap for SECA results including/ excluding HLA region ..... 95	
Supplementary Figure 2.7: Genetic Risk Score (GRS) results. ............................................... 96	
Supplementary Figure 2.8: Genetic risk score (GRS) results .................................................. 97	
Supplementary Figure 2.9: Regional plots for the significant non-HLA loci in the joint 
EBNA-1 and MS meta analysis. .............................................................................................. 98	
 
 
Papers directly arising from the work described in this thesis 
Papers directly arising from the work described in this thesis 
Papers published 
Chapter 1:  
Zhou Y, Simpson S, Jr., Holloway AF, Charlesworth J, van der Mei I, Taylor BV. 
The potential role of epigenetic modifications in the heritability of multiple sclerosis. 
Mult Scler. 2014;20(2):135-40. 
Chapter 2: 
Zhou Y, Zhu G, Charlesworth J, Simoson S, Jr., Rubicz R, Göring H, Patsopoulos 
AN, Laverty C, Wu FT, Henders A, Ellis J, van ver Mei I, Montogomery G, Blangero 
J, Curran J, Johoson M, Martin N, Nyholt D and Taylor BV. Genetic loci for Epstein-
Barr Virus nuclear antigen-1 are associated with risks of multiple sclerosis. Mult 
Scler.2016 
Chapter 3: 
Zhou Y, Taylor B, van der Mei I, Stewart N, Charlesworth J, Blizzard L, Ponsonby 
AL, Dwyer T, Pittas F and Simpson SJ. Genetic variation in PBMC-produced IFN-
gamma and TNF-alpha associations with relapse in multiple sclerosis. Journal of the 
neurological sciences. 2015 Feb 15;349(1-2):40-4. 
 
Conference presentations arising from work in this thesis 
Conference presentations arising from work in this thesis 
• Two oral presentations in MSRA meeting at Melbourne, 28-30 Oct 2015 
• Two poster presentations in ECTRIMS meeting at Barcelona, 07-10 Oct 2015 
• One oral and one poster presentations at PACTRIMS meeting, Taipei, 06-08 Nov 2014 
• Two poster presentations in 2014 Joint ACTRIMS-ECTRIMS Meeting Boston, USA, 
10-13 Sep 2014 
• One oral presentation at GeneMappers meeting 2014 at Adelaide, 11-14 May 2014 
• One oral presentation as finalist for ASMR Medical Research Week, 2014 Tasmanian 
Postgraduate Student Research Awards 
 
Awards received from the work described in this thesis 
Awards received from the work described in this thesis 
• Educational Grant Award provided by ECTRIMS meeting at Barcelona, 07-10 Oct 
2015 
• Travel Grant Award provided by China CDC for PACTRIMS meeting, Taipei, 06-08 
Nov 2014 
• Educational Grant Award provided by 2014 Joint ACTRIMS-ECTRIMS Meeting at 
Boston, USA, 10-13 Sep 2014 
 
List of abbreviations 
List of abbreviations 
 
Abbreviation Full term 
µg Micrograms 
1,25(OH)2D 1,25-dihydroxyvitamin D 
25(OH)D 25-hydroxyvitamin D 
95% CI 95 percent Confidence Interval 
APC Antigen Presenting Cell 
BMI Body Mass Index 
CDMS Clinical definite Multiple Sclerosis 
CNS Central Nervous System 
CSF Cerebrospinal fluid 
DIS Dissemination in space 
DIT Dissemination in time 
EBNA Epstein-Barr Nuclear Antigen 
EBV Epstein-Barr Virus 
EDSS Kurtzke Expanded Disability Severity Scale 
ELISA Enzyme-linked Immunosorbent Assay 
FDE First demyelination event 
GRS Genetic risk score 
GWAS Genome wide association analysis 
HERV Human Endogenous Retrovirus 
HHV Human Herpesvirus 
HHV-6 Human Herpesvirus 6 
HLA Human Leukocyte Antigen 
HLA-DRB1 Major Histocompatibility Complex, Class II, DR beta 1  
HR Hazard Ratio 
IFN-β Interferon beta 
IgG Immunoglobulin class G 
IgM Immunoglobulin class M 
IL Interleukin 
IQR Interquartile Range 
IU International Units 
Km Kilometers 
LD Linkage disequilibrium 
MBP Myelin basic protein 
MRI Magnetic Resonance Imaging 
MS Multiple Sclerosis 
MSL Multiple Sclerosis Longitudinal Study 
MSSS Multiple Sclerosis Severity Score 
nmol/L Nanomoles per Liter 
PBMC Peripheral Blood Mononuclear Cells 
PCR Polymerase Chain Reaction 
PPMS Primary-Progressive Multiple Sclerosis 
RCT Randomised Controlled Trial 
RRMS Relapsing-Remitting Multiple Sclerosis 
SD Standard Deviation 
SPMS Secondary-Progressive Multiple Sclerosis 
List of abbreviations 
SNP Single nucleotide polymorphism 
Th1 Helper T-lymphocyte class 1 
Th2 Helper T-lymphocyte class 2 
Th17 Helper T-lymphocyte class 17 
Treg Regulatory T-lymphocyte 
UK United Kingdom of Great Britain and Northern Ireland 
USA United States of America 
UVR Ultraviolet radiation 
VCA Viral Capsid Antigen 
 
Chapter 1: Multiple sclerosis background and literature review 
 
1 
Chapter 1: Multiple sclerosis background and literature 
review 
Multiple sclerosis (MS) is a chronic inflammatory autoimmune disease of the central 
nervous system (CNS) with pathological hallmarks of inflammation, demyelination, 
remyelination, and neurodegeneration. Although not fully delineated, its cause is 
thought to be an interplay between environmental and genetic factors1,2.  
MS was identified as an important clinical disorder by Jean-Martin Charcot in 18683, 
when he described three patients who had the symptoms subsequently associated with 
the disease dating back to 1855; he effectively gathered the first clinical and 
pathological observations of the condition. A landmark paper by James Dawson in the 
early 20th century marked the beginning of an improved understanding of MS etiology 
and pathogenesis4; he described the disease as “classically exhibited in irregular, 
reversible attacks, while the proportion of axonal loss could be observed in autopsy 
tissue sections as resulting from an inflammatory action of microglia”. Another 
important discovery in the comprehension of MS was the discovery in the 1930s by 
River and colleagues of the animal brain inflammation model experimental 
autoimmune encephalomyelitis (EAE)5. This model, although not a perfect analogue 
to human pathogenesis, nonetheless ushered in an era of the discovery of the 
molecular mechanisms underlying the inflammatory process involved in human CNS 
demyelinating diseases. A number of terms for the condition have been used, 
including disseminated sclerosis and encephalomyelitis disseminate, but in the 1950s, 
a consistency of nomenclature for MS was finally achieved with the publication of 
Multiple Sclerosis by Douglas McAlpine, Nigel Compston, and Charles Lumsden6.  
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In the 21st century, various technologies have allowed further understanding of MS, 
both in terms of diagnostic mechanisms in clinical practice and pathogenesis. For 
example, the use of magnetic resonance imaging (MRI) has revolutionized the 
diagnosis of MS and is useful in evaluating neuroprotection in MS.  
For identifying the role of genetic factors in the etiology of MS, perhaps the most 
powerful methods are genome-wide association studies. These studies typically 
evaluate millions of single nucleotide polymorphisms (SNPs) to identify MS 
susceptibility loci that modulate disease risk. However, currently discovered risk loci 
from such genome-wide association studies can explain only approximately 28% of 
the perceived heritability of MS, leading to the following question: where is the 
missing heritability? Moreover, in addition to the role of genetic factors in disease 
onset, the role of genetic determinants in clinical course, both in early and established 
MS, has not been as well studied. In this thesis, I present my efforts to address these 
aspects. This introductory chapter provides some background information for the 
understanding of the remainder of the thesis. 
1.1 The epidemiology of MS 
According to the latest report of the Atlas of MS 2013,7 which assessed the 
epidemiology of MS around the world, the estimated number of people with MS was 
approximately 2.3 million, increasing by approximately 200,000 since 2008. MS is 
more than twice as common among women as men. Figure 1.1 shows the prevalence 
by country; countries with large populations of European descent have the highest 
prevalences. The average age of MS onset is 30 years; only 2-5% of people with MS 
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are diagnosed under age 18, and there is some suggestion that this pediatric-onset MS 
is a separate condition. 
Figure 1.1: The prevalence of MS by country (reproduced from report7). 
 
1.2 Clinical manifestation of MS 
The course of MS can be characterized in terms of two distinctive clinical aspects: 
relapse and progression. Relapses, also known as exacerbations, attacks, or episodes, 
occur as a result of new focal inflammatory lesions or the reactivation of old lesions. 
Relapses are defined as the neurological symptom’s first occurrence, recurrence, or 
worsening with clearly noticeable onset that lasts for a stable period followed by 
partial or complete recovery8. The clinical definition of relapse typically requires the 
event to last more than 24 hours in the absence of fever or infection8.  
Progression is defined as a persistent deterioration in neurologic function, which is 
particularly evident in the progressive phases of the disease, though it is also present 
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to an extent in the relapsing-remitting form8. The primary metric for assessing 
disability is the Kurtzke Expanded Disability Status Scale (EDSS), which assigns 
scores for the functioning of eight functional systems9, and the combined score ranges 
from 0 (normal) to 10 (death due to MS) in increments of 0.5 units.  
The classifications of MS clinical subtypes are based on the presence or absence of 
relapses and progression. The most common type is relapsing-remitting MS (RRMS), 
which is characterized by intermittent relapses during periods of relative clinical 
inactivity (remission). Approximately 65% of patients with RRMS convert to 
secondary progressive MS (SPMS), which features a fairly uniform progression rate 
without relapses. The least common subtype is primary progressive MS (PPMS), 
which manifests as a slow accumulation of disability from disease onset10,11 (Figure 
1.2). 
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Figure 1.2: Classification of the course of multiple sclerosis (reproduced from 
Compston and colleagues8) 
 
1.3 Diagnosis of multiple sclerosis 
The diagnosis of MS is now based on the McDonald/Polman criteria, which include 
clinical and paraclinical assessments that are used to define requirements for 
demonstrating disease dissemination in space and dissemination in time. These 
criteria use a combination of clinical and paraclinical evidence to substantiate two 
demyelinating events separated in time and space within the central nervous system 
and for which there are no better explanations.  
1.3.1 McDonald Criteria 
The most commonly used diagnostic criteria are the McDonald/Polman Criteria, now 
in the 2010 revision iteration. For relapsing-remitting MS, this involves the 
demonstration of the dissemination of neurological demyelination events in space and 
time, whereas for the progressive-onset types, a sustained disability progression over 
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at least 12 months and supported by paraclinical evidence is necessary. Both of these 
diagnoses presume the exclusion of other potential explanatory mechanisms. The first 
iteration, the archetypal McDonald criteria, was presented in 2001 by the International 
Panel on the Diagnosis of Multiple Sclerosis12 led by W. Ian McDonald. 
Subsequently, these criteria underwent two major revisions in 200513 and 201014 that 
served to simplify the diagnostic criteria, enhance the diagnostic sensitivity and 
specificity, make better use of improved MRI technology, and improve the 
applicability in other non-Caucasian populations (Figure 1.3).  
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Figure 1.3: 2010 revision to the McDonald criteria (reproduced from Polman 
and colleagues14) 
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1.3.2 The use of conventional MRI in the diagnosis of MS 
Conventional MRI, which uses magnetic fields and radio waves to measure brain 
lesion number, volume, and changes over time, has become a critical tool in the 
diagnosis of MS. The widely used techniques for conventional MRI include T2-
weighted, fast fluid-attenuated inversion recovery (FLAIR) and T1-weighted imaging, 
with and without contrast (gadolinium) administration15. Compared with T2-weighted 
MRI, FLAIR imaging has greater sensitivity for detecting white matter 
hyperintensities in the periventricular and cortical/juxtacortical regions, which are 
shown as bright areas against a gray background15 (Figure 1.4).  
Figure 1.4: Axial and sagittal FLAIR images showing common sites of MS 
involvement (reproduced from Andreadou15). 
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1.4 The immunopathogenesis of MS 
The immune system plays an important role in the development of MS. The human 
leukocyte antigen (HLA) locus, located on chromosome 6, is the most well-
established MS genetic risk factor; the HLA class II allele DRB1*1501 has the 
strongest association of any genetic determinant studied (OR=3.1) for the 
development of MS16. The HLA genes encode the major histocompatibility complex 
(MHC) proteins MHC I and II, which are essential components of antigen 
presentation to CD4+ and CD8+ T lymphocytes. The largest genome-wide 
association studies to date by the International Multiple Sclerosis Genetics 
Consortium (IMSGC) discovered 110 common genetic variants associated with MS, 
most of which were enriched in inflammatory pathways17. In line with these genetic 
findings, histopathological studies have found the infiltration of mononuclear 
phagocytes, T lymphocytes, B lymphocytes, plasma cells, and dendritic cells in acute 
white matter lesions, which are important diagnostic MRI markers for MS18. In the 
last 20 years, the use of immunotherapies that target these immune system 
components have been demonstrated to be particularly effective in the early stage of 
MS for reducing relapse rates and disability progression. However, in the progressive 
phase of the disease, immunotherapeutics have had little or no clinical effects19, 
suggesting that as the disease activity progresses, the inflammatory process decreases, 
and other mechanisms drive the underlying disease processes.  
1.4.1 The innate immune response 
There are two key aspects to the immune system, the innate and adaptive immune 
responses, both of which are involved in the development of MS20. The innate, or 
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nonspecific, immune response is an evolutionarily older defense mechanism that acts 
nonspecifically against pathogens. Although many cells are involved in the innate 
immune responses in the CNS, the predominant cells involved in the pathological 
process are macrophages and microglia20. Macrophages, which are generated through 
a series of changes after the circulating blood monocyte enters the tissue, can not only 
cause tissue damage through direct neuroinflammatory processes but are also 
involved in the remyelination process that repairs the tissue21. Work in the EAE 
model suggests that the deleterious macrophages are primarily differentiated from 
inflammatory monocytes, whereas the remyelinating macrophages are derived from 
patrolling monocytes22. A similar dichotomy is observed for microglia, which not 
only play an important role during CNS inflammation but also seem to act in CNS 
surveillance to maintain local environmental stability23,24.  
1.4.2 The adaptive immune response 
Unlike the innate immune system, the adaptive immune system is highly specific to 
particular epitopes, with antigen-specific receptors on T-cells and B-cells20. T-cells 
mature in the thymus and consist of two major subsets—CD4+ helper T-cells and 
CD8+ cytotoxic T-cells25. In the development process, antigen-binding domains are 
reshuffled into forms that can bind virtually any structural epitope, including those 
that comprise host cell structures. The potential negative impacts of this type of 
recognition are addressed in the process of thymic negative T-cell selection, resulting 
in the induction of T-cell apoptosis after the binding of the host self-epitopes and 
therefore preventing the subsequent possible appearance of an autoimmune response. 
An autologous selection process occurs in the bone marrow during B-cell 
development to eliminate the creation of self-reactive autoimmune B-cells. However, 
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because the selection process is sometimes incomplete, some autoreactive T- and B-
cells can persist in the peripheral immune system. These autoreactive cells may never 
be activated. However, they maintain the potential to be activated by encountering a 
self-antigen that binds to their T- or B-cell receptor or a sufficiently similar 
pathogenic epitope via the mechanisms of molecular mimicry, or they can even be 
activated via bystander activation, potentially resulting in autoimmune disease26.  
CD4+ T-cells can be differentiated into four major subsets: Th1, Th2, regulatory T-
cells (Treg), and Th17. Th1 cells secrete pro-inflammatory cytokines, including TNF-
α, interleukin-2 (IL-2), and the prototypical Th1 cytokine IFN-γ, all of which induce a 
cell-mediated immune response against intracellular pathogens that does not involve 
antibodies27. Th2 cells produce IL-4, IL-5, IL-13, and IL-10, among others, which 
stimulate a humoral immune response against extracellular pathogens that involve 
antibodies 27. Treg cells produce regulatory cytokines, particularly TGF-β, which 
downregulates the immune response, maintaining homeostasis between immune 
activation and immune suppression28. It has been shown that TGF-β prevents Th1 and 
Th2 differentiation and initiates Th17 differentiation in combination with IL-6. The 
Th17 cells secrete lineage-specific factor RAR related orphan receptor C (RORC) and 
have been identified as a distinct linage of CD4+ T-cells29; they also produce pro-
inflammatory cytokines including IL-17, IL-21, IL-22, and IL-2630,31, typically during 
more long-term immune responses.  
In the CNS, antigens presented by the cells (microglia and B-cells, etc.) expressing 
HLA class II molecules can be recognized by CD4+ T-cells, whereas antigens 
presented by HLA class I molecules can be recognized by CD8+ T-cells. In MS, the 
clonal expansion of both CD4+ T-cells and CD8+ T-cells can be observed in brain 
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lesions, suggesting that antigen-specific T-cell responses contribute to the 
development of the pathology32,33. 
1.4.3 The role of the adaptive immune system in the induction of MS 
Despite the emerging consensus regarding the involvement of the adaptive immune 
system in the development of MS, its role in the induction of the early inflammatory 
phase and the progressive phase of MS remains controversial; specifically, it is not 
known which process happens first. One hypothesis suggests that the first event—the 
activation of a CNS antigen-specific immune response—may take place in the 
periphery, followed by the invasion of autoreactive immune cells into the CNS. This 
hypothesis is supported by most findings from EAE models with similar processes. In 
MS, as a result of molecular mimicry, bystander activation, or viral persistence with 
or without epitope spreading26, autoreactive T-cells and B-cells are activated in the 
peripheral tissues, which then migrate to the lymph nodes and ultimately invade the 
CNS. The cytokines and antibodies released by the cells can target the myelin sheath 
and glial cells, resulting in the demyelination process that underlies the earliest phases 
of the disease. During the chronic inflammation phase, the unbalanced 
demyelination/remyelination process can lead to the formation of lesions18. The 
inflammation process continues to drive the progression of the disease. In the lesions 
of patients with progressive disease, the immune cell infiltration correlates with 
axonal injury, and the aggregation of B-cells in the meninges is associated with the 
increasing severity and clinical manifestations of the disease34.  
However, this hypothesis has been subject to criticism because the loss of 
oligodendrocytes and the activation of microglia can be observed in the normal-
appearing white matter without the infiltration or presence of lymphocytes18. 
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Therefore, another hypothesis has been proposed—that the initial pathological event 
for MS is the neurodegenerative process, which is followed by a secondary activation 
of innate and adaptive immune responses. Supporting this hypothesis, the currently 
used immunomodulatory interventions have limited success in changing the disease 
course for progressive MS35-37. Despite the apparent conflict, it should be noted that 
both processes are not mutually exclusive; both intra- and extra-CNS immune 
activation may act synergistically to contribute to the development of MS.  
1.5 Environmental factors in the development of MS 
The uneven distribution of MS by geography and the change in risk as people migrate 
suggest that environmental factors acting at the personal and population levels have a 
role in the development of MS38,39. Although the environmental factors involved have 
not all been identified, extensive studies support three environmental risk factors in 
MS etiology: infection with human herpesviruses, particularly Epstein-Barr virus 
(EBV) and human herpesvirus 6 (HHV-6); vitamin D deficiency; and cigarette 
smoking38-40. These factors can exert effects long before MS becomes clinically 
evident. 
1.5.1 Infection with Epstein-Barr virus (EBV) 
EBV, also called human herpesvirus 4 (HHV-4), is a ubiquitous double-stranded 
DNA virus with a diameter ranging from 122 to 180 nm that is covered by 
nucleocapsid, viral tegument, and envelope41. After the acute infection of B-cells and 
epithelial cells, EBV undergoes lytic replication and produces infectious virions42. It 
then goes into a latency phase—Latency I, Latency II, or Latency III, depending on 
the cell type—in which only a portion of the EBV genes are expressed. In this stage, 
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the EBV genome exists as an episome in the host cell’s nucleus and is copied by 
cellular DNA polymerase42. A summary of the key viral antigens, which are 
expressed during the lytic and latent stages and can be used for serological tests for 
EBV infection, is shown in Table 1.1.  
Table 1.1: Summary of the key EBV viral antigens. 
Protein/antigen Stage Description 
EBNA-1 latent+lytic The first EBV protein detected and the only viral protein expressed in all forms of latency 
EBNA-2 latent+lytic EBNA-2 is the main viral transactivator 
EBV-EA lytic early antigen 
EBV-VCA lytic viral capsid antigen 
EBV infection is common in the general population (~90%), but its frequency is even 
higher among persons with MS, typically approaching 100%43. The first evidence that 
EBV might play a role in the pathogenesis of MS was reported in 1979 when Fraser 
and colleagues found that peripheral blood lymphocytes from MS patients had an 
increased tendency to transform to EBV-induced B lymphocytes in vitro44. In a nested 
case-control study involving over 3 million US military personnel, Levin and 
colleagues found that, before the age of 20, the mean anti-EBNA IgG antibody titers 
were similar for controls and individuals who in the future would develop MS. 
However, a remarkable increase in anti-EBNA antibody titers was observed for 
individuals who later developed MS, while the level for controls remained constant45. 
Levin and colleagues also found that the risk for developing MS was extremely low 
for individuals with no EBV infection, but the risk increased sharply for those 
individuals after EBV infection46. The consistency of the association of anti-EBNA 
IgG seropositivity in developing MS was validated in a recent meta-analysis47.  
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To explain the mechanisms by which EBV might contribute to the development of 
MS, four hypotheses have been proposed. In the molecular mimicry hypothesis, 
activated T-cells after EBV infection could cross-react and attack EBV antigens and 
CNS antigens because both antigens share similar epitopes48,49. In the bystander 
damage hypothesis, the direct and specific immune response against EBV infection 
and/or reactivation results in bystander damage to the CNS50. The αB crystalline 
hypothesis posits that the small heat shock protein αB crystalllin, which is derived 
from oligodendrocytes, is expressed after EBV infection. Then, the immune system 
mistakenly targets the αB crystalllin by generating a CD4+ T-cell response, resulting 
in demyelination51. In the fourth hypothesis, the EBV-infected autoreactive B-cell 
hypothesis, EBV-infected autoreactive B-cells infiltrate the CNS, clonally expand in 
the target site, and activate autoreactive T-cells, initiating an autoimmune attack on 
the CNS52.  
1.5.2 Infection with HHV-6  
HHV-6, which has two variants (HHV-6A and HHV-6B) and shares some genetic 
attributes with EBV, was first discovered in 198653. Both variants are double-stranded 
DNA viruses; the HHV-6A viral genome is 159 kb long and contains 119 unique 
open reading frames (ORFs), whereas the HHV-6B viral genome is 162 kb with 119 
unique ORFs54,55. Their genomic architectures can be categorized into two major 
regions: the unique long region (~143 kb) consists of the genes involved in 
replication, cleavage, and viral genome packaging, and the short region (~8 kb) 
contains the genes responsible for viral integration into host chromosomes55. The 
genome is packaged within a capsid surrounded by tegument and then encased in a 
lipid envelope derived from the host cell membrane56.  
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HHV-6 infection is highly prevalent (>90%) in the general population; the primary 
infection occurs in early childhood, which then establishes a latent infection within 
peripheral blood mononuclear cells (PBMCs)57 and saliva58. The ORF U94 transcript 
is the only molecular marker that can be detected during latency and may control the 
establishment and maintenance of these processes56.  
The first study that provided evidence supporting the potential role of HHV-6 in MS 
was performed by Challoner and colleagues59. The authors found the presence of anti-
HHV-6 monoclonal antibodies specific to virion proteins in MS-derived 
oligodendrocytes, but these antibodies were absent in control individuals. In addition, 
in some cases, the presence of these antibodies was located around MS plaques and 
not within the surrounding CNS white matter. However, the role of HHV-6 in MS 
remained controversial, and subsequent studies reported contrasting results. One study 
showed significantly higher anti-HHV-6 IgM in MS sera compared to controls,60 
whereas others reported similar titers of anti-HHV6-IgM and IgG between MS and 
controls61. In PBMCs from MS patients, Chapenko and colleagues62 observed active 
HHV-6 mRNA transcription. However, Rotala and colleagues63 did not observe 
HHV-6 mRNA expression; one explanation may be that all of the patients in their 
study were at advanced stages of the disease and received anti-inflammatory 
medication. Interestingly, the authors performed a second study on patients64 with 
early stages of MS with no medication and found that the HHV-6 virus was 
replicating in various parts of the CNS closely associated with active demyelinating 
regions.  
In longitudinal studies, consistent results show that increased anti-HHV-6 IgG titers 
predict a worse clinical outcome (relapses and disability) in MS patients65-67. A 
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potential explanation the involvement of HHV6 in MS is molecular mimicry because 
HHV-6 shares significant sequence homology (HHV-6 U24, residues 4-10) with 
myelin basic protein (MBP, residues 96-102). This homology is relevant, given the 
key role of MBP in maintaining the integrity of the myelin sheath; MBP dysfunction 
can result in the development of demyelinating diseases such as MS68. Research has 
also found that the level of MBP-reactive T-cells is elevated in MS, potentially 
allowing these cells to recognize and initiate an immune response towards both MBP 
and HHV-668.  
1.5.3 Vitamin D deficiency  
The geoepidemiology of MS correlates not only with age at EBV infection but also 
with winter ultraviolet radiation (UVR) exposure and vitamin D deficiency40,69. In 
individuals of European descent, vitamin D is predominantly produced upon the 
photolysis of precursor sterols in the skin following exposure to UV, whereas dietary 
vitamin D intake is a relatively minor contributor70,71. The biologically active form of 
vitamin D is 1,25-dihydroxyvitamin D (1,25(OH)2D), and the major circulating and 
diagnostic form is 25-hydroxyvitamin D (25(OH)D), the optimal levels of which are 
disputed but thought to be at least 75 nmol/L for immunomodulatory functions71. In a 
nested case-control study, non-Hispanic white individuals in the highest quintile of 
25(OH)D levels (>99 nmol/L) showed a 62% lower risk for developing MS compared 
to those in the lowest quintile (<66 nmol/L)72. The mechanism by which vitamin D 
exerts a protective effect on MS is unclear, but its immunomodulatory effects and/or 
the actions of the ubiquitous vitamin D receptor, which functions in the regulation of 
many genes, including those found in nervous and immune system cells, are thought 
to be involved.  
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1.5.4 Cigarette smoking 
In addition to the diverse negative impacts on health of tobacco use and particularly 
smoking, smoking is suggested to have a role in MS onset and progression. Unlike 
EBV infection and vitamin D/UV deficiency, cigarette smoking cannot explain the 
uneven distribution of MS by geography and the altered risk upon migration. 
However, the evidence supports smoking as an important risk factor in MS38. 
MS risk in ever-smokers is approximately 50% higher than never-smokers, and 
studies have shown a direct association with the duration and intensity of 
smoking73,74. Possible mechanisms that may explain the effects of smoking on MS 
risk include the disruption of the blood-brain barrier by nicotine75, the alteration of 
normal immune function, and inflammation induced by smoking76. Smoking has been 
recognized to elevate important markers of inflammation and autoimmunity such as 
C-reactive protein, intercellular adhesion molecule-1, and E-selectin76. Furthermore, 
cigarette smoke contains an array of potent oncogenic compounds, and thus an impact 
on DNA and RNA is highly probable.  
1.6 Genetic factors associated with MS 
The earliest evidence that genetic factors might be involved in the development of MS 
came from the findings of familial aggregation and MS risk variation among ethnic 
groups living in the same geographical regions. Compared with the age-adjusted risk 
in the general population, the recurrence risk increases to 1% for second degree and 
third degree relatives and further increases to 3% in first degree relatives77-79. Twin 
studies have consistently shown that the concordance rate in monozygotic twins 
(25%) is five times higher than for dizygotic pairs80,81. Among first degree but non-
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biological relatives (adopted) living with the index case, the risk for MS was 
significantly lower than for biological relatives and not clearly different from the 
overall population risk82. The same is true for offspring recurrence rates, in which 
children of one MS affected parent had lower risk than when both parents had MS83. 
Taken together, this evidence suggests that in addition to environmental exposures, 
genetic factors also influence an individual’s susceptibility to MS. The advances in 
identifying the genetic factors derive primarily from linkage analysis and genome-
wide association analysis, which we will explore below.  
1.6.1 Linkage analysis 
The concept of linkage analysis is based on the observation that genes located 
physically close to each other on a chromosome remain linked during meiosis84. In 
the latter half of the twentieth century, it was the primary mode for statistical genetic 
mapping of Mendelian and complex traits with familial aggregation85. A logarithm of 
odds (LOD) score ≥3, which is computed as the logarithm of the odds that the loci are 
linked divided by the odds that the loci are unlinked, is generally considered evidence 
of linkage.  
Despite the success of linkage analysis in other neurodegenerative diseases such as 
Parkinson’s disease84, it has been less successful in MS. Unlike other complex 
diseases, it is rare to find more than three or four affected individuals within families; 
it is also thought that the existence of rare, highly penetrant alleles in MS is 
uncommon if it occurs at all86. In late 2005, the IMSGC performed the largest non-
parametric genome-wide linkage screen in 730 multiple MS families. They found 
significant linkage within the HLA locus with a peak LOD score of 11.7, whereas 
none of the loci outside the HLA locus reached statistical significance for linkage87.  
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1.6.2 Genome-wide association studies (GWAS) 
Given that common variants have relatively modest effects on the development of 
complex diseases such as MS (OR ranging from ~1.05 to 1.30 for non-HLA loci17), 
studies have shifted from linkage analysis to association analysis. Accordingly, 
GWAS utilizing the genomic variation marker, the single nucleotide polymorphism 
(SNP), have become the preferred mapping tool88. To increase efficiency and cost, 
GWAS typically use a multistage design. In stage one, a full set of SNPs is genotyped 
in a relatively small number of samples, and a subset of SNPs with a liberal p-value 
threshold are then selected for follow-up. In stage two and beyond, as applicable, the 
SNPs selected from stage one are genotyped in a larger sample size. Finally, p-values 
from the different stages are combined, and a p-value of 5.0x10-8 (Bonferroni 
correction of p-value 0.05 for 1 million independent tests) is widely used as the 
conservative genome-wide significance threshold89.  
Since the first GWAS publication in 2005 and continuing until 2016, GWAS have 
successfully identified over 1,800 loci that confer susceptibility to more than 600 
complex diseases90. However, there are some major challenges for GWAS. The first 
is population stratification, in which systematic differences of allele frequencies 
between cases and controls are due to different ancestry91. If not properly corrected, 
this can lead to an increasing number of false positive results. A common method for 
measuring population stratification is the calculation of the genomic control (λGC) 92-
94, which is defined as the median χ2 (1 degree of freedom) association statistic across 
SNPs divided by its theoretical median under the null distribution. If λGC =1, this 
suggests no population stratification is present, whereas λGC >1 suggests possible 
population stratification is present or may indicate the presence of other confounders 
Chapter 1: Multiple sclerosis background and literature review 
 
21 
such as cryptic relatedness95. In GWAS, a λGC<1.05 is generally considered to be 
acceptable for presenting association results91. To adjust for population stratification, 
methods such as principal components analysis and multidimensional scaling analysis 
have been used. However, these methods cannot account for other confounders such 
as cryptic relatedness.  
Another major challenge is deriving the multiple testing thresholds, because 
thousands to millions of tests are conducted. Currently, the simplest and most widely 
used method is Bonferroni correction. However, this method can sometimes be 
excessively conservative because some markers are in linkage disequilibrium (LD), 
leaving the effective number of independent tests (Neff) much lower than the actual 
number of tests conducted (N). Many researchers96 have proposed algorithms to 
establish the correlation among tests and calculate the Neff, upon which N is replaced 
by Neff in the corresponding formula of Bonferroni correction. Another widely used 
correction method is to determine the false discovery rate (FDR)97, which estimates 
the proportion of false positives from the significant results (α=0.05). Under the null 
hypothesis that there are no true associations for the GWAS, the p-values of the 
associations would follow a uniform distribution from 0 to 1. The gold standard 
correction method used in GWAS is permutation testing98, although it can be 
computationally intensive. Permutation testing generates the empirical distribution of 
test statistics for a specified dataset assuming the null hypothesis is true. It then 
randomly reassigns the dataset samples’ phenotypes, while the genotypes are kept the 
same. A predefined number of replications are repeated to generate an empirical 
distribution with resolution equal to the number of replication cycles. These methods 
have already been incorporated into genetics analysis tools such as Plink99. 
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1.6.3 GWAS in MS 
The first MS GWAS was published in 2007 by the IMSGC, and it identified 
associations with variants in both IL7R and IL2RA3100. Since this first MS GWAS 
publication, only 15 genome-wide association studies have been published86,101. The 
susceptibility role of the HLA region has been replicated in all 15 GWAS analysis, but 
the successful identification of new risk loci has required a large number of subjects. 
The first GWAS (sample size <5,000) only identified two non-HLA SNPs, whereas 
the latest GWAS published by the IMSGC in 2013 included 29,300 cases and 104,185 
controls and identified 97 statistically independent non-HLA SNPs17.  
1.6.3.1 The HLA region in MS 
The extended HLA gene complex, which primarily includes HLA class I, class II, and 
class III genes, and the extended region, is located on the short arm of chromosome 6 
and spans a region of 7.6 Mb102. The HLA class I region includes classical class I 
genes (HLA-A, -B, and -C), genes encoding the MHC I proteins that present 
endogenous antigens to CD8+ T-cells. The HLA class II region includes classical 
class II genes (HLA-DP, -DQ, and -DR), genes encoding the MHC II proteins that 
present exogenous antigens to CD4+ T-cells. The HLA class III region includes the 
genes encoding components of the complement system102. The gene map of the 
extended HLA region is shown in Figure 1.5.  
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Figure 1.5: Gene map of the extended HLA region (reproduced from Horton and 
colleagues102) 
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The association of the HLA locus as a major susceptibility region for MS has been 
validated in all populations and in different subtypes of MS86. However, due to the 
strong linkage disequilibrium within the region103, it is hard to identify true 
independent risk loci. The thorough work by Patsoupolous and colleagues utilized 
imputation methods to investigate the independent effects in the HLA region using 
5,091 MS and 9,595 healthy controls104. They found that the most significant variant 
was HLA-DRB1*15:01 (OR=2.92), which is in agreement with other published 
results16,87. They also performed a conditional analysis by adding the top significant 
variants as model covariates and identified another nine statistically independent 
effects within the extended HLA region, including the following: five HLA-DRB1 
(HLA-DRB1*03:01, HLA-DRB1*13:03, HLA-DRB1*04:04, HLA-DRB1*04:01, and 
HLA-DRB1*14:01) and one HLA-DPβ1 (rs9277489/Leu65) in class II and one HLA-
A (HLA-A*02:01) and two HLA-B (HLA-B*37:01 and HLA-B*38:01) in class I. 
Cumulatively, all these independent effects accounted for 14.2% of the total variance 
in MS susceptibility.  
Functional studies have suggested a possible functional role for HLA-DRB1 in 
susceptibility to MS. The shape and charge of the P4 pocket in the HLA molecule 
containing HLA-DRB1*15:01 is distinct from other HLA-DRB1 molecules (Figure 
1.6). Such a difference would lead to high affinity binding to the MS autoantigen 
MBP and potentially result in a more severe inflammatory response105,106.  
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Figure 1.6: Molecular modeling of HLA-DRB1 susceptibility alleles and 
resistance alleles in MS, reproduced from Oksenberg and colleagues106 
 
1.6.3.2 The 110 non-HLA established variants associated with MS 
To date, GWAS studies have identified 110 non-MHC susceptibility variants, 
showing moderate effects with ORs ranging from ~1.05 to 1.30. Of the 110 SNPs, 15 
are coding variants, whereas 35 are in high LD with coding variants according to the 
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prediction tool Variant Effect Predictor107. However, upon further prediction of the 
damaging effects of these coding variants using PolyPhen108 and SIFT109, only 14 are 
missense, and 7 are possibly damaging to the transcriptional product. By checking 
whether the SNPs are quantitative trait loci for expression (eQTL) using an eQTL 
database (University of Chicago), researchers found that 15 SNPs are eQTLs and that 
16 SNPs are in LD with SNPs that are eQTLs86. The IMSGC has undertaken a further 
GWAS combining all genotyping MS experiments to date from approximately 40,000 
cases and 40,000 controls and has increased the number of associated SNPs to 193 
(manuscript under preparation).  
The primary role of these established MS risk loci has been in the T-cell-mediated 
inflammation process16. Although inflammation itself has been causally linked to 
neurodegeneration, risk genes that are immune independent and primarily act in a 
neurodegenerative role remain largely undiscovered. It is likely that these immune-
independent risk genes have not been discovered because almost all MS GWAS have 
used a case-control study design, thereby necessarily focusing on initiating events (the 
first hallmark of MS, the inflammation process in greater than 85% of cases) rather 
than severity and the neurodegenerative pathways involved in MS progression110. Of 
these studies, only three GWAS101,111,112 have focused on MS severity. The results 
were not consistent, although two of the studies111,112 demonstrated a significant 
association of GRIN2A, which encodes a member of the glutamate-gated ion channel 
protein family, with the protein products that affect the efficiency of synaptic 
transmission and are possibly involved in memory and learning. Larger studies that 
focus on MS severity must be performed to confirm these findings and potentially 
identify other novel genes. 
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For MS, efforts to identify susceptibility loci that predict the MS clinical course 
(relapse, disability progression) are still in their comparative infancy relative to onset-
associated genetic studies. Recently, we investigated the association between 52 non-
MHC MS risk alleles16 and disease severity in a large meta-analysis that included 
7,125 MS cases. A weighted genetic risk score (wGRS) was calculated for each MS 
patient using the log value of the discovery odds ratios as the weight for each of the 
52 non-MHC risk alleles. The number of risk alleles for each SNP was multiplied by 
the weight for that variant, and then the sum across all 52 variants was calculated. 
This wGRS was not strongly associated with disease severity after adjusting for 
cohort, gender, age of onset, and HLA-DRB1*15:01 genotype. After restricting the 
analysis to cases with disease duration ≥ 10 years, all associations were null (p-value 
all ≥ 0.50). No single SNP was associated with disease severity after adjusting for 
multiple testing113. 
1.6.4 The missing heritability in MS 
Cumulatively, however, these loci (110 non-HLA + HLA) can only explain 
approximately 28% of the perceived heritability of MS17. The exact component of MS 
risk that is heritable is difficult to determine due to the impact of environmental 
factors, but estimates based on twin studies and MS families suggest that the risk may 
be between 15 and 40%2. Therefore, our current level of genetic knowledge can 
explain in the region of 5 – 8% of the risk of MS, depending on ethnicity and 
environment. 
This leads to the following question: where is the missing heritability? The strategy 
we discussed previously, which is to focus on SNPs that predict clinical course using 
a longitudinal study design, may be able to explain part of the missing heritability 
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problem in MS. Other hypotheses include lower frequency variants and rare variants, 
gene-gene interaction, gene-environmental interaction, and epigenetics.  
1.6.4.1 Lower frequency variants and rare variants 
A current popular hypothesis suggests the presence of lower frequency variants (0.5% 
< MAF (minor allele frequency) < 5%) and rare variants (MAF < 0.5%) that exert a 
much larger effect (OR > 2) may account for a large fraction of this missing 
heritability114. A GWAS based on the “common disease-common variants 
hypothesis”, seeking to examine SNPs with MAF > 5% that exert small to modest 
effects (OR<1.3), could not accurately capture the lower frequency/rare variants. 
Thus, researchers now favor a shift toward the use of next generation sequencing 
(NGS) technologies to identify these rarer variants, either by sequencing the extended 
genomic regions strongly indicated in GWAS or simply sequencing the whole 
genome115. However, attempts to discover relevant rare variants have not been as 
fruitful as expected. The first whole-exome sequencing in MS was published in 2011 
and included the sequencing of forty-three individuals with MS (1 from each family). 
A rare variant in the CYP27B1 gene that results in the complete loss of gene function 
was identified116. However, in subsequent independent replication studies, this result 
could not be confirmed117-119. Recently, Hunt and colleagues performed sequencing 
for the coding exons of 25 GWAS risk genes in 24,892 subjects with six autoimmune 
disease phenotypes (MS included) and 17,019 controls. Their results did not support 
the hypothesis that unobserved rare causal variants resulted in significant associations 
at common tag variants. Instead, they concluded that rare coding region variants at 
known loci have a negligible role in common autoimmune disease susceptibility120. 
The 1000 Genomes Project has revealed that on average, each person carries some 
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proportion of rare variants, but their role in the development of disease could not be 
presumed if no other functional studies were performed to validate them121. 
Therefore, other researchers have argued that rare variants may be unlikely to 
contribute significantly to the heritability in MS. Although controversial, this will 
remain a hot area of study in the near future. Interestingly, the IMSGC has presented 
in poster form the preliminary results of its large exome array study in MS. This 
experiment has been extremely difficult and has thus far yielded only a small number 
of potential rare variant targets that do not significantly add to the heritability of MS, 
suggesting that this hypothesis is unlikely to explain the bulk of missing heritability. 
1.6.4.2 Gene-gene interaction 
Thus far, GWAS have been successful in identifying susceptibility loci that exhibit 
additive and independent effects on traits using a single locus analysis strategy. 
However, for complex diseases such as MS, where genes may not act in isolation but 
interact with each other through complex mechanisms, suggests that analyses that 
take into account gene-gene interactions may yield greater effects on MS risk and 
clinical course. Therefore, analyzing the statistical gene-gene interactions, which are 
defined as the interaction variance explained by the combinations of causal variants 
that were not due to their independent effects, may explain a portion of the missing 
heritability of MS122,123.  
Regression models were widely used to test for the interaction of two or more genetic 
loci that contribute to disease risk123. For binary outcomes (cases and controls), the 
most straightforward approach to analyze the two loci interactions was to define two 
logistic regression models, one that takes into account only marginal effects of both 
SNPs and another with a full logistic regression that includes pairwise interaction 
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between the two SNPs. A likelihood ratio test with four degrees of freedom can then 
be used to test whether there is a difference between the two models124. However, 
these methods have some challenges to exhaustively search for interactions using 
GWAS data, because the number of tests would exponentially increase with the 
number of SNPs included, which is not only time consuming but also raises 
significant multiple testing issues123.  
Therefore, in MS, the reported gene-gene interaction results were largely based on the 
plausible candidate gene /pathway approach or by selecting a liberal p-value (for 
example, p < 1.0x10-4) for the SNPs in a GWAS discovery stage and then testing the 
interactions between them. The most commonly identified gene-gene interactions 
were genes within the HLA region125-129 or non-HLA genes that interact with HLA 
genes130,131. For HLA gene interactions, Lincoln and colleagues found interactions 
between HLA-DQA1*0102 and HLA-DRB1*15 within the HLA class II region, in 
which HLA-DQA1*0102 strongly increased MS risk in the presence of HLA-
DRB1*15 while showing a protective role in its absence125. The interaction of HLA-
DRB1*15 with HLA-DRB1*01 not only predicts MS risk126,127 but also influences the 
clinical course of MS128. The latest work by the IMSGC, which used 17,465 and 
30,385 controls to further substantiate the class II HLA interactions, found the 
following two new interactions: HLA-DQA1*01:01-HLA-DRB1*15:01 and HLA-
DQB1*03:01-HLA-DQB1*03:02129. For interactions between HLA and non-HLA 
genes, the ANZgene consortium130 found a statistical interaction for SNPs within the 
non-HLA gene EVI5 and HLA-DR15; these results were further validated by Johnson 
and colleagues131. For non-HLA gene interactions, using a knowledge-driven 
interaction analysis, Bush and colleagues132 found significant interactions for genes 
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enriched in calcium signaled cytoskeletal regulation, in which CHRM3 interacts with 
MYLK, PLCβ1 interacts with PLCβ4, and ACTN1 interacts with MYH9.  
1.6.4.3 Gene-environmental interaction 
Recognition and emphasis is growing that gene-environmental interactions, which are 
defined as the joint effects of genes and environmental factors that cannot be 
explained based on their independent marginal effects, also accounted for a part of the 
missing heritability of MS133,134. Two primary models are used to investigate this 
form of interaction. One interaction model is the multiplicative model, in which the 
joint effects of genetic and environmental factors on the relative risk of disease differs 
with the product of the relative risks of each factor separately. Another interaction 
model is the additive model, in which the joint effect differs with the sum of the 
relative risks of each factor separately133.  
To test and identify gene-environmental interactions, the widely used study design is 
the case-control study, in which genetic factors and environmental exposures are 
measured with the recruitment of disease cases and samples of disease-free 
controls135. In a population-based case-control study, van der Mei and colleagues 
found a significant interaction between HLA-DR15 and infant sibling exposure in 
MS; the combined effect of HLA-DR15 positivity and low infant sibling exposure 
(cumulative exposure to younger infant siblings (< 1 year) before the subjects were 
aged 6 years) 3.9 fold greater than expected136. To further explicitly evaluate the 
relationship of the combined effects of having known risk factors (HLA-DR15 
genotype, the prior acquisition of infectious mononucleosis, high anti-EBV nuclear 
antigen IgG status, low lifetime sun exposure, low 25(OH)D level, and having ever 
smoked), they performed an incident case-control study using cases with a first 
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clinical diagnosis of central nervous system demyelination (FCD) and population-
based controls. They discovered a significant interaction on the additive scale 
between HLA-DR15 and a history of infectious mononucleosis in predicting FCD 
onset. The five known risk factors accounted for 63.8% of the FCD onset, mostly 
driven by HLA-DR15 genotype, smoking, and lifetime sun exposure137.  
However, results produced using the above study design can only suggest association 
but not causality, because this design typically retrospectively investigates for 
evidence of interactions that existed before disease onset. The important advantage of 
the case-control design is in the study of rare diseases, because it is relatively easier to 
recruit these samples through specialized centers that identify and diagnose the 
disease. However, case-control studies are subject to significant sources of bias, for 
example, survival bias, diagnosis bias, surveillance bias, etc.135,138 By contrast, the 
prospective cohort study design, which investigates representative samples of the 
population before disease onset and follows until the specified endpoints occur, 
significantly reduces the weaknesses and biases of a case-control design. The results 
derived from this design can provide evidence for causality because it identifies the 
factors that predispose an individual to the development of a disease in the latter 
follow-up period. The prospective study standardizes and details the collection of 
exposure information and follows all participants in a systematic way. Therefore, the 
environmental factors, especially with respect to gene-environmental interactions, can 
be more precisely assessed, and this study design is less prone to bias compared with 
case-control designs135.  
Compared to the more commonly published gene-environmental interactions in 
predicting MS using a case-control design (detail reviewed in134), the use of 
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prospective studies assessing the gene-environmental factors in predicting the MS 
clinical course is in its infancy because these studies typically require many years of 
follow up. In work by our group using a prospective cohort of 141 participants with 
RRMS and followed between 2002-2005, Rui and colleagues found a significant 
interaction between rs2248359 in CYP24A1 and the 25(OH)D level in predicting 
relapse; carriers of the CC genotype showed protection for relapse with increased 
levels of 25(OH)D139. In another study using the same cohort, two novel genes 
(CYP2RA and PRKCB) were identified that interact with 25(OH)D levels in 
predicting relapse140. In chapters 3, 4, and 5, I will discuss in detail our novel findings 
using such a strategy to investigate the gene-environment interactions in predicting 
the MS clinical course.  
1.6.5 Epigenetic modifications 
Epigenetics refers to a functionally relevant changes of gene expression without 
permanent modification of the DNA sequence141. In MS, epigenetic changes can 
mediate the response to environmental signals (e.g., EBV infection, vitamin D 
deficiency, and smoking)38,39, which can then also influence gene expression. 
Epigenetic mechanisms include DNA methylation, the modification of nucleosomal 
organization, and miRNA-associated post-transcriptional gene silencing 142.  
DNA methylation is the most extensively studied epigenetic mechanism. Methylation 
predominantly occurs by adding methyl groups (-CH3) at carbon-5 of cytosine amino 
acids in regions of the genome called CpG islands, which contain highly frequent 
repetitions of cytosine and guanine and are typically found in gene promoters143. 
Histone modifications include acetylation, methylation, citrullination, 
phosphorylation, and ubiquitination; each is distinguished by the addition of a 
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chemical structure to specific histone amino acids to alter their structure and thus their 
activity144.  
MicroRNAs (miRNAs) are a family of 21- to 25-nucleotide noncoding small RNAs, 
which play a key role in post-transcriptional gene silencing by targeting message 
RNAs (mRNAs), primarily at the 3’ untranslated regions, and thus controlling the 
translation of mRNAs into proteins145.  
In MS, these epigenetic mechanisms have been involved in the processes of 
inflammation, demyelination, remyelination, and neurodegeneration in MS, thus 
explaining part of the heritability of MS by altering the target gene expression.  
1.6.5.1 Epigenetic changes associated with MS 
1.6.5.1.1 Inflammation 
Inflammation is an important mechanism of CNS damage in MS, and the proper 
transcriptional control of genes involved in the immune responses is mediated in part 
by epigenetic regulation. Kumagai and colleagues found that SHP-1, a negative 
regulator of proinflammatory signaling, had significantly greater promoter 
methylation in leukocytes in more than a third of MS subjects compared with healthy 
controls146, potentially leading to decreased SHP-1 expression and increased 
leukocyte-mediated inflammation. A study of CD4+ T-cells from RRMS patients 
showed significantly greater demethylation of the FOXP3 and IL-17A loci compared 
to healthy controls. They further showed that the demethylation of FOXP3 can inhibit 
Th1 and Th2 cell differentiation while promoting Treg and Th17 cell lineage 
commitment, whereas the hypomethylation of IL-17A can lead to increased 
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differentiation towards the Th17 cell lineage147. In EAE, an animal model of CNS 
inflammation, brain inflammation was primarily mediated through the activities of 
Th17 cells, whereas Th1 cells were the primary causes of inflammation in the spinal 
cord. In addition to discrete levels of each T-cell type, the balance between Th17 and 
Treg cells can affect disease status; the balance between Th1 and Th2 can thus lead 
not only to injury but also repair in the CNS148.  
Most of the studies focusing on miRNAs in inflammation and MS are in agreement 
that miRNA dysregulation favors some T-cell differentiation and promotes disease 
progression. In CD4+ T-cells isolated from RRMS patients, miR-17-5p, which can 
target lipid kinases that regulate lymphocyte development, activation, and survival, is 
highly expressed in RRMS patients compared to controls149. Guerau-de Arellano and 
colleagues found increased expression of miR-128 and miR-27b microRNAs in the 
naïve T-cells of MS patients and increased expression of miR-340 in memory T-cells. 
The authors concluded that these altered expression levels lead to the inhibition of 
Th2 cell development and favor a pro-inflammatory Th1 response. miR-128, miR-
27b, and miR-340 directly suppress the expression of B lymphoma Mo-MLV 
insertion region 1 homolog (BMI1), and miR-340 also suppresses the expression of 
interleukin-4 (IL4), resulting in an immune profile shift from Th2 to Th1150. 
Comparing the miRNA profile in Treg cells from 12 RRMS patients and 14 healthy 
controls, miR-25 and miR-106b were downregulated in cases compared to controls. 
These two miRNAs act on CDKN1A/p21 and BCL2L11/Bim and therefore modulate 
the TGF-β signaling pathway, which is involved in Treg cell differentiation and 
maturation151. By analyzing peripheral blood mononuclear cells (PBMCs) from 43 
MS cases and 42 healthy controls, Du and colleagues found that Th17 differentiation 
was partially controlled by miR-326152. Moreover, miR-326 overexpression was 
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highly correlated with disease severity in patients with MS and EAE mice. They also 
found that miR-326 promoted Th17 differentiation by targeting and blocking the 
expression of Ets-1, whose function is the inhibition of the differentiation of naïve T-
cells toward Th17152.  
1.6.5.1.2 Demyelination and remyelination 
CNS inflammation may lead to demyelination and oligodendrocyte death, resulting in 
many of the clinical manifestations of MS. Early in the course of disease, these insults 
can be mild and reversible, with remyelination occurring thereafter153. Later in the 
disease course, however, the repair of this damage is increasingly incomplete or 
wholly unresolved, leading to increasing neurological damage and functional deficits.  
Mastronardi and colleagues demonstrated that during the demyelination of white 
matter in MS patients, the promoter of peptidylarginine deiminase type-2 (PAD-2) 
was demethylated at cytosine residues in the CpG islands, leading to its 
overexpression in the brain. However, this change was only found in MS and was not 
found in other neurological diseases, including Alzheimer’s disease, Parkinson’s 
disease, and Huntington’s disease154. PAD-2 can destabilize myelin basic protein 
(MBP) and the myelin multilayers, rendering myelin vulnerable to autoimmune 
attack155. Mastronardi and colleagues further revealed that in normal-appearing white 
matter from MS patients and EAE animal models, nucleosomal histone H3 can be 
citrullinated by another peptidylarginine deiminase, PAD-4.156 In the early stages of 
MS, marked histone H3 deacetylation is found in oligodendrocytes. This increased 
histone H3 deacetylation correlates with the impaired differentiation of 
oligodendrocytes and may lead to impaired remyelination in MS patients157.  
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Junker and colleagues established miRNA profiles from active and inactive MS 
lesions158, finding that miR-214 and miR-23a were upregulated in both lesion types. 
During oligodendrocyte differentiation, both miR-214 and miR-23a are 
overexpressed, indicating that they may be involved in remyelination. They found that 
miR146a, which is primarily involved in the regulation of inflammation, was only 
upregulated in active brain lesions, whereas miR-219 and miR-338-5p were repressed 
only in inactive MS lesions. One of the target genes of miR-219 is ELOVL7, which 
maintains the integrity of myelin and axons in the CNS of adult mice159. miR-219 and 
miR-338-5p can also target the genes Sox6, Hes5, and Zfp238, inhibiting the 
differentiation of oligodendrocyte precursors and therefore affecting the 
remyelination process160,161. Another study showed that miR-155, miR-338, and miR-
491 are upregulated in patients with a more progressive disease course. The 
overexpression of these miRNAs inhibited the translation of their target genes (aldo-
keto reductase family members C1 and C2), which are involved in neurosteroid 
synthesis. In humans, neurosteroids have an important role in the regulation of 
myelination, neuroprotection, and the growth of axons and dendrites162. These 
researchers came to the conclusion that the shift of miRNA expression can 
significantly affect the regulation of demyelination and remyelination in MS.  
1.6.5.1.3 Neurodegeneration 
To date, there are no specific studies exploring the epigenetics of neurodegeneration 
associated with MS; however, we have interesting leads from other conditions. 
Chestnut and colleagues identified a link between DNA methylation and neuron death 
by using cultured NSC34 cells163. In cultured spinal cord neurons, the overexpression 
of Dnmt3a, which is responsible for DNA methylation, induced degeneration, 
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whereas the inhibition of Dnmt3a protected cultured neurons from apoptosis. Further 
studies in samples from cases with amyotrophic lateral sclerosis (ALS) found similar 
effects. These results indicate that DNA methylation might contribute to 
neurodegeneration164 in MS patients. Because neurodegeneration develops 
concurrently with inflammatory demyelination, the epigenetic changes involved in 
inflammation and demyelination may also play important roles, although there is 
currently no direct evidence for this. The miRNAs that discussed above were 
summarized in Table 1.2 
Table 1.2: Summary of the miRNAs discussed. 
Diseases processes in MS miRNAs 
Inflammation miR-17-5p,miR-128,miR-27b,miR-340,miR-25,miR-106b and miR-326 
Demyelination and 
remyelination 
miR-214,miR-23a,miR-146a,miR-219,miR-
338-5p,miR-155,miR-338 and miR-491
1.6.5.2 Environmental risk factors for MS and epigenetic changes 
Environmental risk factors can exert effects long before MS becomes clinically 
evident. Recent studies have revealed that the effects of these environmental risk 
factors on MS risk are mediated by epigenetic changes.  
In EBV-transformed B-cells, Riley and colleagues found that EBV miRNAs 
cooperated with host miRNAs to target host mRNAs, particularly interacting with 
members of the miR-17-92 miRNA cluster, which induce lymphomas and inhibit 
apoptosis, and with miR-142-3p and miR-155, which are highly abundant 
immunomodulatory miRNAs165. In MS, miR-142-3p expression has been linked to 
immune tolerance166, whereas miR-155 has been shown to associate with T-cell 
differentiation and promote CNS inflammation in EAE167. In addition, in EBV-
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induced nasopharyngeal cancer168, the enzymes DNMT1, DNMT3a, and DNMT3b 
increased the methylation of tumor suppressor gene promoters, thus reducing the 
expression of these genes.  
Clinical trials in MS have demonstrated that the vitamin D has dose-dependent effects 
on the immune system169; higher vitamin D doses are associated with a greater 
reduction in T-cell proliferation169,170. Part of the effects of vitamin D on immune 
function may be via the induction of epigenetic changes that modulate the immune 
response. A single study has examined the effects of 1,25(OH)2D3 on human IL-17A 
production using CD4+ T-cells, and it provides some support for such a mechanism. 
This study showed that 1,25(OH)2D3 directly repressed the transcription of the 
proinflammatory cytokine locus IL-17 by the dissociation of histone acetylase activity 
in the IL-17A promoter and the recruitment of HDAC2 to the nuclear factor for 
activated T-cells (NFAT) binding sites, thus preventing its binding and the subsequent 
enhancement of IL-17A expression171. These results from one study alone emphasize 
the need for further work in this area. 
By examining blood samples from adolescents whose mothers smoked during 
pregnancy, Toledo-Rodrigues and colleagues found that prenatal exposure to maternal 
cigarette smoking was associated with higher promoter methylation of brain-derived 
neurotrophic factor (BDNF), which supports the growth and differentiation of new 
neurons172. Maccani and colleagues found that three miRNAs, miR-16, miR-21, and 
mi4-146a, were downregulated as a result of maternal cigarette smoking during 
pregnancy173. Thus, cigarette smoking may modulate DNA methylation and miRNA 
activity in MS. However, there is currently no published research on the effects of 
such changes in MS. 
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1.6.5.3 Interaction of multiple environmental risk factors and epigenetic changes 
Environmental risk factors and epigenetic changes do not occur through a single 
mechanism but through a complex interaction of several factors; they can interact and 
act synergistically. Epidemiological studies suggest that the risk for developing MS is 
much higher in the presence of multiple environmental risk factors. For example, the 
association between higher anti-EBNA IgG titers and increased MS risk is 
approximately two-fold greater among ever smokers compared to never smokers in 
some but not all studies174,175. Research suggests that miRNAs can regulate DNA 
methylation and histone modification176-178. In turn, these modifications can also 
regulate the expression of miRNAs179. As discussed earlier, each environmental risk 
factor can act via epigenetic effects to modulate MS. It is possible that the epigenetic 
changes caused by smoking influence the epigenetic changes caused by EBV or 
vitamin D deficiency, and vice-versa. Environmental risk factors and epigenetic 
changes associate with each other through a complex network, gradually 
accumulating effects and possibly amplifying the risk for MS. These networks and 
interactions may be highly complicated and act in different directions depending on 
the levels of exposure. Consequently, the study of gene-environment interactions and 
the interplay of epigenetics require careful studies of large MS cohorts in which all 
relevant confounders, both genetic and environmental, are measured and controlled 
for in analyses. 
1.7 Summary 
It is now well established that both environmental and genetic factors contribute to 
and interact in the development of MS. The well-established environmental factors 
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include infection with EBV and HHV-6, vitamin D deficiency, and cigarette smoking. 
Despite the success of genetic studies (linkage analysis and GWAS studies) in 
identifying the role of the MHC region and 110 non-MHC regions in the development 
of MS, the currently described causal genetic variants do not explain the majority of 
the heritability of MS, resulting in “missing heritability”. Hypotheses to explain the 
missing heritability include lower frequency variants and rare variants, gene-gene 
interactions, gene-environmental interactions, and epigenetics. However, significant 
challenges exist in discovering the drivers of the missing heritability. For the lower 
frequency variants and rare variants hypothesis, large exome array studies in MS have 
yielded to date only a small number of potential rare variant targets that do not 
significantly add to the heritability of MS. For gene-gene interaction, multiple testing 
issues have limited its use at the GWAS scale. For gene-environmental interaction, 
the use of prospective studies assessing genetic and environmental factors in 
predicting the MS clinical course typically requires many years of follow up and the 
concurrent assessment of these factors in a systematic way. Unlike the GWAS that 
can be conducted using blood samples, epigenetic changes are cell-specific, and these 
changes are difficult to monitor in brain tissue.  
Despite these challenges, we proposed three ways in this thesis to address some of the 
missing heritability. First,  combine both environmental and genetic factors to predict 
MS using a cross-sectional study design and large sample size. For example, although 
most studies have shown that higher levels of antibodies against the EBV virus (anti-
EBNA-1 IgG titer) are associated with higher MS risk, few studies have tried to 
determine which genes are associated with EBNA-1 titers and how these genes 
contribute to MS risk.  
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Second, use a prospective cohort study design with participants followed for a period 
of time to identify the single gene, gene-gene interactions, and gene-environmental 
interactions in predicting the clinical course.  
Third, examine the functional variation within MS-related miRNA genes and 
determine how this variation can predispose one to MS. 
1.8 Structure of the thesis 
This thesis covers a variety of topics from my PhD research, but it mainly focuses on 
the three aspects discussed above: genetic susceptibility for MS (Chapter 2), genetic 
determinants of clinical course (Chapters 3-4), and functional variation in miRNA 
genes creating a predisposition to MS (Chapter 5). 
In Chapter 2, I hypothesize that an altered immune response to EBV 
infection―manifested by increased anti-EBNA-1 IgG titers or a potentiated 
inflammatory response to EBV infection―may be influenced by genetic factors and 
that these genetic variants can also create a predisposition to MS. To test this 
hypothesis, I performed a genome-wide association study of anti-EBNA-1 IgG titers 
in 3,599 individuals from an unselected twin family cohort followed by a meta-
analysis with data from an independent EBNA-1 GWAS. I then examined the shared 
polygenic risk between the EBNA-1 GWAS (effective sample size (Neff) = 5,555) and 
a large MS GWAS (Neff = 15,231). 
In Chapter 3, I hypothesize that SNPs within genes for relevant cytokines and their 
receptors modulate the previously demonstrated associations of PBMC-produced 
cytokines, TNF-α and IFN-γ, with relapse, thus providing additional information 
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about these cytokine effects and the roles of these genes in MS. I tested this 
hypothesis using The Southern Tasmanian Multiple Sclerosis Longitudinal Study 
(MSL), which followed a cohort of 203 persons with clinically defined MS
 
living in 
southern Tasmania, Australia from 2002 to 2005.  
In Chapter 4, I hypothesize that variation in myelin basic protein altered the clinical 
course (conversion to MS after a first demyelinating event, relapse rate, and 
annualized change of disability) of MS. I tested this hypothesis using the 
Ausimmune/AusLong Longitudinal Study―an ongoing > 10-year prospective cohort 
study following a population of 282 patients initially identified with a first 
demyelinating event (FDE) suggestive of, but not diagnostic for, MS. 
In Chapter 5, I hypothesize that polymorphisms in the miR-146a gene predict the MS 
clinical course (conversion to MS after a first demyelinating event, relapse rate, and 
annualized change of disability) of MS. We tested this hypothesis using the 
Ausimmune/AusLong Longitudinal Study as above. 
Finally, in Chapter 6, I have summarized the main findings of my thesis and suggest 
directions for future work.  
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Chapter 2: Genetic loci for Epstein-Barr Virus nuclear 
antigen-1 are associated with risk of multiple sclerosis 
2.1 Preface 
The Epstein-Barr virus (EBV) has been extensively studied as an environmental 
causative factor in MS. However, which genes are associated with the level of 
immune response to EBV and how these genes contribute to the development of MS 
remain largely unknown. Thus, we performed a genome-wide association study 
(GWAS) in a large twin family cohort recruited in Queensland, Australia to study the 
genetic drivers of elevated titers of Epstein Barr Nuclear Antigen 1 (EBNA-1). 
EBNA-1 titers have been strongly associated with MS risk, and conversion to EBNA-
1 positivity is directly correlated with EBV infection. We conducted a meta-analysis 
combining these results with the Mexican-American family GWAS that examined the 
same question. We examined the shared polygenic risk utilizing our EBNA-1 GWAS 
meta-analysis results and the results from a large, well-validated MS GWAS meta-
analysis to determine the genetic architecture of anti-EBNA-1 immune responses and 
whether these loci were over-represented in MS cases compared to healthy controls, 
thus potentially representing novel MS susceptibility loci. This chapter was published 
in Multiple Sclerosis Journal in 20161 (Appendix 3.A). 
2.2 Introduction  
Epstein-Barr virus (EBV) is a double-stranded DNA human herpesvirus also known 
as HHV-4, which infects more than 90% of the world’s adults and persists as a 
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lifelong latent infection2. It primarily infects B-lymphocytes and permanently 
transforms them into latently infected lymphoblastoid cell lines, which  produce a 
group of viral proteins, including EBV nuclear antigens (EBNAs) and latent 
membrane proteins3. Infection with EBV has been associated with the development of 
autoimmune diseases including multiple sclerosis (MS), systemic lupus erythematous 
and rheumatoid arthritis4. Despite the high prevalence of EBV infection―only a 
small number of infected individuals will develop one of these diseases5.  
EBV nuclear antigen-1 (EBNA-1) may act as an important viral antigen in MS 
pathogenesis6,7. Recent work has suggested that HLA-dependent and independent 
immune responses to EBNA-1 are important drivers of MS pathogenesis and may 
modulate effects on MS risk of protective and deleterious HLA antigens8. 
Additionally, EBNA-1-specific T-cells that cross react with myelin have been 
demonstrated9, and anti-EBNA-1 antibodies have been described in cerebrospinal 
fluid oligoclonal bands in MS cases10. Higher anti-EBNA-1 titers have been 
associated with a worse outcome in MS, both clinically11 and radiologically12. 
A number of studies have observed an association between anti-EBNA-1 IgG titers 
and MS risk7,13,14. In a study of US military personnel who were anti-EBNA-1 IgG 
positive at study entry, the relative risk of MS over an average follow-up of five years 
was 36 times higher among those with high anti-EBNA titers compared with those 
with low titers. Importantly, in this study, in blood samples collected before the age of 
20, the mean anti-EBNA-1 IgG titers were identical between participants who later 
developed MS and age and sex-matched controls that remained healthy. However, 
after the age of 20, the anti-EBNA-1 IgG titers in those that later developed MS 
increased four-fold, while that of controls remained constant13. Similarly, in ten cases 
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who were seronegative for anti-EBNA-1 IgG at their first blood sample who 
subsequently developed MS, all became seropositive generally within a few months 
of MS onset15. These findings suggest that the elevation in anti-EBNA-1 IgG titers 
may either directly predispose to the development of MS or may be a biomarker of 
immune dysregulation that results in an increased risk of MS16.  
Recent work in Mexican-American families17 suggested that particular HLA variants 
are associated with elevated anti-EBNA-1 IgG titers. Thus, we hypothesized that an 
altered immune response to EBV infection―manifested by increased anti-EBNA-1 
IgG titers or a potentiated inflammatory response to EBV infection―may be 
influenced by genetic factors, and that these genetic variants may also predispose to 
MS.  
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2.3 Materials and methods  
A flow chart of the study design is shown in Figure 2.1. 
Figure 2.1 Flow chart of the study design. EBNA-1: EBV nuclear antigen-1; 
GWAS: genome wide association analysis study; SNP: single nucleotide 
polymorphism; EA: Effect allele; LD: linkage disequilibrium; Q-Q plot: quantile-
quantile (q-q) plot. 
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2.3.1 Genome-wide association analysis 
2.3.1.1 QIMR Twin Families EBNA-1 GWAS (QTFEGWAS) 
In total, 3,760 individuals from 1,020 families in the Queensland Institute of Medical 
Research (QIMR) Twin Family Cohort Study were studied. Details of the clinical 
protocol for blood collection and processing have been described elsewhere18,19. For a 
more detailed description of the sample, please see Supplementary Table 2.1. The 
ImmunoWELL EBNA IgG Test kit (GenBio, San Diego, CA) was used for detection 
of anti-EBNA-1 IgG in human serum (N = 3,760) at the Monash Antibody 
Technologies Facility, Monash University. The following values were used to 
determine the status for seropositive/seronegative according to the manufacturer’s 
protocol: negative (<200 units/mL); equivocal (200-300 units/mL); and positive 
(>300 units/mL). To determine which data transformation should be used for analysis, 
the distribution of standardized residuals was examined by treating anti-EBNA-1 IgG 
titers as both continuous and categorical values (four groups: <250; 250-1,001; 1,001-
2,000; >2,000 (units/mL)). The residuals were derived from generalized linear model 
(GLM) analysis by using box effect, row effect and column effect as fixed factors 
while also controlling for sex, age, age×sex, age2 and age2×sex. Because the residuals 
were normally distributed (Supplementary Figure 2.1), we utilized these modelled 
residuals as continuous outcomes and predictors in place of as-measured anti-EBNA-
1 IgG.  
Genome-wide genotyping was performed using the Illumina 610-Quad BeadChip and 
imputed to extend the genomic coverage to 2.4 million SNPs20. As part of quality 
control, individuals from families with pedigree errors and a call rate <0.95 were 
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excluded. SNPs with a call rate <0.95 or with a low imputation quality score (R2 < 
0.3), minor allele frequency <0.01 in the population, or significant deviation from 
Hardy-Weinberg equilibrium (PHWE < 1.0×10-6), were excluded. In total, the data from 
3,599 individuals from 992 families, and 2,428,106 SNPs passed quality control and 
were used for further analysis.  
The association analysis of imputed dosage scores was performed using a family-
based score test implemented in Merlin-offline21 which corrects for relatedness of 
twins and family members. To detect whether there were independent effects at 
significant loci we carried out conditional analysis by including the most significant 
SNP as a covariate.  
2.3.1.2 Mexican-American families EBNA-1 GWAS (MAFEGWAS) 
We used summary results from the Mexican-American families EBNA-1 GWAS17. In 
brief, the SNPs were typed on several versions of Illumina’s microarrays and quality 
controls were done according to standard requirements. A total of 944,565 genotyped 
SNPs from 1,956 individuals within 63 families were available for analysis. The anti-
EBNA-1 quantitative antibody titer level was used for genome-wide joint linkage and 
association analysis in SOLAR22.  
2.3.2 GWAS meta-analysis 
2.3.2.1 EBNA-1 GWAS Meta-Analysis (EGMA) 
Summary results from the two EBNA-1 GWAS [QTFEGWAS (N = 3,599) and 
MAFEGWAS (N = 1,956)] were used to carry out a meta-analysis using an inverse 
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variance fixed-effect model in META23. Because we synthesized less than four 
studies, random effect modeling (and all tests and metrics of statistical heterogeneity) 
was inappropriate. T2 (the between studies variance) is heavily underestimated, and 
this affects Cochran Q and I2. The random effects model which uses T2 to weight, 
hence suffers as well. To facilitate comparison with p-values for all 110 established 
non-HLA risk loci recently published by the International Multiple Sclerosis Genetics 
Consortium24, we used the Direct Imputation of summary Statistics (DIST) program, 
to directly impute EGMA summary statistics based on the 1,000 genome project 
reference data. The direct imputation of summary statistics is achieved by employing 
a conditional expectation formula for multivariate normal variants and using the 
correlation structure from a relevant reference population. Details of the formula used 
please refer to paper25. Default and recommended parameters of DIST were utilized in 
this study. 
2.3.2.2 MS GWAS Meta-Analysis (MGMA) 
The MS GWAS meta-analysis was comprised of data from seven datasets of non-
overlapping case and control subjects of European descent. A total of 5,545 cases and 
12,153 controls with 2,529,394 SNPs were used for analysis. For a detailed 
description, see Patsopoulos et al26. 
2.3.2.3 Shared polygenic risk between EBNA-1 GWAS and MS GWAS 
To determine whether the SNPs associated with anti-EBNA-1 IgG titers may also 
contribute to MS risk, we first matched the genome-wide significant SNPs (P < 5×10-
8) in the EGMA with MGMA results. We also matched EGMA p-values for all 110 
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established non-HLA risk loci recently published 24. We then carried out SNP effect 
concordant analysis and genetic risk score analysis to further investigate the shared 
polygenic risk between the EBNA-1 GWAS and the MS GWAS, including and 
excluding the extended HLA region (chr6: 25-35Mb).  
2.3.2.4 SNP effect concordant analysis (SECA) 
SECA was undertaken using the EGMA and MGMA, utilizing one study as a 
discovery sample while the other acted as a target sample, and vice-versa. Subsets of 
independent autosomal SNPs were extracted via linkage disequilibrium (LD) 
clumping. The approach iterated from the first to last SNP on each chromosome 
sorted from smallest (most significant) to largest p-value (less significant) in the 
discovery sample that had not already been clumped (denoting this as the index SNP) 
and formed clumps of all other SNPs that were within 10 Mb of and not in LD with 
the index SNP (r2 > 0.1) based on HapMap2 CEU genotype data. In total, for 
autosomal SNPs including the HLA region, there were 24,722 SNPs clumped using 
the EGMA as a discovery sample, and 24,642 SNPs clumped using the MGMA as a 
discovery sample. For autosomal SNPs excluding the HLA region, there were 24,688 
SNPs clumped using the EGMA as a discovery sample, and 24,621 SNPs clumped 
using the MGMA as a discovery sample. To test for concordant SNP effects between 
the two datasets, a total of 144 key SNP subsets were examined, each generated using 
twelve P-value thresholds (P = 0.01, 0.05, 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9 and 
1.0). Fisher’s exact test was applied to test whether the overlapping effects were in the 
same direction after conditioning on their GWAS p-value, where a Fisher’s exact test 
p-value (PFT < 0.05) means the SNP effects are nominally correlated. 1,000 
permutations were performed to examine the significance of observing a specific 
Chapter 2:  Genetic loci for Epstein-Barr Virus nuclear antigen-1 are associated with 
risk of multiple sclerosis 
 
73 
proportion of subsets with correlated SNP effects―adjusted for testing all 144 subsets 
(PFTsig-permuted)27.  
2.3.2.5 Genetic risk score analysis (GRS) 
To further validate the SECA results, genetic risk scores (GRS)28 were constructed 
using the independent shared SNPs separated by <10 Mb that are not in linkage 
disequilibrium (r2 < 0.1) and selected as having the smallest p-value in the discovery 
sample with a nominally significant p-value <0.05, and in the target sample with p-
value <1.0 (the different genotyping platforms between the two datasets had no 
impact on the analysis). GRS analysis requires individual-level GWAS SNP data for 
the target sample. As only part of the genotype data for the EGMA and MGMA could 
be obtained, the first GRS analysis (EGMA as a discovery sample) used 5,862 
clumped SNPs to generate EGMA-based genetic risk scores in the MS GWAS 
obtained from dbGaP (phs000275, phs000171 and phs000139) and ANZgene (cases = 
3,252; controls = 5,725).For details on data cleaning, please refer to our previous 
paper29. The second GRS analysis (MGMA as a discovery sample) used 5,770 
clumped SNPs to generate MGMA-based genetic risk scores in the QIMR Twin 
Families EBNA-1 GWAS. For binary disease traits (cases and controls), the GRS was 
used as a predictor to test whether higher mean GRS were observed for cases (MS) 
than for controls in the target samples. For quantitative traits, the GRS was used to 
test the correlation between GRS and the target phenotype (anti-EBNA-1 IgG titers).  
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2.3.2.6 Joint EBNA-1 and MS Meta-Analysis 
To identify genetic risk factors contributing to both anti-EBNA-1 IgG titer and MS 
risk outside the HLA region, a joint meta-analysis of EGMA results and MGMA 
results was carried out using a sample size-weighted method based on p-values in 
METAL30.  The power analysis showed that to achieve 80% power for detecting a 
common variant with OR of a modest magnitude (OR=1.15) would require N=10,000 
samples. 
2.3.2.7 Gene-gene interaction analysis 
To determine whether interactions existed between the loci that were found to 
contribute to both anti-EBNA-1 IgG titer and MS risk, we defined two logistic 
regression models; one took into account only the marginal effects of both SNPs and 
the other was a full logistic regression model including a pairwise interaction between 
the two SNPs. A likelihood ratio test with four degrees of freedom was then used to 
determine whether there was any statistical difference between the two models 31. The 
datasets used for the analysis were the MS GWAS obtained from dbGaP and 
ANZgene listed above (cases = 3,252; controls = 5,725).  
2.4 Results  
2.4.1 HLA region as major quantitative trait loci influencing anti-EBNA-1 IgG 
titer 
The distributions of anti-EBNA-1 IgG titers using four groups (<250; 250-1,000; 
1,001-2,000; >2,000) in different age ranges are shown in Figure 2.2. As age 
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increased, the percentage of individuals with higher anti-EBNA-1 IgG titers increased 
dramatically. Heritability for anti-EBNA-1 IgG titers was 42%. The HLA region on 
chromosome 6 contained multiple SNPs exceeding the threshold for a significant 
association with anti-EBNA-1 IgG titers (P < 5×10-8) (Supplementary Figure 2.2). A 
Q-Q plot is shown in Supplementary Figure 2.3. Of these HLA SNPs, the most 
significant imputed SNP was rs9268923 (P = 1.22×10-11), located between the genes 
HLA-DRA and HLA-DRB5. The most significant genotyped SNP was rs2516049 (P = 
4.11×10-9; Table 2.1), located between the genes HLA-DRB1 and HLA-DQA1. 
Figure 2.2: Anti-EBNA-1 IgG titer distribution in different age ranges for twins and their 
parents. Anti-EBNA-1 IgG titers are divided into four groups (<250, 250-1000,1001-2000, >2000). 
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Figure 2.3: Association analysis of HLA region and EBNA-1 titers in QIMR Twin Families 
EBNA-1 GWAS (QTFEGWAS)(N=3,599). Results are shown (a) unconditional analysis. (b) 
conditional analysis on rs9268923. (c) conditional analysis on rs9268923 and rs2267647. The top 
significant genotyped SNP rs2516049 was also highlighted in red. SNPs with a P value <1.0x10-5 are 
highlighted in green. 
Chapter 2:  Genetic loci for Epstein-Barr Virus nuclear antigen-1 are associated with risk of multiple sclerosis 
 
77 
Table 2.1 : Genome-wide association analysis results of QIMR twin families. Here E(A) refers to the effect allele. O(A) refers to the opposite allele. 
Score refers to the imputed or genotype score of the SNP. Freq refers to the E(A) frequency. Effect corresponds to standard deviation units for the 
transformed phenotype. Children1 refers to using all the children samples, while children2 refers to only for anti-EBNA-1 IgG titers positive 
children. 
              Parents+children(N=3,599) Parents(N=1,243) Children1(N=2,356) Chidren2(N=1,488) 
SNP CHR POS E(A) O(A) SNP Type Score Freq Effect P Effect P Effect P Effect P 
              
 
 
rs9268923 6 32540813 C T Imputed 0.905 0.552 0.180 1.22´10-11 0.252 1.37´10-13 0.148 2.93´10-05 0.225 9.72´10-12 
rs9268969 6 32542327 C T Imputed 0.905 0.552 0.180 1.22´10-11 0.252 1.37´10-13 0.148 2.93´10-05 0.225 9.72´10-12 
rs6916742 6 32561169 C T Imputed 0.879 0.569 -0.176 3.12´10-11 -0.200 2.40´10-09 -0.160 5.95´10-06 -0.215 5.05´10-11 
rs2516049 6 32678378 T C Genotyped 0.999 0.666 0.162 4.11´10-09 0.210 1.31´10-09 0.142 1.36´10-04 0.180 1.68´10-07 
rs522308 6 32689900 C T Imputed 0.989 0.664 0.159 8.56´10-09 0.207 1.89´10-09 0.138 2.03´10-04 0.178 2.36´10-07 
rs11757159 6 32628250 C T Imputed 0.972 0.636 0.154 1.24´10-08 0.206 1.44´10-09 0.130 3.59´10-04 0.170 4.07´10-07 
rs9405112 6 32553578 G A Imputed 0.977 0.662 0.156 1.57´10-08 0.215 8.08´10-10 0.128 5.30´10-04 0.176 2.38´10-07 
rs9268853 6 32537621 T C Imputed 0.989 0.657 0.152 3.30´10-08 0.206 3.36´10-09 0.125 6.96´10-04 0.172 4.64´10-07 
rs9268858 6 32537736 T C Imputed 0.989 0.657 0.152 3.30´10-08 0.206 3.36´10-09 0.125 6.96´10-04 0.172 4.64´10-07 
rs9268877 6 32539125 G A Imputed 0.977 0.585 -0.146 3.35´10-08 -0.184 3.46´10-08 -0.130 2.33´10-04 -0.176 7.00´10-08 
rs7739203 6 32549533 G A Imputed 0.973 0.585 -0.145 3.90´10-08 -0.187 1.99´10-08 -0.129 2.65´10-04 -0.175 8.13´10-08 
rs7739357 6 32549619 G A Imputed 0.973 0.585 -0.145 3.90´10-08 -0.187 1.99´10-08 -0.129 2.65´10-04 -0.175 8.13´10-08 
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As the HLA region is genetically complex, with a low rate of recombination and long-
range linkage disequilibrium, we carried out two conditional analyses to check 
whether there were independent peaks, first by conditioning on rs9268923, and then 
on both rs9268923 and rs2267647 (Figure 2.3). However, after conditional analysis, 
no other SNPs showed a significant association, suggesting these top SNPs are within 
one haplotype block that contains all the variants modulating anti-EBNA-1 IgG titers.  
Association analyses were also conducted separately for parents and children 
(Supplementary Table 2.1:). Analysis of parents only (N = 1,243), implicated the 
same SNPs in the HLA region (Supplementary Figure 2.2), that were found using all 
samples: imputed SNP rs9268923 (P = 1.37×10-13) and genotyped SNP rs2516049 (P 
= 1.31×10-9; Table 2.1). In contrast, analysis of all children (N = 2,356), did not 
identify any significant SNPs in the HLA region (Supplementary Figure 2.2). 
However, once we restricted analyses to only EBNA-1 positive (>300 units/ml) 
children (N = 1,488), we again observed the same significant associations in the HLA 
region (Supplementary Figure 2.2). Q-Q plots are shown in Supplementary Figure 2.3 
respectively.  
In the EBNA-1 GWA meta-analysis (EGMA) (inflation factor, l = 1.017), 45 SNPs 
that reached genome-wide significance were located in the HLA region (P < 5.0×10-8; 
Supplementary Table 2.2). Of these, rs2516407 remained the most significant (P = 
3.32×10-20). No other loci were genome-wide significant outside the HLA region 
(Supplementary Figure 2.4). The inflation factors (l) for the analyses were close to 1, 
suggesting population stratification had minimal influence on test statistical 
distribution; therefore, we did not adjust for genomic control in our analysis. 
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2.4.2 Anti-EBNA-1 IgG titers as possible risk factors for the development of 
MS: the effect of HLA and non-HLA region genes 
The Q-Q plot (Figure 2.4) shows a significant excess of smaller EGMA p- values for 
the 110 non-HLA MS SNPs recently published by the International Multiple Sclerosis 
Genetics Consortium 24 than expected by chance (l = 1.25). In SNP effect concordant 
analysis, using the EGMA as a discovery sample, the clumped SNP effects were 
positively correlated with MGMA effects, either including (PFTsig-permuted = 0.026; 95% 
CI: 0.018 – 0.038) or excluding (PFTsig-permuted = 0.049; 95% CI: 0.037 – 0.064) the 
HLA region (Supplementary Figure 2.5). However, using the MGMA as a discovery 
sample, the clumped SNP effects were not positively correlated with the EGMA SNP 
effects, either including (PFTsig-permuted = 0.173; 95% CI: 0.151 – 0.197) or excluding 
(PFTsig-permuted = 0.157; 95% CI: 0.136 – 0.181) the HLA region (Supplementary Figure 
2.6).  
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Figure 2.4:  QQ plot for 110 non-HLA MS SNPs in the EBNA-1 GWAS Meta-
Analysis (EGMA). The 95% confidence envelope (shaded grey) was formed by 
calculating, for each order statistic (p-values ranked from smallest to largest), 
the 2.5th and 97.5th centiles of the distribution of the order statistic under 
random sampling and the null hypothesis. 
 
The SNP effect concordant analysis results (excluding the HLA) were further 
validated by genetic risk score analysis. A significantly higher GRS, constructed 
using the EGMA as a discovery sample, was observed in MS cases than controls in 
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the target dbGaP and ANZgene GWAS (P = 0.007; Supplementary Figure 2.7). In 
contrast, a GRS constructed using MGMA as a discovery sample, did not correlate 
with anti-EBNA-1 IgG titers in the target QIMR Twin Families EBNA-1 GWAS 
samples (P = 0.270, correlation coefficient = -0.030; Supplementary Figure 2.8). 
Altogether, these results indicate that the genetic risk for elevated anti-EBNA-1 IgG 
titer is positively correlated with increased MS susceptibility, whereas the reverse 
does not hold. That is, the genetic risk for MS is not positively correlated with 
elevated anti-EBNA-1 IgG titer level. 
The combined meta-analysis of the EGMA and MGMA results (excluding the HLA 
region) (l = 1.046) showed several SNP associations that reached genome-wide 
significance (P < 5.0×10-8; Supplementary Table 2.3). The approximate chromosomal 
location of the significant SNPs are shown in the Manhattan plot in Figure 2.5 and 
labelled with the nearest gene.  
Figure 2.5 Manhattan plot for the pooled meta-analysis of EBNA-1 GWAS 
Meta-Analysis (EGMA) and MS GWAS Meta-Analysis (MGMA) (excluding the 
HLA region). The 22 autosomal chromosomes separated by two different colors 
are displayed on the X-axis. The -log10(P) values are displayed on the Y-axis. 
Genome-wide association significance level is shown as the red line (P<5.0x10-8). 
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These genes include EVI5(1p22.1), EOMES(3p24.1), ILDR1(3q13.33) and 
IL2RA(10p15.1). For detailed regional plots, see Supplementary Figure 2.9. Of these, 
the most interesting gene is Ecotropic viral integration site 5 (EVI5) on chromosome 
1, in which a missense mutation SNP rs11808092 (P = 1.71×10-8) results in an amino 
acid change from glutamine to histidine. The impact of this amino acid substitution on 
the structure and function of the protein product was predicted as benign using 
PolyPhen-232, with a score of 0.003 (sensitivity: 0.98; specificity: 0.44). SIFT33 gave 
similar results (tolerated), whilst MutationAssessor34 scored it as “medium” (2.255).  
In the interaction analysis, tagged SNPs within each genome-wide significant peak 
were selected (r2 > 0.65). In total we studied five SNPs: rs11808092 (1p22.1), 
rs427221 (3p24.1), rs2255214 (3q13.33), rs2516049 (6p21.32), and rs12722561 
(10p15.1). We observed a suggestive synergistic interaction between rs2516049 and 
rs11808092 (P = 0.006; Supplementary Table 2.4, Supplementary Table 2.5).  
2.5 Discussion  
We have undertaken a large GWAS of anti-EBNA-1 IgG titers and provide strong 
evidence that the HLA region serves as the main quantitative trait locus for anti-
EBNA-1 IgG titers. Our results strongly suggest that there are shared genetic risk 
factors that influence both anti-EBNA-1 IgG titers and MS risk. Our results further 
indicate that the genetic risk for elevated anti-EBNA-1 IgG titer is positively 
correlated with increased MS susceptibility but the reverse importantly is not 
supported, i.e, MS risk genetic differences do not increase anti-EBNA-1 titers. In our 
study the heritability of anti EBNA1 titers is 42% clearly suggesting that other factors 
besides genetic differences are also important in MS pathogenesis and that there is 
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still a clear strong association with prior EBV infection in MS risk modulated by the 
individual’s genetic make-up. 
In our results the strongest non-HLA EBNA-1 association was found for EVI5. The 
major function of EVI5 is the modulation of cell cycle progression, cytokinesis and 
cellular membrane traffic35. Several studies have described the involvement of EVI5 
in the risk and severity of MS using case-control and cross-sectional study designs. 
Using the candidate gene approach, Hoppenbrouwers et al found that SNPs within 
EVI5 showed a moderate association with MS risk (OR = 1.90 – 2.01; P = 0.01)36. 
The ANZgene consortium, found a significant interaction between SNPs in EVI5 and 
HLA-DR15 in predicting MS risk (P = 0.001)37. This finding is supported by recent 
work demonstrating that EVI5 genotype is associated with a greater odds of having a 
more severe relapse among individuals who carry the risk allele of HLA-
DRB1*150138. These studies showed associations with MS parameters, but did not 
consider genetic effects in concert with anti-EBNA-1 IgG levels. Direct evidence of a 
link between EBV infection and gene expression changes has been provided by the 
work of van Aalderen et al.39, who found that EOMES expression was altered after 
EBV infection. While in another study by Parnell et al.40 analyzing the expression of 
MS associated transcription factors using whole blood, EOMES expression was 
significantly lower in MS cases compared with healthy controls.   
In addition to the correlation in genetic risk between anti-EBNA-1 IgG titer and MS, 
the observed excess of smaller EBNA-1 GWA meta-analysis p-values for the recently 
reported 110 non-HLA MS risk SNPs24,  suggests that other genetic factors likely 
influence the interaction between MS risk and EBV infection. Hence, analysis of 
larger EBNA-1 GWAS datasets and/or analysis of other markers of EBNA immune 
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responses (e.g., EBNA-2 or EBNA-3 titers) using the healthy population should 
provide a novel opportunity to identify new and characterize existing genetic risk 
factors for MS. Our findings indicate that these studies offer a powerful approach to 
identify the specific immune responses components that contribute most to MS 
susceptibility. Indeed, considering the high cost and difficulty in amassing larger 
samples of MS cases, we suggest focus could switch to performing large studies; such 
as these, aimed at identifying genetic loci influencing EBNA immune response. Such 
studies should also provide insight into other EBV-associated autoimmune diseases or 
cancers such as Burkitt’s lymphoma, nasopharyngeal carcinoma.  
In conclusion, our results suggest that genetic factors influencing differential immune 
system reactivity to EBV infection increase the risk of MS in genetically predisposed 
individuals exposed to EBV, most notably in adolescence or adult life.  
2.6 Summary 
Background: Infection with the Epstein-Barr virus (EBV) is associated with an 
increased risk of multiple sclerosis (MS).  
Objective: We sought genetic loci influencing EBV nuclear antigen-1 (EBNA-1) IgG 
titers and hypothesized that they may play a role in MS risk.  
Methods: We performed a genome-wide association study (GWAS) of anti-EBNA-1 
IgG titers in 3,599 individuals from an unselected twin family cohort, followed by a 
meta-analysis with data from an independent EBNA-1 GWAS. We then examined the 
shared polygenic risk between the EBNA-1 GWAS (effective sample size (Neff) = 
5,555) and a large MS GWAS (Neff = 15,231). 
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Results: We identified one locus of strong association within the human leukocyte 
antigen (HLA) region, of which the most significantly associated genotyped SNP was 
rs2516049 (P=4.11x10-9). A meta-analysis including data from another EBNA-1 
GWAS in a cohort of Mexican-American families confirmed that rs2516049 
remained the most significantly associated SNP (P=3.32x10-20). By examining the 
shared polygenic risk, we show that the genetic risk for elevated anti-EBNA-1 titers is 
positively correlated with the development of MS, and that elevated EBNA-1 titers 
are not an epiphenomena secondary to MS. In the joint meta-analysis of EBNA-1 
titers and MS, loci at 1p22.1, 3p24.1, 3q13.33 and 10p15.1 reached genome-wide 
significance (P < 5×10-8).  
Conclusions: Our results suggest that apart from the confirmed HLA region, the 
association of anti-EBNA-1 IgG titer with MS risk is also mediated through non-HLA 
genes, and that studies aimed at identifying genetic loci influencing EBNA immune 
response provide a novel opportunity to identify new and characterize existing genetic 
risk factors for MS. 
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Supplementary Figure 2.1 : Distribution of standardized residuals for continuous anti-
EBNA-1 titers in the QIMR sample after generalized linear model (GLM) analysis 
with box effect, row effect, and column effect as fixed factors while also controlling 
sex, age, age x sex, age2 and age2 x sex. Here the Res_con refer to the residual value 
of anti-EBNA-1 titres, while Frequency refer to the number of samples. 
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Supplementary Figure 2.2: Manhattan Plot for QIMR Twin Families EBNA-1 GWAS 
(QTFEGWAS) a) using all samples (N = 3,599). b) only parents (N = 1,243). c) only 
children (N = 2,356).d) only children with positive anti-EBNA-1 IgG titres (N = 
1,488) 
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Supplementary Figure 2.3: QQ plot for QTFEGWAS using a) both parents and 
children (N = 3,599). b) only parents (N = 1,243). c) only children (N = 2,356). d) 
only children with positive anti-EBNA-1 IgG titres (N = 1,488) e)QQ plot for EGMA 
(effective N = 5,555). f) QQ plot for MGMA excluding HLA region (chr6: 25Mb-
35Mb) (effective N = 20,786). 
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Supplementary Figure 2.4 : Manhattan plot for Meta-Analysis of EBNA-1 IgG 
GWAS fixed effect (EGMA): QIMR Twin Families EBNA-1 GWAS (QTFEGWAS) 
(N = 3,599) and Mexican-American families EBNA-1 GWAS (MAFEGWAS) (N = 
1,956). 
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Supplementary Figure 2.5: Heatmap for SECA results including/ excluding HLA 
region using EBNA-1 GWAS Meta analysis (EGMA) as the discovery sample 
(dataset1), and the MS GWAS Meta analysis (MGMA) as the target sample 
(dataset2). PFTsig-permuted refers to permutation p value for the observed significant 
Fisher’s test . The four colors represented all the 4 outcomes for the Fisher’s 
tests(OR>=1,P<=0.05; OR>=1,P>=0.05; OR<=1,P<=0.05; OR<=1,P>=0.05) 
a. Including HLA region.  PFTsig-permuted= 0.026 (95% CI: 0.018-0.038)
b. Excluding HLA region. PFTsig-permuted=0.049 (95% CI: 0.037-0.064)
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Supplementary Figure 2.6: Heatmap for SECA results including/ excluding HLA 
region using the MS GWAS Meta analysis (MGMA) as the discovery sample 
(dataset1), and the EBNA-1 GWAS Meta analysis (EGMA) as the target sample 
(dataset2). 
a. Including HLA region. PFTsig-permuted = 0.173 (95% CI: 0.151-0.197)
b. Excluding the HLA region. PFTsig-permuted= 0.157 (95% CI: 0.136-0.181)
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Supplementary Figure 2.7: Genetic Risk Score (GRS) results using the EBNA-1 
GWAS meta analysis (EGMA) as the discovery sample, and dbGaP and ANZgene 
(MS cases) as target samples. a) The EBNA-1 constructed GRS values (5,682 SNPs 
with PEGMA ≤ 0.05) are higher in MS than controls and this difference is significant 
using an independent sample t-test (p=0.007) and borderline significant using a 
nonparametric test (p=0.082). b) Using the enriched SNP set (597 SNPs with PEGMA ≤ 
0.05 and PMGMA ≤ 0.1) for which the correlation of SNP effects is strongest, the result 
is more significant whether using an independent sample t test (p=0.003) or 
nonparametric test (p=0.002).  Below are the plot results for the nonparametric test. 
The mean rank value was used to compare which was higher. A.   
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Supplementary Figure 2.8: Genetic risk score (GRS) results using the MS GWAS 
meta-analysis (MGMA) as the discovery sample, and the QIMR Twin Families 
EBNA-1 GWAS as a target sample. The MS constructed GRS values (5,770 SNPs 
with PMGMA ≤ 0.05) do not correlate with the anti-EBNA-1 titres in QIMR Twin 
Families EBNA-1 GWAS, whether using Pearson correlation (P = 0.752, r = -0.013) 
or Spearman’s correlation (P = 0.453, r = -0.030); indicating that MS case status itself 
does not predict anti-EBNA-1 titres.  Below is the scatter plot for the correlation. 
Here the GRS_5770 refers to the constructed GRS values using 5,770 SNPs, while the 
Res_EBNA1 refers to the residuals of anti-EBNA-1 titres in QIMR Twin Families, as 
using actual titers was not appropriate due to batch effects for the measurement of 
anti-EBNA-1 IgG. We therefore utilized modelled residuals. 
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Supplementary Figure 2.9: Regional plots for the significant non-HLA loci in the joint 
EBNA-1 and MS meta analysis.   
a. Regional plots for the significant loci (1p22.1). The top significant SNP is 
rs11808092 in the gene EVI5. 
 
b. Regional plot for the significant loci (3p24.1). The top significant SNP is 
rs427221. 
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c. Regional plot for the significant loci (3q13.33). The top significant SNP is
rs2255214.
d. Regional plot for the significant loci (10p15.1).  Significant SNP rs17147986
is used as reference.
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Supplementary Table 2.1:  
a. Descriptive data for QIMR Twin Families (N = 3,760 individuals). MZ 
represents monozygotic twins. DZ represents dizygotic twins. 
 
 
 
 
b. The number of complete pairs and single twins. 
 
  
Twins Zygosity   
MZ DZ Total 
Single Twin 24 55 79 
Twin Pair 333 563 896 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Groups 
Sex Age (years) 
Female Male Mean Std. Deviation 
Parents Fathers 0 661 47.54 5.22 
  Mothers 725 0 45.31 4.53 
Children MZ 473 466 15.48 1.61 
 DZ 465 467 15.5 1.6 
  Siblings 270 233 15.26 2.87 
  Total 1933 1827 26.84 15.31 
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Supplementary Table 2.2: Top 45 significant SNPs within the HLA region in EBNA-1 GWAS Meta-Analysis (EGMA)(effective sample size: 
5,555) and related P-values for these SNPs in MS GWAS Meta-Analysis (MGMA)(effective sample size: 17,698) (fixed effect).  Of these, 40 
SNPs are in complete LD (r2 = 1) and showed the same direction of effect; these are in weak LD (r2 = 0.089) with the other 5 SNPs (r2 = 1 for 
these five SNPs) which showed opposite direction of effect. E(A) represents the effect allele. Effect(EGMA) represents the beta value for each 
SNP in EGMA. P(EGMA) represents the p-value for SNPs in EGMA. P(QTFE) represent the p-value for QTFEGWAS(parents+children). 
P(MAFE) represents the p-value for MAFEGWAS. OR(MS) represents the OR value for each related SNP in MGMA. P(MS) represents the p-
value for each related SNP in MGMA. 
 
SNP CHR POS E(A) O(A) Effect(EGMA) P(EGMA) P(QTFE) P(MAFE) OR(MS) P(MS) 
rs2516049 6 32678378 T C 0.204 3.32E-20 4.11E-09 6.43E-14 1.321 4.49E-20 
rs9268853 6 32537621 T C 0.188 9.81E-18 3.30E-08 6.18E-12 1.415 4.59E-30 
rs2395185 6 32541145 G T 0.184 3.97E-17 6.95E-08 9.76E-12 1.413 1.02E-29 
rs204999 6 32217957 A G 0.180 9.78E-14 7.03E-05 1.14E-13 1.133 1.01E-04 
rs3891175 6 32742445 C T 0.194 1.41E-13 5.25E-06 2.89E-11 1.139 1.31E-04 
rs3130284 6 32248465 T C 0.186 9.15E-12 3.24E-05 5.81E-11 1.166 1.37E-05 
rs3096697 6 32242488 G A 0.186 9.68E-12 3.33E-05 6.07E-11 1.159 5.25E-04 
rs2395182 6 32521295 T G -0.169 1.04E-11 5.22E-06 2.47E-07 0.426 3.68E-163 
rs3134608 6 32225949 T G 0.184 1.70E-11 2.17E-05 3.94E-10 1.151 7.05E-05 
rs3132965 6 32254975 A G 0.183 1.93E-11 3.35E-05 2.92E-10 1.168 1.08E-05 
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rs3134945 6 32254470 C A 0.183 1.93E-11 3.24E-05 2.92E-10 1.167 1.14E-05 
rs3134947 6 32253183 C T 0.183 1.93E-11 3.24E-05 2.92E-10 1.166 1.29E-05 
rs5020946 6 32558067 G T 0.143 3.75E-11 7.68E-06 2.01E-07 1.556 7.95E-54 
rs443198 6 32298384 A G 0.141 6.37E-11 6.94E-08 1.61E-04 1.297 3.33E-17 
rs3129888 6 32519704 A G -0.163 1.04E-10 5.22E-06 3.78E-06 0.430 1.34E-161 
rs3129882 6 32517508 A G -0.134 1.14E-10 3.15E-07 1.42E-04 0.624 7.88E-65 
rs2073045 6 32447526 G A 0.139 1.79E-10 3.71E-05 1.48E-07 1.403 4.44E-19 
rs204993 6 32263559 A G 0.151 2.98E-10 2.18E-06 1.74E-05 1.260 2.70E-12 
rs9268516 6 32487467 C T 0.138 5.65E-10 4.27E-05 1.71E-06 1.404 5.35E-26 
rs3763316 6 32484724 C T 0.138 6.27E-10 4.27E-05 2.05E-06 1.380 3.02E-24 
rs9268494 6 32483330 A C 0.136 7.22E-10 5.65E-05 1.71E-06 1.375 6.41E-24 
rs2076524 6 32478662 A G 0.136 1.10E-09 5.65E-05 2.64E-06 1.395 6.81E-26 
rs2076525 6 32478594 T C 0.136 1.10E-09 5.65E-05 2.64E-06 1.412 3.49E-28 
rs3817962 6 32476292 C A 0.136 1.10E-09 5.65E-05 2.57E-06 1.352 2.39E-14 
rs9268474 6 32465143 T C 0.136 1.10E-09 5.92E-05 2.64E-06 1.396 6.14E-26 
rs204995 6 32262263 A G 0.159 1.17E-09 1.57E-04 6.48E-08 1.156 3.95E-05 
rs9268493 6 32483308 G A 0.134 1.51E-09 1.48E-04 6.73E-07 1.327 4.40E-20 
rs2395157 6 32456123 A G 0.134 1.65E-09 1.12E-04 1.90E-06 1.387 5.71E-25 
rs204994 6 32262976 C T 0.160 1.66E-09 1.20E-04 1.16E-07 1.157 3.15E-05 
rs3817963 6 32476065 T C 0.134 2.01E-09 5.65E-05 6.14E-06 1.395 6.55E-26 
rs3763311 6 32484154 C T 0.133 2.12E-09 4.14E-05 9.37E-06 1.357 2.87E-14 
rs9268403 6 32449451 T C 0.133 2.77E-09 1.12E-04 3.44E-06 1.389 4.96E-25 
rs3130048 6 31721718 T C 0.148 3.52E-09 2.40E-03 1.54E-10 1.182 3.02E-07 
rs176095 6 32266297 A G 0.153 5.92E-09 1.56E-04 6.74E-07 1.154 3.84E-05 
rs2267647 6 33083489 G A -0.124 6.51E-09 8.90E-07 1.58E-03 0.920 2.70E-03 
rs2076536 6 32447326 T C -0.131 8.04E-09 3.53E-05 2.79E-05 0.590 1.34E-49 
rs6901158 6 32313920 C T 0.188 1.42E-08 1.31E-04 3.65E-07 1.136 2.48E-03 
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rs9268499 6 32483673 G A 0.124 2.52E-08 1.48E-04 2.69E-05 1.328 3.76E-20 
rs1265159 6 31248026 G A 0.142 2.89E-08 5.36E-04 9.19E-07 1.050 1.60E-01 
rs652888 6 31959213 A G 0.151 3.05E-08 1.81E-03 5.08E-09 1.195 3.03E-06 
rs4248166 6 32474399 T C -0.160 9.55E-10 1.86E-02 9.19E-11 1.274 2.74E-11 
rs2294881 6 32475582 T C -0.152 3.87E-09 1.86E-02 1.11E-09 1.271 4.64E-11 
rs2294882 6 32475493 T C -0.152 3.87E-09 1.86E-02 1.11E-09 1.240 1.70E-06 
rs2294884 6 32475237 T G -0.151 7.19E-09 1.86E-02 2.53E-09 1.246 2.73E-07 
rs10947261 6 32481210 G T -0.177 3.90E-08 9.95E-02 2.02E-08 1.061 2.35E-01 
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Supplementary Table 2.3: The combined meta-analysis of EBNA-1 GWAS Meta-Analysis (EGMA) results(N = 5,555) and MS GWAS Meta-
Analysis results(N = 17,698) (MGMA) (excluding the HLA region); only significant SNPs are listed (P_Meta < 5.0´10-8).  E(A) represents the 
effect allele. P_MGMA represents the p-value for SNPs in MGMA. P_EGMA represents the p-value for related SNPs in EGMA.  P_Meta 
represents the meta-analysis results of the MGMA and EGMA. I2 represents the percentage of total variation in SNP effects across MGMA and 
EGMA. Phet represents p-value for heterogeneity between EGMA and MGMA. 
            SNP E(A) O(A) CHR POS P _MGMA OR_MGMA P _EGMA Beta_EGMA P _Meta I2 Phet 
rs11808092 A C 1 92845816 2.94´10-06 1.149 1.25´10-03 0.025 1.71´10-08 0 0.605 
rs669607 A C 3 28046448 2.10´10-08 0.854 0.0484 -0.041 4.12´10-09 0 0.659 
rs427221 T C 3 28050989 2.28´10-08 0.855 0.0382 -0.043 3.72´10-10 0 0.738 
rs2255214 T G 3 123253229 4.95´10-07 0.872 0.0300 -0.047 4.73´10-08 36.4 0.209 
rs17147986 C A 10 6078484 2.57´10-08 1.274 0.1910 0.043 3.04´10-08 0 0.812 
rs12722561 C T 10 6109899 2.20´10-08 1.240 0.3110 0.033 5.78´10-08 0 0.553 
rs2104286 T C 10 6139051 3.52´10-10 1.215 0.7450 0.009 1.15´10-08 57.8 0.124 
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Supplementary Table 2.4: Interaction analysis (p-value) results for two paired SNPs (MS GWAS obtained from dbGaP and ANZgene (cases = 
3,252; controls = 5,725)). P < 0.005 were defined as significant after Bonferroni correction. 
SNP rs11808092 rs427221 rs2255214 rs2516049 rs12722561 
rs11808092 NA 0.656 0.389 0.006 0.311 
rs427221 0.656 NA 0.917 0.416 0.671 
rs2255214 0.389 0.917 NA 0.177 0.158 
rs2516049 0.006 0.416 0.177 NA 0.198 
rs12722561 0.311 0.671 0.158 0.198 NA 
 
          
Supplementary Table 2.5 Detailed interaction results for rs2616049 (between HLA-DRB1 and HLA-DQA1) and rs11808092 (EVI5) at each 
genotype level. The reference genotype is C/C-C/C  
Genotype Frequency (%) OR (95% CI) P-value 
C/C-C/C 400 (4.5) 1.00 [Reference]  
C/C-C/A 318 (3.5) 0.83 (0.56, 1.20) 0.47 
C/C-A/A 51 (0.6) 0.88 (0.42, 1.83) 0.90 
C/T-C/C 2,046 (22.8) 1.63 (1.26, 2.13) 0.11 
C/T-C/A 1,442 (16.1) 1.76 (1.34, 2.30) 0.96 
C/T-A/A 238 (2.7) 3.05 (2.10, 4.41) 6.73´10-5 
T/T-C/C 2,350 (26.2) 2.23 (1.71, 2.88) 0.04 
T/T-C/A 1,826 (20.4) 2.68 (2.06,3.45) 0.01 
T/T-A/A 301 (3.4) 2.25 (1.59, 3.18) 0.59 
Trend:   P = 0.006 
Genotype presented as rs2616049 genotype/rs11808092 genotype. 
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Appendix 2.A: Publication of “Chapter 2:  Genetic loci for Epstein-Barr 
Virus nuclear antigen-1 are associated with risk of multiple sclerosis” 
Zhou Y, Zhu G, Charlesworth JC, et al. Genetic loci for Epstein-Barr virus nuclear 
antigen-1 are associated with risk of multiple sclerosis. Mult Scler 2016. 
This article has been removed
for copyright or proprietary
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Chapter 3: Genetic variation in PBMC-produced IFN-γ 
and TNF-α association with relapse in multiple sclerosis 
3.1 Preface 
The preceding chapter reported a cross-sectional design approach in a large sample 
size study that was aimed at investigating the association of genetic variation with MS 
development and the role that the genetic variation plays. This strategy is widely used 
in GWAS because it is relatively easy to obtain large sample sizes. However, there is 
currently very little research based on longitudinally designed studies for finding 
genetic variation in longitudinally monitored patients to predict the clinical course of 
MS. In this chapter and the next two chapters, I will present my work focusing on this 
area. In this chapter, I will assess whether SNPs within a number of genes encoding 
cytokines and their receptors, which have been strongly associated with MS 
inflammatory relapses, significantly modulate the associations of the pro-
inflammatory cytokines TNF-α and IFN-γ with MS relapse, thus providing 
information about the effects of these cytokines and the potential role of their 
respective genetic loci in the MS clinical course. This chapter was published in the 
Journal of Neurological Sciences1 (Appendix 3.A).  
3.2 Introduction 
In our previous work, we found that stimulated peripheral blood mononuclear cell 
(PBMC)-produced TNF-α was associated with a lower risk of relapse, while 
stimulated PBMC-produced IFN-γ was significantly associated with an increased risk 
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of relapse. We further found that one MS-related SNP, rs1800693, within the TNF-α-
receptor gene significantly modified the TNF-α association with relapse, such that the 
secreted form blocked the protective effect of TNF-α2.  
In this paper, we provide further genetic context by assessing whether SNPs within a 
greater number of genes for cytokines and their receptors significantly modulate the 
associations of TNF-α and IFN-γ with relapse, thus providing information about the 
effects of these cytokines and the potential role of their respective loci in MS. 
3.3 Methods 
3.3.1 Study design 
The Southern Tasmanian Multiple Sclerosis Longitudinal Study (MSL) followed a 
cohort of 203 persons with clinically definite MS living in southern Tasmania, 
Australia over 2002 – 20053. As the primary clinical outcome was the occurrence of 
relapse during the study, analysis was restricted to the 119 persons with relapsing-
remitting MS (Table 3.1) followed beyond one review with data on all cytokines (IL4, 
IL10, IFN-γ and TNF-α), of which, 91 participants had data on genotype.  
At each biannual review participants were asked about relevant environmental and 
behavioural factors, including medications, smoking, physical activity, time in the sun 
and diet.  
Ethics approval was obtained from the Southern Tasmania Human Research Ethics 
Committee. All participants provided informed consent. 
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3.3.2 Measurement of relapses 
A relapse was defined according to the 2001 McDonald Criteria4
 
as the acute or 
subacute appearance or reappearance of a neurological abnormality (lasting at least 24 
hours), immediately preceded by a stable, improving, or slowly progressive 
neurological state for 30 days, in the absence of fever, known infection, concurrent 
steroid withdrawal, or externally derived increases in body temperature. Relapses 
were reported in real time by phone or at biannual review, and all reports validated by 
the study neurologist. While MRI was a component of neurologist diagnosis of MS 
conversion, it was not a component of our relapse allocation which was just symptom 
based. Since there weren’t systematic MRIs so the possibility of persons having 
subclinical exacerbations which might be detectable on MRI could not be 
systematically measured across all participants. Thus our definition of relapse was 
just clinical.  
3.3.3 Biological samples 
At each biannual review, blood samples were obtained by standard venepuncture and 
processed to separate serum and buffy coat on the day by study personnel. All 
reviewers were fact to face.  Relapse reports were done by phone but these did not 
entail a blood sample. For two of these reviews, Summer 2004 and Winter 2004, 
buffy coats were processed to separate out PBMCs: collected blood was layered over 
histopaque (Sigma), spun at 400 g for 30 minutes, and the interface containing the 
PBMC was removed and washed twice in incomplete RPMI-1640 (JRH Biosciences, 
Melbourne, Australia). The cells were then resuspended in a 10% DMSO/RPMI 
solution and stored at - 80°C until required. To avoid a storage effect, as soon as a 
Chapter 3: Genetic variation in PBMC-produced IFN-γ and TNF-α association with 
relapse in multiple sclerosis 
119 
season's collection was completed, the cells were thawed and counted using a 
haemocytometer. Cell viability was ascertained by Trypan blue exclusion, and any 
samples with viability below 90% were discarded. Cells were then washed twice in 
incomplete RPMI and resuspended in complete RPMI containing 2 mM L-glutamine 
(Sigma, Castle Hill, Australia), 100U Penicillin, 100U Gentamicin (Pharmacia, 
Murarrie, Australia) and 10% FCS (JRH Biosciences) at 1×106cells/ml in 24 well cell 
culture plates. Five µg/ml phytohaemaglutinin (PHA) (Sigma) was added to each 
sample, and the samples were incubated for 24 h at 37°C, 8% CO2. Supernatant was 
then stored at -80°C for the duration of the study, for analysis by ELISA thereafter. 
3.3.4 ELISA protocol 
To avoid a batching effect, the ELISA was performed at a single time by a single 
operator. Samples for IL-4 and IL-10 analysis were assayed undiluted, and those for 
IFN-γ and TNF-α analyses were diluted 1:4 with Assay Diluent (BD Biosciences, San 
Diego). ELISAs were performed using BD OptEIA ELISA kits and reagents, as per 
the manufacturer's instructions. To ensure consistency, each plate (Nunc, Roskilde, 
Denmark) contained matched MS summer/winter samples, control samples and 
standards. Preliminary analyses showed that storage of supernatants for 
approximately 12 months had no effect on cytokine levels. 
3.3.5 SNP Identification & Genotyping 
SNPs (N=361) within a window of 10kb around all the cytokine genes and their 
receptors genes (total N=83, Supplementary Table 3.1) were selected, of which, 3 
(IL9R, IL3RA and IL13RA1) are within the X chromosome, 7 genes (IFNA1, IL2, 
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IL28B, LI4, IL8, IL8RA and TXLNA) with small window having no SNPs available in 
the datasets, leaving 73 genes used for analysis. Different gene boundaries 
(5kb,10kb,20kb and 50kb) have different advantages and limitations5. The use of 
conservative window (10kb) in this paper is partly as a function of reducing multiple 
comparison issues. 
These SNPs were directly genotyped in 189 of our samples as either part of the 
ANZgene MS GWAS or by an additional GWAS, extensively described in our 
previous study6. Briefly, 164 MS cases were genotyped as a part of ANZgene MS 
GWAS and additionally 29 MS cases were newly genotyped using the Illumina 
HumanOmniExpress-12v1_A array. After quality control, 4 duplicated samples were 
removed. All the samples were previously identified as being from individuals of 
European descent7.  
3.3.6 Statistical analysis 
As in the previous work2, the associations of cytokines with time to relapse were 
evaluated in a multivariable model wherein IFN-γ, TNF-α and IL-10 were mutually 
adjusted, while a categorical of IL-4 was stratified upon (allowing the baseline hazard 
to vary by level of the IL-4 categorical) due to its violation of the proportional hazards 
assumption. Stratification in this context means a statistical procedure whereby the 
baseline hazard was allowed to “float” by level of the variable stratified on, in this 
case the 4 levels of the IL-4 categorical. 
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Predictors of PBMC cytokines were evaluated using multilevel mixed-effects linear 
regression. Transformation was applied as required to satisfy homoscedasticity; 
however all coefficients are reported on the scale of the original value. 
All covariates satisfied the proportional hazards assumption, except IL-4, so all 
models were stratified by a four-level categorical rendition of IL-4 (11.5 – 52.9, >52.9 
– 86.8, >86.8 – 127.6, >127.6 – 511.9). 
Interaction of SNPs and cytokines with time to relapse was evaluated by Cox 
proportional hazards for repeated events, as described previously8, whereby multiple 
relapses by the same persons are treated as independent observations but accounted 
for at the intra-individual level, and the time until a prior event does not influence the 
composition of the risk set for a subsequent event. Where interaction was assessed, a 
product term of the SNP and cytokine was generated and included in the multivariable 
model, the significance of this term defining significance of statistical interaction. 
We defined p<1.39×10-4 as a threshold of significance after adjusting for multiple 
comparison with Bonferroni correction. All analyses were performed using 
STATA/SE for Windows (Version 12.1; StataCorp LP College Station, TX USA). 
3.4 Results 
As discussed previously, our cohort was majority female, of middle age and low 
disability, and a minority had any relapses, both during the study and during the 
analysis period here, reflecting their largely being on immunomodulatory therapy 
(Table 3.1).  
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Table 3.1 Cohort characteristics of sample analysed. 
  n (%) 
All persons 119 
Sex  
   Male 31 (26.1) 
   Female 88 (74.0) 
Age at study entry (years)  
   21 – 39 30 (25.2) 
   >39 – 45 28 (23.5) 
   >45 – 52 31 (26.1) 
   >52 – 77 30 (25.2) 
Progression to SPMS during study  
   No 105 (88.2) 
   Yes 14 (11.8) 
Relapse during study?  
   No  
   Yes 59 (49.6) 
Relapse during analysis period?  
   No  
   Yes 33 (27.7) 
Any immunomodulatory therapy during study?   
   No  
   Yes 98 (82.4) 
  
MS duration from symptom onset  (years) 10 (5 – 17) 
EDSS 2.5 ( 2 – 4) 
Number of relapses during analysis period 0 (0 – 1) 
SPMS = Secondary-progressive multiple sclerosis; EDSS = Expanded 
Disability Status Scale. 
The use of medication includes Betaferon, Avonex, Rebif and Copaxone. 
3.4.1 Cytokine SNPs to evaluate associations with TNF-α and IFN-γ production 
After adjusting for multiple testing using the Bonferroni correction method 
(P<1.39×10-4 was defined as significant), we did not observe any cytokine-related 
SNPs which significantly impacted on TNF-α and IFN-γ production (data not shown).  
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3.4.2 Differential associations of TNF-α and IFN-γ with time to relapse by SNP 
genotype 
We found one SNP, rs3218295, located within the gene IL2RB, which showed a 
significant interaction with TNF-α as a predictor of time to relapse 
(pinteraction=5.04×10-5). Carriers of the GG genotype showed a significant protective 
effect of TNF-α on relapse (p=1.46x10-5), while carriers of the GA or AA genotypes 
showed a significantly increased risk of relapse from increased TNF-α (p=0.001) 
(Table 3.2). Additionally, the SNP rs522807, located within the 3’ region of the gene 
TNFRSF1B, interacted with TNF-α’s reduction in the risk of relapse 
(pinteraction=3.83×10-4), such that carriers of the minor A allele showed a much greater 
protective effect of TNF-α on relapse risk than those homozygous for the CC 
genotype, who had an association no different from the parent cohort.
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Table 3.2 SNP for an interactive association with TNF-α as a predictor of time to relapse. 
SNP Type Related Genes Genotype # of Relapses HR (95%CI) Significance 
Aggregate      0.48 (0.18,1.29) p=0.150 
rs522807 (A/C) 3' region, intronic TNFRSF1B CC 35 0.47 (0.15, 1.43) p=0.180 
 
TFBS 
 
CA+AA 3 0.05 (0.01, 0.32) p=0.001 
      pnteraction=3.83x10
-4  
rs3218295 (A/G)  Within gene, intronic IL2RB GG 30 0.18 (0.08, 0.39) p=1.46x10-5 
   
GA+AA 8 7.41 (2.20, 24.95) p=0.001 
            pinteraction =5.04x10-5 
All analyses mutually adjusted for cytokines (IFN-γ, TNF-α, and IL-10), and for age, sex, time in sun in preceding 2/52 (time in the sun in the preceding two weeks before review), ever smoked, IFN-beta medication 
use (sensitivity analysis showed similar effect as adjusting for immunomodulatory therapy), and stratified by IL4 quartile categorical. Exposure to EBV was not a significant covariate in the analysis. Results are 
presented for 100-unit increments of the cytokine.  
Pinteraction <0.0001 was defined as significant(Pinteraction represents the P value for interaction) 
Abbreviations: TFBS: transcriptional factor binding sites.  
Table 3.3 SNP for an interactive association with IFN-γ as a predictor of time to relapse. 
SNP Type Related Genes Genotype # of Relapses HR (95%CI) Significance 
Aggregate          1.75 (1.04, 2.94) p=0.035 
rs522807 (A/C) 3' region, intronic TNFRSF1B CC 35 2.51 (1.46, 4.30) p=0.001 
 
TFBS 
 
CA+AA 3 0.56 (0.25, 1.27) p=0.160 
      pinteraction =8.21x10
-5 
rs25879 (G/A) 5' region, intronic IL3/CSF2 AA 29 2.65 (1.48, 4.74) p=0.001 
 
TFBS 
 
AG+GG 9 0.50 (0.21, 1.22) p=0.130 
            pinteraction =1.7x10-5 
All analyses mutually adjusted for cytokines (IFN-γ, TNF-α, and IL-10), and for age, sex, time in sun in preceding 2/52(time in the sun in the preceding two weeks before review), ever smoked, IFN-beta medication 
use (sensitivity analysis showed similar effect as adjusting for immunomodulatory therapy), and stratified by IL4 quartile categorical. Results are presented for 100-unit increments of the cytokine. 
Pinteraction <0.0001 was defined as significant(Pinteraction represents the P value for interaction). Exposure to EBV was not a significant covariate in the analysis 
Abbreviations: TFBS: transcriptional factor binding sites.  
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We also found two SNPs showing interactive associations with IFN-γ as a predictor 
of time to relapse (Table 3.3). The rs522807 SNP, located within the 3’ region of the 
gene TNFRSF1B, showed a significant interaction with IFN-γ (pinteraction=8.21x10-5), 
such that carriers of the CC genotype had an enhanced risk of relapse from increased 
IFN-γ, while carriers of the CA or AA genotypes showed no association between 
IFN-γ and relapse. Likewise the rs25879 SNP, located within the 5’ region of the 
gene of IL3, interacted significantly with IFN-γ (pinteraction=1.70x10-5), showing a 
significantly increased association of IFN-γ with relapse among carriers of the AA 
genotype, while carriers of the AG or GG genotypes showed no association between 
IFN-γ and relapse. Both SNPs are within the transcriptional factor binding sites of 
their respective genes.  
3.5 Discussion 
In this work, we systematically examined the SNPs within a large number of genes 
for cytokines and their receptors to assess whether there was an interaction with the 
previously demonstrated associations2 of TNF-α and IFN-γ with relapse. Individuals 
of GG genotype of rs3218295 (within the gene IL2RB) demonstrated a significant 
protective effect of TNF-α on relapse while those of GA/AA genotype did not 
(Pinteraction = 5.04×10-5). Carriers of CC genotype of rs522807 (3’ region of 
TNFRSF1B) and the AA genotype of rs25879 (5’region of IL3) showed a strong 
association between IFN-γ and increased relapse risk (Pinteraction =8.21×10-5 and 
1.70×10-5 respectively). That we have here shown allelic variants in a SNP in the 
TNF-α receptor gene modulates both the associations of TNF-α and IFN-γ, with 
carriers of the A allele showing a potentiated protective effect against relapse from 
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increased TNF-alpha, and an abrogation of the increased relapse hazard from 
increased IFN-gamma, is supportive of a true effect for this SNP. The finding of 
significant interactions with SNPs in the IL-2 receptor and IL-3 genes with TNF-α 
and IFN-γ, respectively, are also interesting and reflect the complex interplay between 
the various cytokines and cytokine receptors of the immune system. 
Despite multiple MS risk GWAS9,10, no susceptibility loci in or near the gene of 
IL2RB9 or IL3 have previously been demonstrated, though certainly TNF-α receptor is 
now a well-recognised MS susceptibility locus11. That these loci have not been 
identified in MS GWAS is not unexpected, because GWAS are focused more on 
cross-sectional data and are limited by a greater multiple testing burden. This reflects 
the utility in examining SNPs in parameters relevant to the already demonstrated 
cytokine risk factors, because by casting the net in this fashion and using a systems 
biology approach, we have identified results that may uncover modulators of these 
biological risk factors. Similar approaches have been taken with regard to vitamin 
D/UV12-14, childhood infections15 and EBV16 that have either uncovered novel 
mechanisms of already known risk alleles for MS 12-16 or uncovered novel loci that 
modulate the course of MS 17. 
Our findings of effects for the three SNPs presented here are not wholly novel in 
terms of relevance to neurological function. The impact of TNFRSF1B SNPs on MS 
has been well-demonstrated11. Our other SNPs have additional evidence in support of 
them being biologically plausible candidates. A locus near IL3 (rs31480) is in high 
linkage disequilibrium with our significant SNP (rs25879, r2>0.8). This SNP could 
influence the binding affinity of the transcription factor SP1 and thus impact upon the 
expression of IL3. Others have shown that the level of IL3 promoted the proliferation 
Chapter 3: Genetic variation in PBMC-produced IFN-γ and TNF-α association with 
relapse in multiple sclerosis 
 
127 
and survival of neural progenitors 18. Consistent with this finding, our major allele 
genotype AA of rs25879 and the major allele genotype CC of rs31480 showed the 
same effect direction. That is, AA of rs25879 interacted significantly with IFN-γ to 
increase relapse risk, while CC of rs31480 in their findings was associated with lower 
brain volume and lower IL3 expression which would decrease neural progenitors’ 
survival and proliferation. These results suggest a possible mechanism by which IL3 
might interact with IFN-γ, potentially regulating brain processes and affecting 
susceptibility to relapse.  
IL2RB encodes the beta chain of the IL-2 receptor, expressed on T and B-cells, 
monocytes, neutrophils and dendritic cells. In mice, the blocked expression of IL2RB 
manifested in the dysregulation of T and B-cell activation and behaviour, as well as 
the loss of thymocytes, leading to death by 12 weeks of age19. Thus, IL-2R-beta 
appears to be required for proper control and function of immune cell activation, 
reducing the potential for inappropriate immune activation19. IL-2R-beta can bind to 
IL-15, whose three-dimensional structure is similar to that of IL-220. IL-15 plays an 
important role in the maintenance and activation of CD8 T lymphocytes, a prominent 
lymphocyte population found in MS lesions21. In MS, IL-15 serum levels were higher 
in patients with relapse compared with patients in stable periods of the disease 
(p=0.001)22. Although a role of IL2RB in susceptibility to other inflammatory diseases 
like rheumatoid arthritis23 and asthma24 has been found in some studies, its role in MS 
remains unknown, so further studies are required to better understand its role in 
disease. 
This study benefits from its prospective cohort design and real-time reporting of 
relapses. The current analysis is limited to some extent in its being conducted on only 
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a subset of the MSL study cohort, but nonetheless provides valuable information on 
the nature of the immune response in MS clinical course and the potential genetic 
impacts thereon. The biannually obtained PBMCs do reasonably represent the 
immune state between relapses, allowing these to be a predictor of subsequent relapse 
risk. There is variability over time due to changing season, changes in medication and 
infection state, among others, which can impact on the responsiveness of immune 
cells. Our use of a standardised and appreciable stimulus to induce cytokine 
production25 should allow a comparable cytokine production between persons that can 
overcome this micro-variation over time to give a representation of the general 
immune state of the individual.  
In conclusion, our results provide insight into the complex interaction of cytokines 
that affect the risk of relapse in MS. Due to the complexity of the immune system, 
having measurements of other cytokines would be relevant and future studies seeking 
to confirm these findings are needed in order to establish them for future use in 
clinical practice. These findings may provide some clues to better understand the 
immunopathology of MS and may suggest possible points of intervention in 
moderating clinical course. They also highlight the potential of more targeted future 
therapeutics for MS that take into account a person’s genotype. 
3.6 Summary  
Background: Alterations in peripheral blood mononuclear cells (PBMC) cytokine 
production have been found in multiple sclerosis (MS) compared to healthy controls. 
We have previously found that stimulated PBMC-produced TNF-α and IFN-γ 
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modulated MS relapse risk, such that raised TNF-α was protective, while raised IFN-γ 
increased relapse risk.  
Objective: To assess whether SNPs within genes for relevant cytokines and their 
receptors modulate the associations of TNF-α and IFN-γ with relapse, thus providing 
additional information about these cytokine effects and the roles of these genes in 
MS. 
Methods: Prospective cohort of 91 participants with relapsing-remitting MS and 
cytokine and genotype data. SNPs (N=361) within a window of 10kb around each 
cytokine/cytokine receptor gene (N=83) selected for analysis. Predictors of PBMC 
cytokines evaluated by multilevel mixed-effects linear regression. Predictors of 
relapse evaluated by Cox proportional hazards regression. Bonferroni correction used 
to adjust for multiple testing; thus P<1.39x10-4 defined as significant.  
Results: Individuals of GG genotype of rs3218295 (within the gene IL2RB) 
demonstrated a significant protective effect of TNF-α on relapse while those of 
GA/AA genotype showed a significant positive association (Pinteraction=5.04×10-5). 
Carriers of CC genotype of rs522807 (3’ region of TNFRSF1B) and the AA genotype 
of rs25879 (5’region of IL3) showed a strong association between IFN-γ and 
increased relapse risk (Pinteraction=8.21×10-5 and 1.70×10-5, respectively).  
Conclusions: Our results show novel modulation of TNF-α and IFN-γ associations 
with relapse by SNPs in major cytokines. These findings suggest the potential for 
these genes and/or their products as potential therapeutic targets in MS.  
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Supplementary Table 3.1: List of genes selected for analysis. Here the genomic 
location for the genes were based on hg18. Chr refers to chromosome  
Gene Start End Chr Gene Start End Chr 
TNFRSF1B 12149646 12191863 1 IL6 22733342 22738144 7 
IL22RA1 24318847 24342197 1 IL7 79807559 79880312 8 
TXLNA 32417931 32436472 1 IL33 6231677 6247981 9 
IL23R 67404756 67498249 1 IFNB1 21067103 21067942 9 
IL12RB2 67545634 67635170 1 IFNA1 21430439 21431314 9 
IL6R 152644292 152706811 1 IL11RA 34643931 34651883 9 
IL10 205007570 205012461 1 TGFBR1 100907232 100956294 9 
IL19 205038837 205082947 1 IL15RA 6034339 6060147 10 
IL20 205105776 205109190 1 IL2RA 6093511 6144277 10 
IL24 205137411 205144106 1 IL18BP 71387605 71391221 11 
TGFB2 216586490 216681595 1 IL18 111519185 111540049 11 
IL1R1 102136833 102162765 2 IL10RA 117362318 117377403 11 
IL18RAP 102401685 102435456 2 TNFR1 6308183 6321521 12 
IL1A 113247962 113259441 2 CD4 6768911 6800236 12 
IL1B 113303807 113310826 2 IL23A 55018929 55020460 12 
IL36A 113479920 113482092 2 IFNG 66834816 66839787 12 
IL36B 113496139 113526915 2 IL26 66881395 66905837 12 
IL1RN 113591940 113608063 2 IL22 66928291 66933547 12 
IL8RB 218698990 218710219 2 IL31 121222529 121224698 12 
IL8RA 218735812 218739960 2 IL25 22911857 22915451 14 
IL5RA 3086420 3127030 3 TGFB3 75494194 75517241 14 
IL17RC 9933781 9950313 3 IL16 79276273 79392156 15 
IL17RB 53855616 53874866 3 IL32 3055313 3059668 16 
IL12A 161189322 161196499 3 IL4R 27232751 27283599 16 
IL8 74825138 74828296 4 IL21R 27321223 27369615 16 
IL2 123592074 123597099 4 IL17C 87232501 87234382 16 
IL21 123739271 123761661 4 EBI3 4180539 4188524 19 
IL15 142777203 142874061 4 IL27RA 14003261 14025025 19 
IL7R 35892747 35912680 5 IL12RB1 18031370 18058696 19 
IL6ST 55272450 55326519 5 IL28B 44426111 44427450 19 
IL3 131424245 131426794 5 IL28A 44450996 44452571 19 
CSF2 131437384 131439758 5 IL29 44478804 44481151 19 
IL5 131905034 131907112 5 TGFB1 46528490 46551655 19 
IL13 132021763 132024699 5 IL11 60567568 60573625 19 
IL4 132037271 132046266 5 IFNAR2 33524100 33558696 21 
IL9 135255833 135259414 5 IFNAR1 33619083 33653998 21 
IL17B 148734022 148739030 5 IL17RA 15945848 15971404 22 
IL12B 158674368 158690058 5 IL2RB 35851823 35875907 22 
LTA 31648071 31650076 6 IL3RA 1415508 1461581 X|Y 
TNF 31651328 31654090 6 IL13RA1 117745586 117812523 X 
LTB 31656313 31658180 6 IL9R 154880439 154893675 X|Y 
IL17A 52159143 52163394 6 
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Chapter 4: Variation within the myelin basic protein 
gene predicts disease course in multiple sclerosis 
4.1 Preface 
The previous chapter provided evidence that genetic variations in major cytokine 
genes modulate the associations of the cytokines TNF-α and IFN-γ with relapse using 
a prospective cohort of 91 participants followed for 3 years. In this chapter, we will 
assess whether genetic variation in myelin basic protein may directly or by interaction 
with HHV6 or EBV determine clinical outcomes (conversion to MS after a first 
demyelinating event, relapse rate and disability) using the prospectively followed 
Ausimmune/Auslong Longitudinal Study, an ongoing > 10 -year prospective cohort 
study following a population of 282 patients who were initially identified as having a 
first demyelinating event (FDE) suggestive of, but not diagnostic for, MS. 
4.2 Introduction  
Myelin basic protein (MBP) is a major component of the myelin sheath and is 
believed to play an important role in the process of myelination in the CNS1. In 
patients presenting with a first demyelinating event (FDE), the presence of serum 
antibodies against MBP significantly predicts conversion to clinically definite 
multiple sclerosis (CDMS)2. Despite its potential role in MS, none of the large 
genome-wide association studies (GWAS)3,4 have found any variants in MBP that 
predict MS risk.. In fact no MS GWAS has been able to establish any markers that 
predict severity or clinical course.  Therefore, candidate gene approaches with a priori 
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hypotheses can be used to avoid the burden of correcting for the large number of tests 
associated with GWAS studies.  
Emerging evidence suggests that autoimmune responses targeting the myelin sheath  
indicates the existence of myelin-reactive T-cells, which can recognise MBP peptides, 
trigger an immune response against MBP and thus affect the integrity of the myelin 
sheath5. The molecular mimicry hypothesis suggests that these myelin-reactive T-
cells can be activated because certain viral agents, particularly human herpesvirus-6 
(HHV6) and Epstein-Barr virus (EBV), share similar antigenic profiles with MBP, 
resulting in T-cells cross-reacting to both virus and MBP6,7. 
Given the high prevalence of prior exposure and seropositivity (>90%) against 
HHV68 and EBV9 in the general population, and the existence of myelin-reactive T-
cells in healthy individuals10, we have therefore hypothesised that by using a 
biologically plausible candidate gene approach; that genetic variations in MBP may 
directly, or by interaction with HHV6 or EBV, determine clinical outcomes 
(conversion to MS after a first demyelinating event, relapse rate and  disability). We 
have therefore studied this a priori hypothesis in a well-characterised cohort who had 
an FDE at baseline, and who had both genetic data and EBV and HHV6 antibody 
serology. 
4.3 Material and Methods 
4.3.1 Study design 
The Ausimmune Longitudinal (AusLong) Study, which built upon the original 
Ausimmune case-control study, seeks to elucidate environmental, genetic and 
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personal risk factors for the onset and early progression of MS. This study has 
followed 169 cases with a classical first demyelination event (FDE)11(Figure 4.1). The 
present analysis is for the period from first recorded symptom onset, to the 5-year 
review, as this is the most recent face-to-face review which all currently enrolled 
participants have completed.  
Figure 4.1: Flow chart of the Auslong Study 
 
The Ausimmune Study and AusLong Study were approved by nine regional Human 
Research Ethics Committees (Health & Medical Research Ethics Committee, 
University of Tasmania, Project No. H0010499; Barwon Health Human Research 
Ethics Committee (HREC), Project No. 09/24, Project No. 03/46; Hunter New 
England HREC, John Hunter Hospital, Project No.HREC/09/HNE/139, Project No. 
09/04/15/5.04; Griffith University HREC, Project No: MED/02/10/HREC; Royal 
Brisbane and Women’s Hospital, Queensland Health, Project No: 
HREC/09/QRBW/299; Queensland Institute for Medical Research, Project No. 
QIMR-HREC /P1252; HREC of Northern Territory Department of Health & Menzies 
School of Health Research, Project No. HREC 2011-1694.). All participants gave 
written informed consent. 
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4.3.2 Exposure & clinical course measures 
Several clinical outcomes were evaluated, including conversion to MS, occurrence of 
relapse and annualised disability progression from FDE to five-year review. 
Conversion to MS was defined primarily as the occurrence of two or more clinical 
demyelinating episodes, thus satisfying the diagnostic requirements of dissemination 
in space and time, or a single episode plus paraclinical evidence, as per the 2005 
McDonald criteria12 (a minority of cases were diagnosed following MRI based on this 
latter criterion (n=20)). Conversion to MS was reported at annual review and cross-
checked with neurological records. A relapse was defined according to the 2001 
McDonald Criteria13 as the acute or sub-acute appearance or reappearance of a 
neurological abnormality (lasting at least 24 hours) in the absence of other potential 
explanatory factors. Relapses were reported at annual review and only relapses which 
were diagnosed and verified by a neurologist were included in the analysis. Disability 
was assessed by the Kurtzke Expanded Disability Status Scale (EDSS)14, assessed at 
the 5-year review; the EDSS on the day before FDE was assumed to be 0.  
Clinical history was derived from medical records at initial presentation, describing 
the nature of the episode/symptoms which brought the participant into the 
Ausimmune Study, as well as historical symptoms prior to presentation. In the event 
that a person had no history preceding their referral symptoms, the referral symptom 
onset date was taken to be their symptom onset. Where a person had a bout-onset 
presentation and had symptoms some time previous to the referral episode, this was 
validated to the extent possible from available clinical notes contemporaneous with 
the historical episode or taken as valid if judged to be so by the attending neurologist 
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at the referral episode. Finally, where a person was progressive from onset, symptom 
onset was defined as either the earliest onset of symptoms identified by the attending 
neurologist at the referral episode, or one year preceding the referral clinic date, 
whichever was first.  
Anti-EBNA-1 IgG, anti-EBNA-2 IgG and anti-HHV6 IgG titers were measured in 
serum samples collected at baseline, using immunofluorescence assays: Anti-EBNA1 
commercial ELISA (DiaSorin), Anti-EBNA2 in house ELISA and Anti-HHV6 
commercial ELISA (Panbio) as previously described15.  
4.3.3 Genotyping 
DNA from AusLong participants was genotyped using the Illumina customised MS 
exome genotyping array (Illumina Human Exome-12 v1.2 array (~244,000 SNPs) 
plus additional MS relevant variants (~87,000) added as a customized component). 
Genotypes were called using Illumina GenomeStudio software. Individuals were 
excluded for the following reasons: a call rate of <99% or duplicate discordance. 
Variants were excluded on the basis of a call rate of <99% or a deviation from Hardy-
Weinberg equilibrium with P<1.0x10-6. Principal components analysis  was carried 
out twice, once excluding HapMap samples to identify population outliers and once 
including HapMap samples to help interpret outliers16. Eight tagSNPs (rs9676113, 
rs3794832, rs7232502, rs12959006, rs61742988, rs3900176, rs11150997 and 
rs7233242) with r2<0.1 in the MBP gene (chr18: 74690789-74844774) were selected 
for analysis.  
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4.3.4 Data analysis 
Predictors of time to conversion to MS and of relapse were evaluated by Cox 
proportional hazards regression models, the latter for repeated events using the gap-
time model by Prentice and colleagues17. All covariates satisfied the proportional 
hazards assumption.  
Annualised change in EDSS was calculated by taking the five-year review EDSS and 
dividing by the duration between the day before FDE and the five-year review. 
Predictors of annualised change in EDSS were evaluated using linear regression, 
adjusted for whether persons were having a relapse at the time of their 5-year EDSS 
assessment. There were only 22 in total 279 samples that have active relapse at 5-year 
review. The average EDSS at 5-year review for all the samples vs no active relapse 
was 1.87 vs 1.82, such littler difference would not skew the results, thus adjusting for 
relapse at the time of 5-year assessment is adequate. Because the annualised change in 
disability was highly skewed, a log-transformation was applied to satisfy linear 
regression assumptions of minimal heteroskedasticity. All means and coefficients, 
however, were back-transformed and presented on the original scale of the change in 
EDSS.  
Interaction was assessed by generating a product term of the two variables to be 
assessed, with the p-value of this two-component term delineating the significance of 
the interaction. All statistical analyses were conducted in Stata/SE 12.1 (StataCorp 
LP, College Station, Texas, USA).  
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4.4 Results  
Of the 169 case participants in the Ausimmune/AusLong Study that had a classic 
FDE, 127 have undergone genotyping as described and had been assessed at 5 years 
and form the cohort assessed in this study. They were predominantly female  (n=98, 
77.2%), age at study entry (mean: 37.8, SD: 9.5), conversion to MS (n=68, 53.5%), 
relapse number (n=152) and 5-year EDSS (median: 1, IQR: 0 – 2) (Table 4.1). 
Table 4.1: Characteristics of participants with genotype data 
Characteristics 
Classic FDE 
(n=127) 
Female (%) 98(77.2) 
Conversion to MS (%) # 68(53.5) 
Relapse 152 
Age at study entry, mean (SD) 37.8 (9.5) 
EDSS, Median (IQR) 1 (0-2) 
FDE: First demyelinating event 
SD: Standard deviation, EDSS: Expanded Disability Status Scale 
IQR: Interquartile range 
# Participants who had CDMS and with genotype data. 
4.4.1 Risk genotype (CT+TT) of rs12959006 directly predicts progression to 
MS, relapse and annualised change in EDSS 
Among the group of participants with a classic FDE and a second event diagnostic of 
MS within the period after referral to the study, only two persons had the TT 
genotype of rs12959006. Therefore, the homozygous risk genotype was combined 
with the heterozygote as CT+TT. We found the genotype (CT+TT) of rs12959006 
showed a borderline positive association with risk of conversion to MS (HR=1.57 
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(95% CI: 0.93-2.64), p=0.09). Examining this SNP in predicting relapse, a stronger 
and statistically significant result was seen (HR=1.74 (95% CI: 1.19-2.56), p=0.005, 
Table 4.2), partly reflecting the greater number of events (n=68 CDMS vs 152 
relapses). Figure 4.2 showed the survival curves for the rs12959006 genotype for time 
to conversion to MS and relapse, respectively.  
Table 4.2: Results for rs12959006 predicting MS, relapse and annualised ΔEDSS 
in MS among participants with a classic FDE. 
rs12959006 N Conversion to MS N Relapse N ΔEDSS 
CC 41 Ref 70 Ref 37 0.26 (0.20, 0.32) 
CT+TT 27 1.57 (0.93, 2.64) 82 1.74 (1.19, 2.56) 24 +0.18 (0.06, 0.30) 
  p=0.09  p=0.005  p=0.004 
Due to the smaller number of people carrying TT genotype who converted to MS (N=2), we recoded 
the genotype as CT+TT. Results were adjusted for age, sex and study site, and presented as HR (95% 
CI) for time to MS and relapse. Disability results are presented as geometric mean annualised 
disability progression (95% CI) for the reference group, while coefficient relative to reference (β 
(95% CI)) are presented for subsequent levels. N refers to the number of events for each related 
clinical course.  
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Figure 4.2:  
a. Kaplan-Meier survival plot for time to MS by category of rs12959006 
genotype. 
 
b. Kaplan-Meier survival plot for time to relapse by category of rs12959006 
genotype. 
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Evaluating the association of rs12959006 with annualised change in EDSS, the 
CT+TT genotype was associated with a significantly greater rate of disability 
progression, with 0.18 greater annualised EDSS increase per year (β=0.18, 95% CI: 
0.06-0.30, p=0.004). Further when assessing all cases with bout-onset disease 
(n=125), we observed a dose-dependent association for rs12959006 in predicting 
annualised change in EDSS, in which the CT genotype increased EDSS by 0.07 unit 
per year, while the TT genotype increased EDSS by 0.25 unit per year, both relative 
to the reference genotype (ptrend=0.02, Table 4.3). Translating this to a clinical 
outcome, those carrying the TT genotype will have an EDSS score 2.5 points greater 
over 10 years than those carrying the CC genotype.  
Table 4.3: Results for SNP rs12959006 predicting annualised ΔEDSS in MS 
including all bout-onset cases. 
rs12959006 N ΔEDSS 
CC 74 0.26 (0.21, 0.31) 
CT 46 +0.07 (-0.02, 0.15) 
TT 5 +0.25 (-0.02, 0.53) 
  ptrend=0.02 
Results were adjusted for age, sex and study site. Disability results are presented as the 
geometric mean annualised change in EDSS (95% CI) for the reference group; the β (95% 
CI) coefficient represents the difference relative to the reference for other genotypes. N refers 
to the number of events 
We did not observe any association between the other seven MBP SNPs and 
progression to MS, relapse or annualised change in EDSS (data not shown). After 
adjusting for multiple testing ((p=0.05/8)≈0.006 was defined as significant), 
rs12959006 remained significant in predicting relapse and annualised ΔEDSS. The 
effect of the risk allele rs12959006 was in the same direction when predicting all 
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three clinical outcomes and was towards a more active clinical course, providing 
further support for a true effect. 
4.4.2 Rs12959006 genotype interacts significantly with baseline anti-HHV6 IgG 
levels to predict conversion to MS and relapse 
Table 4.4 : Results for SNP rs12959006 interact with baseline HHV-6, baseline 
EBNA-1 and baseline EBNA-2 to predict conversion to MS and relapse in MS 
among classic FDEs. 
 
As shown in Table 4.4, we found a significant interaction between the rs12959006 
genotype and baseline anti-HHV6 IgG levels. In those with the risk genotype 
(CT+TT), there was a significant positive association between anti-HHV6 IgG and 
time to MS (HR=6.95, 95% CI: 1.11-43.31, p=0.04; pinteraction=0.05) and relapse 
(HR=3.00, 95% CI: 1.19-7.53, p=0.02; pinteraction=0.02), whereas there was no 
association amongst the non-risk allele carriers (CC) (HR=0.63, 95% CI: 0.14-2.77, 
p=0.54, for time to MS and HR=0.58, 95% CI: 0.20-1.64, p=0.30 for time to relapse). 
There was no significant interaction between rs12959006 genotype and baseline anti-
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ENBA-1 or anti-EBNA-2 IgG titres for time to MS or relapse, although the effect was 
in the same direction as for HHV6. Rs12959006 genotype did not significantly 
interact with baseline anti-HHV6, anti-EBNA1 or anti-EBNA2 IgG levels in 
predicting annualised ΔEDSS. 
Functional prediction analysis18 using SNPinfo web server (https://snpinfo.niehs. 
nih.gov) showed this variant rs12959006 is the target of many transcription factors 
and the binding sites of miR-218 and miR-188-3p.  
4.4.3 Discussion  
Multiple sclerosis causes a great economic burden and has significant social, 
psychological and physical impacts on people with MS as well as their families. 
Following an FDE there are few good indicators of future conversion to MS or 
subsequent rate of progression, although early treatment may significantly alter 
outcomes. Treatment is expensive and for those with a good prognosis and low risk of 
conversion to MS almost certainly not warranted. Therefore identifying those with a 
higher risk of conversion and a faster rate of progression as early as possible in the 
disease course is of great importance2,13,19. The importance of MRI in early MS has 
been demonstrated19. However, other biomarkers have shown less promise, although 
serum antibodies against MBP have been associated with a significantly higher risk of 
relapse post-FDE2.  
We have shown that people with an FDE who carry the risk SNP of rs12969006 in 
MBP have a worse outcome on all three measures of disease progression (conversion 
to MS, relapse rate, and EDSS progression), and that the risk SNP of rs129569006 in 
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MBP interacts with serological markers of prior HHV6 infection to predict clinical 
course post FDE. Past infection with HHV6 and EBV are both well-recognised risk 
factors for MS onset and there is some evidence that HHV6 IgG levels in particular 
are associated with MS progression20.  
MBP undergoes complex post-transcriptional modification, including methylation, 
phosphorylation and miRNA binding21. The risk locus studied is a target for many 
transcription factors as well as the binding sites of miR-218 and miR-188-3p. Other 
research has shown that miR-218 expression is significantly down regulated in MS 
white matter compared to controls22. However, the exact molecular mechanisms by 
which changes in miR-218 and this MBP variant may modify myelination and 
demyelination remains unknown. Further studies using the deep sequencing to fine-
mapping the MBP causal variants are needed. 
Importantly we have shown that in the post-GWAS MS world, where the focus has 
shifted from defining risk associations to defining determinants of clinical course, 
studying a priori hypotheses such as those we have described, can be undertaken 
successfully in moderate sized, well-characterised longitudinal cohorts, using data on 
multiple aspects of MS clinical course and potential genetic and environmental 
factors.  
There are several potential caveats to our findings. By their nature, longitudinal 
cohort studies are at best of moderate sample size, and further subdivision into those 
with particular phenotypes and exposure parameters decreases the power to detect 
associations. On the other hand, the internal consistency across the three outcome 
measures, the biologically plausible directions of effect and interactions with 
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herpesvirus, as well as the dose-dependency of effect in our disability analysis, is 
evidence supporting a true association rather than statistical artifact. Still, validation 
of our findings in other longitudinal cohorts is essential.  
These data demonstrate that genetic variants in MS candidate genes with high 
biologic plausibility may help predict MS clinical course. Additionally, interaction 
with well-documented serological markers of prior EBV and HHV6 infection enhance 
these effects and further supports the notion of complex gene-environment 
interactions in the onset and progression of MS. These results, if replicated in other 
longitudinal datasets, may aid in developing prognostic algorithms in the early disease 
period in MS as well as providing further mechanistic insights. 
4.5 Summary 
Background: Prognosis following a first demyelinating event is difficult to predict, 
with no genetic markers of MS progression currently identified. MBP is a major 
component of the myelin sheath of CNS neurons and may play a central role in 
demyelinating diseases such as MS. However, genetic variation in MBP has not been 
implicated in MS onset risk in large genome-wide association studies. We 
hypothesised that genetic variations in MBP may be a determinant of MS clinical 
course.  
Methods: We investigated whether variations in the MBP gene altered clinical course 
(conversion to MS and/or relapse, and annualised change in disability), using a 
longitudinal cohort study of persons who had had a first demyelinating event, 
followed up to the 5-year review.  
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Results: We found one variant, rs12959006, predicted worse clinical outcomes. The 
risk genotype (CT+TT) was near-significantly associated with increased risk of 
conversion to MS (HR=1.57, 95% CI=0.93-2.64, p=0.09); and significantly 
associated with relapse (HR=1.74, 95% CI=1.19-2.56, p=0.005) and of greater 
annualised disability progression (β=0.18, 95% CI=0.06-0.30, p=0.004). We also 
found a significant interaction between the risk genotype and baseline anti-HHV6 IgG 
in predicting MS (p interaction=0.05) and relapse (p interaction=0.02). Functional 
prediction analysis showed this variant is the target of many transcription factors and 
the binding sites of miR-218 and miR-188-3p.  
Interpretation: Our results provide novel insights into the role of genetic variation 
within the MBP gene predicting MS clinical course, both directly and by interaction 
with known environmental MS risk factors. 
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Supplementary Table 4-1: Results for other 7 MBP SNPs predicting CDMS, relapse and annualised ΔEDSS in MS among the classic 
FDEs. 
SNP Genoypte N CDMS(HR(95%CI)) N Relapse(HR(95%CI)) N ΔEDSS (β (95%CI)) 
rs9676113 AA 39 Ref 80 Ref 36 Ref 
 
AG+GG 29 0.72(0.43,1.20) 71 1.10(0.70,1.69) 25 0.03(-0.09,0.14) 
      p=0.20   p=0.70   p=0.65 
rs3794832 GG 65 NA 145 Ref 59 NA 
 
AG 3 NA 6 1.06(0.21,5.27) 2 NA 
      NA   p=0.94   NA 
rs7232502 GG 28 Ref 64 Ref 24 Ref 
 
AG 32 0.94(0.55,1.60) 73 0.85(0.54,1.32) 30 -0.08(-0.21,0.05) 
 
AA 8 1.16(0.45,2.98) 14 0.84(0.43,1.64) 7 -0.13(-0.31,0.04) 
      p=0.90   p=0.48   p=0.12 
rs61742988 GG 66 NA 144 Ref 59 NA 
 
AG 2 NA 7 0.92(0.33,2.55) 2 NA 
      NA   p=0.88   NA 
rs3900176 GG 27 Ref 62 Ref 25 Ref 
 
GA 31 1.12(0.66,1.92) 68 0.91(0.56,1.46) 26 -0.01(-0.14,0.12) 
 
AA 10 1.57(0.75,3.31) 22 0.97(0.52,1.78) 10 -0.06(-0.23,0.10) 
      p=0.28   p=0.81   p=0.49 
rs11150997 GG 67 NA 149 NA 60 NA 
 
GA 1 NA 2 NA 1 NA 
      NA   NA   NA 
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rs7233242 GG 26 Ref 62 Ref 24 Ref 
 
GA 31 0.97(0.56,1.68) 79 1.14(0.73,1.79) 27 0.05(-0.08,0.17) 
 
AA 11 1.11(0.51,2.40) 11 0.70(0.38,1.30) 10 -0.12(-0.27,0.02) 
      p=0.86   p=0.73   p=0.30 
For cell with number <5, the analysis was not performed and annotated with NA. Results were adjusted for age, gender and studysite, and 
presented as HR (95% CI) for CDMS and relapse, and β (95%CI) for EDSS.   N refers to the number of events for each related clinical 
course. 
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Chapter 5: Common genetic variation within miR-146a 
predicts disease onset & relapse in multiple sclerosis 
5.1 Preface 
This chapter will address the key question discussed in the Chapter 1 section 
regarding the role of epigenetics in the missing heritability of MS. In Chapter 5, for 
the first time, we assess the effects of a functional genetic variant within the gene 
encoding miR-146a (a miRNA with expression strongly associated with MS disease 
activity) on the MS clinical course in the Ausimmune/Auslong Longitudinal 
Study―an ongoing > 10year prospective cohort study following a population of 282 
patients who were initially identified with a first demyelinating event (FDE) 
suggestive of, but not diagnostic for, MS. miR-146a expression is also known to 
interact with known MS risk factors, including Epstein Barr virus and smoking, 
making it a highly biologically plausible MS risk loci. 
5.2 Introduction  
MicroRNAs (miRNAs) are a family of 21 to 25 nucleotide-long noncoding small 
RNAs that regulate gene expression1. Despite extensive studies focusing on changes 
in the expression of miRNAs in multiple sclerosis (MS) compared to healthy 
controls2, no studies have sought to determine the function of genetic variation in 
miRNAs genes, or to assess whether such variation could predict MS clinical course, 
directly or by interaction with other risk factors.  
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One particular miRNA (miR-146a) has been investigated for its role in MS due to its 
implicated in the regulation of both innate and adaptive immunity. MiR-146a is 
primarily involved in the regulation of inflammation3 and it is up-regulated in active 
MS brain lesions4. In MS patients with relapsing remitting disease, miR-146a 
expression was significantly lower in those treated with glatiramer acetate than in 
treatment-naïve patients5. Additionally the expression of miR-146a is altered by 
infection with Epstein-Barr virus (EBV)6 and smoking7, both of which are well-
known MS risk factors8,9. For these reasons, miR-146a is a biologically plausible 
candidate genetic risk locus in MS.  
The minor allele C of rs2910164, which is the only common SNP located within the 
miR-146a gene (chr5: 159,912,359-159,912,457), causes mis-pairing within the 
hairpin of pre-miR-146a (Figure 5.1) and may decrease the expression of mature miR-
146a10 either by reducing the stability of the pri-miRNA, the efficiency of processing 
of pri-miRNA into pre-miRNA, or the efficiency of processing the pre-miRNA into 
the mature miRNA. Given the potential for both direct and interactive relationships of 
miR-146a with MS risk and clinical course, as well as the impact of this 
polymorphism on the expression and function of miR-146a, we developed an a priori 
hypothesis that this polymorphism may be an important modulator of MS clinical 
activity. 
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Figure 5.1: The predicted secondary structure of pre-miR-146a by rs2910164 
polymorphism. The red represents the mature miR-146a duplex. 
 
We therefore undertook a study of clinical outcomes in a well-established, 
prospectively followed cohort of patients who were first recruited after diagnosis of a 
first demyelinating event (FDE) or initial diagnosis of progressive disease, to assess 
the effect of this functional genetic variation in the miR-146a gene on the transition to 
MS, relapse frequency and disability progression.  
5.3 Methods 
5.3.1 Study design 
Same as the study design section in Chapter 4.  
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5.3.2 Exposure & clinical course measures 
Several clinical outcomes were evaluated as described in Chapter 4, including 
conversion to MS, occurrence of relapse, and annualized disability progression from 
FDE to five-year review.  
5.3.3 Genotyping 
Genotyping for rs2910164 was performed using the predesigned TaqMan® 
genotyping assay C_15946974_10 from ThermoFisher Scientific (catalog number 
4351379). Samples were genotyped in 96-well plates on a Roche LightCycler® 480 
Real-Time PCR system. Per sample 7 µL reaction volumes were used with 1 µL of 
DNA at 10 ng/µL, 4 µL of TaqMan® Genotyping Master Mix (Applied 
BiosystemsTM), 2.9 µL of nuclease free H2O and 0.1 µL of 40× TaqMan genotyping 
probe. 5.9% of samples were genotyped in replicate with 100% replication. 
5.3.4 Data analysis  
The methods for predictors of time to conversion to MS, of relapse and of annualized 
change were the same as described in Chapter 4.  
Interaction was assessed in two fashions, multiplicative and additive. Multiplicative 
interaction was assessed by generating a product term of the two variables to be 
assessed, with the significance of this two-component term delineating the 
interpretation of the significance of the interaction. Additive interaction was assessed 
by generating a four-level categorical term equal to 0 where both genetic and 
environmental risk factors were not present (the background risk (rB)), equal to 1 and 
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2 where only the genetic or environmental risk factors were present (rG and rE), and 
equal to 3 where both genetic and environmental risk factors were present (rGE). 
When evaluating a continuous environmental factor, a dichotomous variable was 
generated by dividing the sample at the median of the continuous term. The relative 
excess risk due to interaction (RERI) on the additive scale was calculated by 
subtracting the sum of risk measures (e.g. hazard ratios, HRs) for the individual 
exposures (rE + rG) from the risk measure for the combined exposure (rGE) and adding 
the background risk (rB =1.00) (i.e., RERI= HRGE – (HRG + HRE) + 1). The statistical 
significance of this RERI (probability of a risk of this magnitude occurring due to 
chance alone) was evaluated by a permutation simulation, randomly redistributing 
participants to one of the four levels of the additive interaction term in proportion to 
their original distribution. For example, the proportions of the four-level EBNA1-
miRNA interaction term (32.5%, 31.5%, 19.8%,16.2%) were retained in the 
simulation, but redistributed randomly amongst the participants who had data on both 
EBNA1 and miRNA genotype. These simulated interaction terms were generated, 
analysed and the magnitudes of the estimates resulting were retained. These 
simulations were run 50,000 times and the proportion of magnitudes resulting that 
were as or more extreme than that found in the as-measured analyses denoted the 
significance of the interaction. 
All statistical analyses were conducted in Stata/SE 12.1 (StataCorp LP, College 
Station, Texas, USA). 
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5.4 Results 
Of the 169 case participants in the Ausimmune/AusLong Study that had a classic 
FDE, 151 have undergone genotyping as described and had been assessed at 5 years 
and form the cohort assessed in this study. They were predominantly female (n=117, 
77.5%), age at study entry (mean: 37.4, SD: 9.5), conversion to MS (n=83, 55.0%), 
relapse number (n=198) and 5-year EDSS (median: 1.25, IQR: 0 – 2) (Table 5.1). 
Table 5.1: Characteristics of participants with genotype data 
Characteristics 
Classic FDE 
(n=151) 
Female (%) 117(77.5) 
Conversion to MS (%) # 83(55.0) 
Relapse 198 
Age at study entry, mean (SD) 37.4 (9.5) 
EDSS, Median (IQR) 1.25 (0-2) 
FDE: First demyelinating event 
SD: Standard deviation, EDSS: Expanded Disability Status Scale 
IQR: Interquartile range 
# Participants who had CDMS and with genotype data. 
5.4.1 Risk genotype (GC+CC) of rs2910164 directly predicts progression to 
relapse 
Among the group of participants whose FDE occurred immediately prior to 
recruitment to the Ausimmune Study (n =151) and who were thus at risk of a second 
event diagnostic of MS within the period after referral to the study, we found that 
having genotype (GC+CC) of rs2910164 compared to GG was associated with an 
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increased hazard of converting to MS (HR: 1.52 (95% CI: 0.97, 2.42), p=0.07, Table 
5.2), although not statistically significant. 
Table 5.2: Association between miR-146a SNP rs2910164 genotype and measures 
of clinical course. 
rs2910164 N Conversion to MS (HR (95% CI)) n Relapse (HR (95% CI)) n 
GG 93 Ref 46 Ref 79 
GC+CC 58 1.52 (0.97, 2.42) 37 2.10(1.43,3.08) 120 
    p=0.071   P=0.0001   
Due to the small number of people carrying the CC genotype who converted to MS (N=1), we 
recoded the genotype as GC+CC. Results were adjusted for age, sex and study site, and presented 
as HR (95% CI) for time to MS and relapses. The N refers to the number of rs2910164 genotype 
in the subgroup with a "classic FDE".  n refers to the number of related clinical course. 
A stronger result was seen for relapse (HR=2.09 (95% CI: 1.42, 3.06), p=0.0001), 
partly reflecting the greater number of events (n=83 Conversion to MS vs. 198 
relapses). Figure 5.2 and Figure 5.3 show the survival curves for the two genotypes 
for conversion to MS and relapse, respectively. The rs2910164 genotype did not 
predict annualised change in EDSS (p=0.25, Table 5.2).  
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Figure 5.2: Kaplan-Meier survival plot for time to conversion to MS by category 
of rs2910164 genotype for those with a classical FDE (n=151). 
 
Figure 5.3: Kaplan-Meier survival plot for time to relapse by category of 
rs2910164 genotype. 
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5.4.2 Interactions of rs2910164 genotype with EBV related variables in 
predicting MS and relapse.  
The rs2910164 SNP did not significantly interact with EBV-related parameters 
(serological, clinical) on the multiplicative scale in predicting either MS or relapse 
(Table 5.3). We did, however, find a significant interaction on the additive scale 
between rs2910164 and baseline anti-EBNA-1 IgG titers predicting risk of conversion 
to MS (RERI: 2.39, p=0.00002,Figure 5.4) and relapse (RERI: 1.20, p=0.006, Figure 
5.5) ( Table 5.3). The combined effect of having both a high baseline anti-EBNA-1-
IgG titer and the risk genotype (GC+CC) of miR-146a was higher than expected 
based on the effects of having high baseline anti-EBNA-1-IgG titer in the absence of 
risk genotype (GC+CC) of miR-146a, and the effects of having risk genotype 
(GC+CC) of miR-146a in the absence of high baseline anti-EBNA-1-IgG titer. 
Supporting these results, similar results were seen for the other EBV correlated 
variables: anti-EBNA-2 IgG titers and having a history of infectious mononucleosis 
(Table 5.3). No significant interactions were observed with smoking (data not shown). 
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Figure 5.4: Hazard ratios for time to convert to MS by different combinations of 
baseline anti-EBNA-1 IgG titers (Low: <=0.53, High:>0.53) and miR-146a 
genotype (GG, GC+CC).  Test for interaction on the multiplicative scale, 
HR=1.48,p=0.38; test for interaction on the additive scale, RERI=2.39, 
p=0.00002. 
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Figure 5.5: Hazard ratios for time relapse by different combinations of baseline 
anti-EBNA-1 IgG titers (Low: <=0.53, High:>0.53) and miR-146a genotype (GG, 
GC+CC). Test for interaction on the multiplicative scale, HR=1.16,p=0.82; test 
for interaction on the additive scale, RERI=1.20, p=0.006. 
 
 
Table 5.3: Interaction between miR-146a SNP rs2910164 with baseline EBV 
antibody levels (anti-EBNA-1 and anti-EBNA-2) and according to history of 
having had infectious mononucleosis on time to conversion to MS and relapse.
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Clinical 
Course Factor E Factor G 
Effects of having 
factor E in absence 
of factor G 
Effects of having 
factor G in absence 
of factor E 
Effects of having 
both factor E and 
factor G 
Interaction Parameters 
Multiplicative 
Interaction 
Additive 
Interaction 
HRE(95%CI) HRG(95%CI) HRGE(95%CI) HRmulti(p) RERI(p) 
Conversion to 
MS 
High baseline EBNA1 miR-146a (GC+CC) 3.54(1.48-8.43) 1.59(0.54-4.67) 6.52(2.41-17.67) 1.48(0.38) 2.39(0.00002) 
High baseline EBNA2 miR-146a (GC+CC) 1.62(0.76,3.46) 1.09(0.40,2.94) 2.49(1.09,5.66) 1.41(0.60) 0.78(0.05) 
Infectious mononucleosis miR-146a (GC+CC) 0.60(0.26,1.38) 1.35(0.79,2.31) 1.38(0.69,2.77) 1.69(0.34) 0.43(0.21) 
Relapse 
High baseline EBNA1 miR-146a (GC+CC) 1.23(0.69-2.17) 1.75(0.90-3.40) 3.18(1.69-5.97) 1.16(0.82) 1.20(0.006) 
High baseline EBNA2 miR-146a (GC+CC) 0.87(0.49,1.54) 1.22(0.68,2.19) 2.65(1.56,4.52) 2.50(0.03) 1.56(0.005) 
Infectious mononucleosis miR-146a (GC+CC) 1.21(0.49,2.98) 1.72(1.15,2.58) 3.40(2.24,5.17) 2.53(0.09) 1.47(0.0006) 
High baseline EBNA1 status (>0.53 vs <=0.53); High baseline EBNA2 status(>0.70 vs <=0.70); Infectious mononucleosis (yes vs no);miR146a (GC+CC) (GC+CC vs GG) 
HR: hazard ratio; CI: confidence interval; RERI: relative excess risk due to interaction on additive scale 
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5.5 Discussion 
Here we have shown that the risk genotype (GC+CC) of miRNA-146a SNP rs2910164 
directly predicts conversion to MS and risk of relapse but not accumulation of 
disability. We also provide evidence of an interaction on the additive scale, between 
the risk genotype of rs2910164 and baseline-measured EBV-related serological and 
clinical variables in predicting MS and relapse, such that these environmental factors 
are significantly more strongly associated with clinical outcomes among those 
carrying the miR-146a risk variant.  
The role of miRNAs in the development and intensity of inflammatory reactions in 
complex disorders such as MS is now being explored. Increased expression of miR-
146a has been found to be associated with a more intense inflammatory state in MS 
brain lesions4 and to be down-regulated by treatment with glatiramer acetate5. 
Jazdzewski et al found that the C allele of rs2910164 demonstrated lower expression 
compared with the non-risk G allele using transfected cells11. In MS, patients with the 
C allele of rs2910164 (compared to those with the GG and GC alleles) had higher 
expression of the prototypical pro-inflammatory cytokines TNF-α and IFN-γ in 
peripheral blood mononuclear cells12. Such changes were modulated by miR-146a 
through signaling pathways targeting TRAF6 and IRAK1 gene expression, which 
establishes a negative feedback loop that controls the intensity and the duration of 
NF-kB signaling. Recently, upregulated miR-146a in the brain of patients with 
Alzheimer's disease (AD) has been shown to significantly increase the severity of AD 
by directly binding the target site of LRP2 mRNA, resulting in decreased protein 
expression. LRP2 is expressed on the surface of many CNS cells including neurons 
and oligodendrocytes and is a critical receptor in axonal guidance. Therefore this 
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genetic variant that potentially alters expression of miR-146a is biologically plausible 
as a causal influence on the clinical course of MS. 
Previous work has shown links between miR-146a and EBV infection. Using EBV de 
novo infection of primary cultured human B cells, miR-146a was down-regulated on 
initial infection, but was dramatically up-regulated upon induction of the lytic cycle6. 
In T-cells, decreased expression of miR-146 can cause hyper-responsiveness to T-cell 
receptor signals and unresolved T-cell-mediated inflammation13. Several studies have 
demonstrated the importance of T-cell driven immune responses in the association 
between EBV infection and onset of MS14. These effects of EBV infection on miR-
146a expression, and on the effectiveness of T-cell responses, provide plausibility to 
enhanced effects on disease course of combined variation in miR-146a genotype and 
markers of EBV infection.  
In our analyses we demonstrated an additive interaction between EBV infection and 
miR-146a genotype. Similar additive interactions have been previously demonstrated 
between markers of EBV infection and the HLA-DRB1*15 genotype15,16 and have 
been interpreted as indicating that the two factors are component causes of the same 
sufficient cause for a substantial proportion of people who are in the at-risk category 
of each factor – in this case the (GC+CC) genotype and a higher than median anti-
EBNA-1 IgG level. We did not find a significant multiplicative interaction . We also 
did not observe interaction between smoking and miR-146a genotype. However, 
interaction between smoking and genetic factors in predicting MS risk has been 
controversial. In both of the above studies15,16 there was no significant additive 
interaction between smoking and HLA-DRB1*15 genotype in predicting MS risk. On 
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the contrary, work by Anna et al.17 observed an additive interaction between passive 
smoking and carriage of HLA-DRB1*15 risk genotype.  
The strengths of our study include that we have detailed information on the clinical 
course from the first diagnosis of CNS demyelination for over five years, with high 
cohort retention. Only medically confirmed relapses were included in the analysis. 
One limitation is that the sample size of participants with a FDE close to the time of 
recruitment with no second event prior to data collection was relatively small, limiting 
the power of the study. A strength of our study is that in Australia treatment with 
disease modifying therapy (DMT) typically does not commence until a diagnosis of 
MS has been made. Our cohort is thus particularly valuable as the results on 
conversion to MS are not significantly confounded by treatment with DMT. 
In conclusion, we provide evidence that a functional genetic variant in miR-146a, 
which has been linked in vitro with a change in miR-146a expression, predicts 
conversion to MS and relapse in MS. The combination of the risk genotype of miR-
146a and higher levels of anti-EBNA-IgG result in a marked increase in risk of 
conversion to MS and relapse, suggesting that these two factors are component causes 
of a sufficient cause. Additional studies are needed to validate the findings and to 
further elucidate the pathways by which miR-146a, independently or in association 
with EBV infection, can influence disease progression following initial CNS 
demyelination.  
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5.6 Summary  
Background: Despite extensive studies focusing on the changes in expression of 
miRNAs in MS compared to healthy controls, no studies have evaluated the 
association of genetic variants of miRNAs with MS clinical course.  
Methods: We investigated whether a functional polymorphism in the MS associated 
miR-146a gene predicted clinical course (hazard of conversion to MS and/or relapse, 
and annualized change in disability), using a longitudinal cohort study of persons with 
a first demyelinating event followed up to their 5-year review. 
Results: We found the genotype (GC+CC) of rs2910164 predicted relapse compared 
with the GG genotype (HR=2.09 (95% CI: 1.42, 3.06), p=0.0001), as well as a near-
significant (p=0.07) association with conversion to MS. Moreover, we found a 
significant additive interaction between rs2910164 and baseline anti-EBNA-1 IgG 
titers predicting risk of conversion to MS (RERI: 2.39, p=0.00002) and of relapse 
(RERI: 1.20, p=0.006). Supporting these results, similar results were seen for the 
other EBV-correlated variables: anti-EBNA-2 IgG titers and past history of infectious 
mononucleosis. There was no association of rs2910164 genotype for disability 
progression. 
Conclusion: Our findings suggest miR-146a and its target genes are potential 
therapeutic targets for modulating clinical course in MS. 
5.7 References: 
1. Baek D, Villen J, Shin C, Camargo FD, Gygi SP, Bartel DP. The impact of 
microRNAs on protein output. Nature. 2008;455(7209):64-71. 
Chapter 5:  Common genetic variation within miR-146a predicts disease onset & 
relapse in multiple sclerosis  
 
175 
2. Zhou Y, Simpson S, Jr., Holloway AF, Charlesworth J, van der Mei I, Taylor 
BV. The potential role of epigenetic modifications in the heritability of 
multiple sclerosis. Mult Scler. 2014;20(2):135-140. 
3. Liu G, Abraham E. MicroRNAs in immune response and macrophage 
polarization. Arterioscler. Thromb. Vasc. Biol. 2013;33(2):170-177. 
4. Junker A, Krumbholz M, Eisele S, et al. MicroRNA profiling of multiple 
sclerosis lesions identifies modulators of the regulatory protein CD47. Brain. 
2009;132(Pt 12):3342-3352. 
5. Waschbisch A, Atiya M, Linker RA, Potapov S, Schwab S, Derfuss T. 
Glatiramer acetate treatment normalizes deregulated microRNA expression in 
relapsing remitting multiple sclerosis. PLoS One. 2011;6(9):e24604. 
6. Godshalk SE, Bhaduri-McIntosh S, Slack FJ. Epstein-Barr virus-mediated 
dysregulation of human microRNA expression. Cell Cycle. 2008;7(22):3595-
3600. 
7. Vrijens K, Bollati V, Nawrot TS. MicroRNAs as Potential Signatures of 
Environmental Exposure or Effect: A Systematic Review. Environ. Health 
Perspect. 2015. 
8. Ascherio A, Munger KL. Environmental risk factors for multiple sclerosis. 
Part I: the role of infection. Ann. Neurol. 2007;61(4):288-299. 
9. Ascherio A, Munger KL. Environmental risk factors for multiple sclerosis. 
Part II: Noninfectious factors. Ann. Neurol. 2007;61(6):504-513. 
10. Gong J, Tong Y, Zhang HM, et al. Genome-wide identification of SNPs in 
microRNA genes and the SNP effects on microRNA target binding and 
biogenesis. Hum. Mutat. 2012;33(1):254-263. 
11. Jazdzewski K, Murray EL, Franssila K, Jarzab B, Schoenberg DR, de la 
Chapelle A. Common SNP in pre-miR-146a decreases mature miR expression 
and predisposes to papillary thyroid carcinoma. Proc. Natl. Acad. Sci. U. S. A. 
2008;105(20):7269-7274. 
12. Li Y, Du C, Wang W, et al. Genetic association of MiR-146a with multiple 
sclerosis susceptibility in the Chinese population. Cell. Physiol. Biochem. 
2015;35(1):281-291. 
13. Baumjohann D, Ansel KM. MicroRNA-mediated regulation of T helper cell 
differentiation and plasticity. Nat. Rev. Immunol. 2013;13(9):666-678. 
14. Pender MP, Burrows SR. Epstein-Barr virus and multiple sclerosis: potential 
opportunities for immunotherapy. Clin Transl Immunology. 2014;3(10):e27. 
Chapter 5:  Common genetic variation within miR-146a predicts disease onset & 
relapse in multiple sclerosis  
 
176 
15. Disanto G, Hall C, Lucas R, et al. Assessing interactions between HLA-
DRB1*15 and infectious mononucleosis on the risk of multiple sclerosis. 
Mult. Scler. 2013;19(10):1355-1358. 
16. Sundqvist E, Sundstrom P, Linden M, et al. Lack of replication of interaction 
between EBNA1 IgG and smoking in risk for multiple sclerosis. Neurology. 
2012;79(13):1363-1368. 
17. Hedstrom AK, Bomfim IL, Barcellos LF, et al. Interaction between passive 
smoking and two HLA genes with regard to multiple sclerosis risk. Int. J. 
Epidemiol. 2014;43(6):1791-1798. 
 
Chapter 6: Conclusion 
 
177 
Chapter 6: Conclusion 
Multiple sclerosis is a complex disease of the central nervous system in which both 
environmental and genetic factors contribute to disease development. The incidence 
of MS is increasing every year, creating a huge economic burden for the patients and 
their families. Despite the increasing understanding of MS, no cure exists. Work is 
ongoing to complete the puzzle that is the etiology of MS, and the ultimate goal of 
research is to identify a cure for the disease. The work presented in this thesis 
provides further insights into the missing heritability in MS using a variety of study 
designs and methodologies. This chapter will summarize some key conclusions from 
the work and provide directions for further research.  
6.1 Genetic loci associated with EBV infection and their roles in MS 
risk 
Infection with EBV has been implicated in the development of MS. Despite extensive 
studies demonstrating the association between anti-EBNA-1 IgG titers and MS risk, 
few studies have investigated the susceptibility genes associated with anti-EBNA-1 
IgG titers and their roles in MS risk. In Chapter 2, we performed a GWAS using 
QIMR twin families by measuring the anti-EBNA-1 IgG titers in the samples and 
treating them as a quantitative trait. Twin studies offer a powerful approach to the 
identification of genetic variation underlying complex traits due to the shared genetic 
and environmental exposures between twins1. With twin family data available by 
collaborating with other research groups and given the high rate of EBV infection in 
the general population2 (>90%), GWAS becomes relatively cheaper, as opposed to 
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collecting a larger number of MS samples, measuring the anti-EBNA-1 IgG titers, and 
conducting a GWAS. 
Using this approach, we identified a strong association with the HLA region for the 
significant SNP, rs2516049, located between genes HLA-DRB1 and HLA-DQA1 in 
the QIMR twin families. In the conditional analysis, adjusting for the top significant 
SNP as a covariate did not demonstrate any other independent signals located within 
the HLA regions, suggesting that these SNPs are within one haplotype block 
containing the variants modulating anti-EBNA-1 IgG titers. Additionally, we did not 
observe any significant loci outside the HLA region. In an effort to identify novel 
non-HLA region loci, we then performed a meta-analysis using data from another 
EBNA-1 GWAS from a cohort of Mexican-American families. Again, we only 
observed a significant signal within the HLA region.  
From this analysis, the question remains: how do genetic loci associated with anti-
EBNA-1 IgG titers modulate MS risk? To answer this question, we examined the 
shared polygenetic risk between the EBNA-1 GWAS and the largest published MS 
GWAS by applying a novel method called SNP effect concordance analysis (SECA)3, 
and we then replicated the SECA findings using the genetic risk score method. We 
found shared genetic risk between the EBNA-1 GWAS and MS GWAS. In the meta-
analysis combining the two datasets, we found that non-HLA loci at 1p22.1, 3p24.1, 
3q13.33, and 10p15.1 reached genome-wide significance (P < 5×10-8). In line with 
functional research work, our results support a role for these loci in EBV infection 
and thus in contributing to MS development. As an example, the gene Eomesodermin 
(EOMES), located on 3p24.1, has been reported in a study performed by Aalderen and 
colleagues4. The authors found direct evidence that EOMES expression was altered 
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after EBV infection. Similarly, Parnell and colleagues5 showed that EOMES 
expression was significantly lower in MS cases compared with healthy controls. Thus, 
our results here provide guidance for further study aimed at analyzing these loci, 
which may yield a better understanding of the possible molecular mechanisms 
involved in these processes. 
Furthermore, some of the study designs and methods that we described in this chapter 
can be further investigated in future research. First, the twin study design can be 
applied to studies analyzing other environmental/behavioral variables, and then the 
genes discovered from this stage can be used as a priori hypotheses for testing in the 
diseases that are caused by such environmental/behavioral variables. Second, shared 
polygenetic risk analysis can be applied to examine the shared risk between different 
diseases. For example, it is known that Alzheimer’s6, Parkinson’s7, and MS are all 
neurodegenerative diseases. However, despite extensive GWAS studies looking for 
susceptibility loci for each disease separately, few studies have sought to ascertain 
whether there is shared genetic risk among these diseases8-12. Our method may 
provide a better approach, potentially leading to the discovery of shared genetic 
determinants involved in the pathways contributing to these diseases. 
6.2 Genetic variations within cytokines and their receptor genes in 
predicting MS 
Abnormal cytokine production by peripheral blood mononuclear cells (PBMC) plays 
an important role in the pathogenesis of MS13. In previous work, we showed that 
increasing levels of IFN-γ were significantly associated with increased risk of relapse, 
whereas TNF-α showed a significant inverse relationship with relapse risk14. In 
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Chapter 3, we further expanded this analysis to systematically assess whether the 
variations within the network of cytokine genes and their receptor genes modulate the 
association of IFN-γ and TNF-α with relapse. All of the known cytokine genes and 
their receptors genes (N=83) within a gene boundary of 10 kb containing 361 SNPs 
were selected for analysis. We showed that rs3218295 (within the gene IL2RB) and 
rs522807 (3’ of the gene TNFRSF1B) showed a significant interaction with TNF-α as 
a predictor of relapse, whereas rs25879 (5’ of the gene IL3) and rs522807 (3’ of the 
gene TNFRSF1B) showed a significant interaction between IFN-γ and relapse. 
Our results demonstrated potential roles for IL2RB and IL3 in the development of MS 
and provided insight into the complex interactions between genetic variations and the 
cytokines in predicting clinical course. Additional evidence has supported a plausible 
biological role for these genes in MS. For example, SNP rs31480, which has high LD 
with our significant SNP, rs25879, significantly influenced IL3 gene expression, 
which then affects the proliferation and survival of neural progenitors15. Although 
there have been no studies showing a role for IL2RB in MS16, this gene has been 
identified as a susceptibility locus for other autoimmune disease such as rheumatoid 
arthritis17. Thus, additional studies are needed to better understand its role in MS. 
Importantly, the genes identified as interacting with PBMC-produced cytokines in 
predicting clinical course were not identified as susceptibility loci in previous GWAS 
studies. This may be because GWAS typically use a cross-sectional study design and 
are limited by multiple testing burdens. Therefore, GWAS is insensitive in identifying 
genetic predictors in clinical course analyses. What we have shown here using an a 
priori hypothesis and testing in a prospective cohort may provide a method for 
explaining part of the “missing heritability” puzzle in MS. Nonetheless, it is essential 
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to replicate our results in other independent longitudinal cohorts to confirm the 
findings for future clinical use.  
Therefore, in the post-GWAS world, the focus should shift from defining risk 
associations (using case-control study design in large GWAS) to defining genetic 
determinates of clinical course (using a priori hypotheses in longitudinal cohort study 
designs), either by assessing risk genes discovered by GWAS or by candidate gene 
studies utilizing GWAS genotype data. Chapters 4 and 5 are primarily based on the 
concepts that we propose here.  
6.3 MBP and MS clinical course 
Most MS patients present with a first clinical episode of demyelination (FDE), which 
has an uncertain prognosis and few generalizable markers of subsequent disease 
severity. Although these patients face an uncertain future, early intervention at this 
time may significantly alter future clinical outcomes. However, differentiating 
patients with good and poor prognoses is not yet possible. Identifying genetic and 
other risk factors that modulate early clinical course may assist the development of 
risk algorithms to better predict subsequent disease.  
After an FDE, there are no clear genetic indicators of future conversion to MS, risk of 
relapse, or rate of disability accumulation. In Chapter 5, we developed an a priori 
hypothesis, considering the significant role of myelin basic protein (MBP) in CNS 
myelination, that genetic variants in the MBP gene may significantly affect MS 
clinical outcomes. Utilizing a longitudinal cohort study of persons who have had an 
FDE and who were followed up to a 5-year review, we found that the risk genotype of 
rs12959006 within MBP not only significantly predicted relapse (HR=1.74, 95% 
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CI=1.19-2.56, p=0.005) but also significantly predicted greater annualized ΔEDSS 
(β=0.18, 95% CI=0.06-0.30, p=0.004). Translating these findings into clinical 
outcomes for the participants followed for 5 years, those carrying the risk genotype of 
rs12959006 would have a 1.74-fold increased risk for relapse occurrence and an 
EDSS score 0.9 points greater compared with those carrying the non-risk genotype. 
We also found that the risk genotype significantly interacted with the known MS 
environmental risk factors to affect baseline anti-HHV6 IgG in predicting time to MS 
(pinteraction=0.05) and relapse (pinteraction=0.02), providing evidence that gene-
environmental interaction can influence the clinical course of MS and thus explaining 
part of the missing MS heritability. The interactions provide evidence to support the 
molecular mimicry hypothesis, in which MBP-reactive T-cells may cross react with 
HHV6 epitopes and result in autoimmunity. 
For the first time, we have demonstrated that genetic variants in biologically plausible 
MS candidate genes predicted worse MS clinical course using three key metrics. 
These results, if replicated, may aid in the development of prognostic algorithms in 
the early disease period of MS. Our results based on in silico analysis also provide 
direction for future studies to investigate the functional variations associated with the 
binding sites of miR-218 and miR-188-3p. Other research has already shown that in 
the white matter of MS patients, miR-218 expression was significantly down 
regulated compared with controls18. Therefore, studies focusing on the roles of these 
miRNAs in the post-transcriptional modification of the MBP gene may provide 
further insights into mechanisms affecting processes involved in myelination and 
demyelination. 
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6.4 miR-146a in predicting disease onset and relapse 
miRNA-associated post-transcriptional gene silencing is an epigenetic control of gene 
expression that also may account for part of the missing heritability in MS19. Until 
now, extensive studies have only focused on the expression of miRNAs. No studies 
have investigated the function of variations within the miRNA coding genes and how 
such variations might predict disease onset and relapse.  
In MS, the expression of miR-146a is known to be altered as a result of EBV 
infection20 and to be upregulated in active MS brain lesions21. The only common 
variant within the miR-146a gene has been found to affect its expression. In Chapter 
5, I assessed the effects of the only functional common variant in miR-146a using a 
longitudinal cohort study of persons who have had a FDE and who were followed up 
to the 5-year review.  
In the univariate analysis, we found that the risk genotype (GC+CC) of rs2910164 
significantly predicted relapse (HR=2.09 (95% CI: 1.42, 3.06), p<0.001). Upon 
further expansion to examine the gene-environmental interaction, we found a 
significant additive interaction between rs2910164 and EBV infection in predicting 
conversion to MS and relapse. The levels of anti-EBNA-1 and EBNA-2 IgG 
interacted with the risk genotype in predicting both MS and relapse, such that the 
combination of both the genetic and environmental risk factors predicted the outcome 
more strongly than the sum of each component alone. A similar additive interaction 
was observed for a history of infectious mononucleosis, but it only reached 
significance in predicting relapse. There was some evidence of a multiplicative 
interaction of similar directionality, particularly for relapse, but this interaction did 
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not reach statistical significance. While the test for multiplicative interaction is often 
applied for its ease, it has been argued that the assessment of interaction on the 
additive scale may be better correlated with biological interaction compared with a 
multiplicative interaction, thus making additive interaction more indicative of the 
underlying causal mechanism22. This demonstration of a significant interaction is 
germane to this study because it provides a supportive line of evidence for the direct 
association of the risk variant with clinical outcomes. In other words, by 
demonstrating that the environmental factors are more strongly associated with 
clinical outcomes among those carrying the risk variant in the manner expected by the 
known relationship between this miRNA and these environmental factors, the veracity 
of the main effects is substantiated.  
Our findings support the hypothesis that we proposed in Chapter 1, that the complex 
interplay of environmental risk factors and epigenetic changes amplifies the risk of 
developing MS. This is one of the first studies to directly support this hypothesis and 
provide guidance for future studies aimed at identifying the role of epigenetics in the 
missing heritability of MS.  
6.5 Final conclusion of PhD 
This thesis covers a variety of topics using different study designs and methods to 
study the genetic variants and environmental factors influencing the onset and 
progression of MS, and it has revealed part of the missing heritability of MS. The key 
conclusions are as follows: 
• There is shared polygenetic risk between EBNA-1 GWAS and MS GWAS; in 
addition to the main effects of the HLA region, the non-MHC region (1p22.1, 
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3p24.1, 3q13.33, and 10p15.1) also mediated the association of anti-EBNA-1 
IgG titer with MS risk.  
• Variations within IL2RB and in the 3’ region of TNFRSF1B showed a 
significant interaction with TNF-α as a predictor of relapse, whereas variations 
in the 5’ region of IL3 and in the 3’ region of TNFRSF1B showed a significant 
interaction between IFN-γ and relapse. 
• People with an FDE who carry the risk SNP of rs12969006 in MBP have a 
worse outcome on all three measures of disease progression (conversion to 
MS, relapse rate, and EDSS progression), and the risk SNP of rs129569006 in 
MBP interacts with serological markers of prior HHV6 infection to predict 
clinical course post FDE. 
• The only common variant within the miR-146a gene not only significantly 
predicts relapse in MS but also interacts with EBV infection in predicting MS 
and relapse.  
6.6 Future directions 
The QIMR twin families study and the AusLong study cohorts are a significant 
potential data source, with much more data that can be evaluated. Based on the results 
presented in this thesis, future work utilizing these datasets and/or collaborating with 
other research groups can be suggested as follows: 
• The analysis of larger EBNA-1 GWAS datasets and/or the analysis of other 
markers of EBNA immune responses (e.g., EBNA-2 or EBNA-3 titers) should 
provide a novel opportunity to identify new and characterize existing genetic 
risk factors for MS. 
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• Functional studies focusing on miR-218 and miR-188-3p in the post-
transcriptional modification of MBP and thus in the modification of 
myelination and demyelination could provide further mechanistic insights. 
• A model that combines all the risk factors (genetic risk factors and 
environmental factors) should be developed to generate a score for each 
individual and determine how the score predicts clinical course. The ultimate 
aim of this model is for clinical prognosis, allowing doctors to determine the 
prognosis and treatment of MS based on this score. 
• Lastly and importantly, the replication of our results from Chapter 3, 4 and 5 
using other studies with larger sample sizes and longer follow-up is essential. 
However, due to the high cost and logistical limitations, there are presently no 
such studies available, thus supporting the importance of collaboration 
between multiple centers to allow these studies.  
As a final conclusion, this thesis presents the condensation of over three years’ work 
in which we sought to reveal the missing heritability puzzle of MS. Hopefully, as an 
ultimate goal of any research study, our work and the future work will be of benefit to 
MS patients.  
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